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Abstract
The aim of the thesis was to determine whether synergistic or additive metabolic 
benefits could be derived with the use of two plant-based components with independent 
physiological activities and whether the use of these two agents would improve 
diabetes control in the long term.
Viscous fibres reduce postprandial glycaemia, insulinaemia and gastrointestinal 
hormones levels, their effectiveness being dependent on the viscosity of the fibre. 
Long term studies with viscous fibre have shown reductions in serum cholesterol, and 
improvements in metabolic control and blood pressure in type 2 diabetes. Konjac 
mannan fibre (KJM) is a high viscosity, viscous fibre. American ginseng (AG) 
increases insulin secretion and improves glycaemic control in type 2 diabetes. The 
, suggested active ginseng components are the ginsenosides. As both AG and KJM have 
been shown to improve diabetes control through independent physiological 
mechanisms, this thesis explores the possible benefits of using them in combination.
To test potential additive effects of KJM and AG, an acute experiment was 
performed in thirteen subjects with type 2 diabetes where AG and/or KJM were 
incorporated into a liquid meal replacement as a breakfast, followed 4 hours later by a 
standard lunch. Contrary to previous findings, neither AG or KJM when given 
individually, reduced postprandial glucose and insulin levels by the expected amounts; 
moreover the combination did not result in glucose levels significantly different from 
control. The study did demonstrate that KJM flattens the postprandial response of 
glucose-dependent insulinotropic peptide (p<0.04) and glucagon like peptide-1 
(p<0.02). In addition KJM reduced the glucose area under the curve to a standard meal 
following the fibre enriched breakfast. Subsequent experiments showed that, despite 
high ginsenoside levels, the AG used was ineffective and the liquid replacement meal 
inhibited the gel formation of the KJM.
In preparation for a long-term intervention study, acute experiments were 
performed to select a physiologically effective AG, and to determine the most effective 
and palatable method of KJM incorporation. Incorporation of KJM into bread, capsules
and margarine reduced the incremental areas under the glucose curve by 3%, 12%and 
34% compared with control, with only the margarine being significantly different 
(p<0.001). Further experiments showed that incorporation of Ig of KJM into margarine 
and 4g of KJM into bread reduced the glucose AUC to a similar extent. KJM capsules 
has no acute effect on postprandial glycaemia, regardless of the timing of their 
administration relative to the meal.
Three months of 6g of viscous fibre and 3g of AG administration to 30 subjects 
with type 2 diabetes resulted in significant percent-change difference from control in 
HbAlc (-4!±1.4%, p<0.01), total cholesterol (-5.7±1.9%, p<0.00), LDL-cholesterol (- 
8.2±3!%, p<0.002) and apoliporotein B (-9.0±2.3%, p<0.0005). It was estimated the 
combination of viscous fibre and AG resulted in a 14% risk reduction in coronary heart 
disease.
The studies in this Uresis illustrate some of the difficulties of working with 
“natural” products but also their potentially effective use in the treatment of type 2 
diabetes.
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Chapter 1 
LITERATURE REVIEW
The use of complementary and alternative medicine (CAM) is increasing 
worldwide. Despite scepticism and lack of scientific data it has been estimated that 
the use of CAM has increased by 68% from 1990-1997 in the US (Eisenberg et al.,
1998). As a result there has been a call for randomised clinical trials to evaluate the 
safety and efficacy of CAM and provide a basis for legitimate health claims (Angell 
and Kassirer, 1998; Ernst et al., 2002). Evidence regarding the health claims for the 
use of CAM is emerging slowly. In a systematic review of the use of herbs and 
dietaiy supplements on glycaemic control by Yeh and colleagues (2003) they 
concluded that, in general, there is still insufficient evidence to draw definite 
conclusions. However out of the 36 herb and 9 vitamin and mineral supplements 
reviewed they identified Coccinia indica (Ivy gourd) and American ginseng as having 
the best evidence for efficacy supported by adequately designed randomised 
controlled trials (Yeh et al., 2003).
American ginseng has been of interest to our research group as it has been 
shown to improve long term diabetic control (Sotaniemi et al., 1995). Our group has 
undertaken a series of acute studies to investigate the effects of ginseng and have 
shown that American ginseng lowers postprandial glycaemia in both healthy 
individuals and those with type 2 diabetes (Vuksan et al., 2000a). A subsequent long­
term study showed that ginseng improved diabetic control (Vuksan et al, 2001b). 
Postulated mechanisms of action of ginseng include: increase of insulin-stimulated 
glucose uptake (Spinas et al., 1998), increase of insulin secretion (Yokozawa et al., 
1985b) and delayed gastric emptying (Onumra et al., 1999). Prior to the interest in 
ginseng our research group had studied the viscous fibre, konjac mannan, and had 
shown, both in short and long term studies, that konjac mannan fibre improves 
metabolic control in individuals with the insulin resistance syndrome and type 2
1.1 General Introduction
1
diabetes. The postulated mechanism of action for viscous fibre is that it delays 
glucose absoiption and so attenuates the postprandial glucose and insulin responses.
Type 2 diabetes is now commonly treated with two or more oral 
hypoglycaemic medications, which employ different mechanisms of action to treat 
diabetes. Combinations have been found to be more effective than mono-therapy; an 
example of such a combination being sulfonylurea taken with metformin. As ginseng 
and konjac mannan both employ different mechanisms of action to improve diabetes 
control, the next logical step was to explore the treatment potential of these two 
compounds used in combination in the treatment of type 2 diabetes .
The following review of the literature will summarise the incidence, aetiology, 
and pathophysiology of type 2 diabetes and the role of insulin, glucose-dependent 
insulinotropic polypeptide (GIP) and glucacon-like peptide 1 (GLP-1) in diabetes. In 
addition the current literature on American ginseng and konjac mannan fibre will be 
reviewed with special emphasis on their possible role in the treatment of diabetes.
1.2. Type 2 Diabetes
1.2! Incidence
Diabetes is a major cause of morbidity and mortality in the US (Harris, 1998) 
with an estimated health burden of $98 billion (ADA, 1998). Over the last ten years a 
dramatic increase of 33% in the incidence of diabetes has been observed in the US 
(Mokdad et al., 2003). Currently at least 16 million Americans have diabetes and this 
figure is expected to rise to 22 million by 2025 (Mokdad et al., 2003) and to 29 
million in 2050 (Boyle et al., 2001). Similarly in Canada there are at present about 1.5 
million people with diabetes (5.8% of the population)(Plealth Canada,1999), and 3- 
5% of the general adult population is thought to have undiagnosed type 2 diabetes 
(Tan and MacLean, 1995; Williams and Wild, 2003). Figures for the UK are more 
difficult to obtain (Williams and Wild, 2003), the WHO estimated the prevalence to 
be 2.7%, but these data were derived from a Dutch study (Mooy et al, 2000). 
Globally the figures are alarming too, it has been estimated that the incidence of
2
diabetes will increase from 135 million in 1995 to 300 million in 2025 (King et al.,
1998). The most recent data from the Centres for Disease Control Behavioral Risk 
Factor Surveillance System show that the greatest increase (70%) came in the younger 
adult cohorts aged 30-39y (Mokdad et al., 2003). The incidence data for insulin 
resistance are also alarming. In the Bothia Study cohort of Finnish and Swedish 
adults, using the euglycaemic-hyperinsulinaemic clamp, it was shown that insulin 
resistance occurred in 10% of men and 15% of women with normal glucose tolerance, 
42 and 64% of those with IFT/IGT and 78 and 84% of those with type 2 diabetes 
respectively (Isomaa et al., 2001). Similar results were obtained using the 
Homeostasis Model Assessment (HOMA) in both the Bruneck Study cohort (Bonora 
et al., 1998) and the San Antonio Heart Study (Haffner et al., 2000) in which insulin 
resistance was observed in 84% and 82.4% respectively in those with type 2 diabetes. 
Estimates suggest that the prevalence of insulin resistance would be >30% in 
Canadian adults (Ekoe, 1999). Therefore strategies for the prevention of the 
development of insulin resistance and ultimately diabetes are urgently needed.
1.2.2 Pathophysiology
Type 2 diabetes represents a heterogeneous group of metabolic disorders 
resulting in hyperglycaemia. In the San Antonio Heart Study it was estimated that 
those who converted to diabetes over the seven year period had significantly higher 
body mass index, waist circumference, triacylglycerol (TAG) concentration, and 
blood pressure and lower HDL cholesterol levels than those who did not convert to 
diabetes (Haffner et al., 2000). The distribution by metabolic status among converters 
to type 2 diabetes were as follows: 54% had both insulin resistance and low insulin 
secretion, 28% were insulin resistant only, 15.9% had low insulin secretion only, and 
1.5% were neither insulin resistant or had reduced insulin secretion (Haffner et al, 
2000). Therefore over 80% of those who developed diabetes over the seven years of 
the study had prior insulin resistance. This fits in well with the postulated sequence 
for development of diabetes which suggests that the earliest detectable abnormality in 
type 2 diabetes is an impairment of the body to respond to insulin. The abnormalities 
in insulin resistance manifest themselves as decreased insulin-stimulated nonoxidative 
glucose disposal (glycogen synthesis) and increased endogenous glucose output
3
glucose disposal (glycogen synthesis) and increased endogenous glucose output 
(Shulman, 1999). This insulin resistance is overcome by a compensatory response 
from the B-cells in the pancreas and euglycaemia is maintained. Eventually the hyper 
secretion of the B-cells causes “B-cell fatigue” and insulin levels decline with 
consequent appearance of hyperglycaemia resulting ultimately in frank diabetes.
In the fasting state, insulin independent tissues, the brain (-50%) and 
splanchnic organs (-25%) account for most of the total-body glucose disposal, 
insulin-dependent tissues, primarily muscle, accounts for the rest (DeFronzo et al., 
1985). Hepatic glucose production (HGP) through gluconeogenesis and 
glycogenolysis, is mainly responsible for the glucose production during the fasting 
state. During prolonged fasting, levels of non-esterified fatty acids (NEFA) and 
ketone bodies slowly increase in the blood and help to generate the small amount of 
gluconeogenesis derived glucose, which is utilised by the brain. It has been estimated 
that after a 14h fast gluconeogenesis accounts for approximately 47% of the 
endogenous glucose production, and this increases to 67% after a 16 hour fast and to 
97% after 42 hours (Landau et al., 1996). This percentage increase is mainly due to 
the reduction in glycogenolysis as the rate of gluconeogenesis does not really change 
when expressed in absolute values (Chen et al., 1999). Acute changes in 
endogenously derived NEFA show that when plasma NEFA falls so does 
gluconeogenesis and conversely when the levels of NEFA rises, gluconeogenesis is 
increased (Chen et al., 1999). These NEFA induced changes are associated with 
reciprocal changes in glycogenolysis. Raising plasma NEFA will partially inhibit 
insulin-induced suppression of endogenous glucose production i.e. cause hepatic 
insulin resistance mainly by interfering with insulin suppression of glycogenolysis. 
This supports the observation that in type 2 diabetic subjects plasma NEFA levels are 
often increased, which may at least in part be responsible for the relative (in relation 
to insulin levels) or absolute elevation in the rates of endogenous glucose production 
seen in these individuals.
In the postprandial state, peripheral tissue is responsible for approximately 70-. 
90% of glucose disposal (DeFronzo et al., 1985; Shulman et al., 1990). It has been 
suggested that in the earliest phase of insulin resistance, the resistance occurs in the
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muscle glycogen synthesis (Shulman et al., 1990). In type 2 diabetes the insulin- 
mediated glucose disposal is reduced by 35-40%(De Fronzo et al., 1983; DeFronzo et 
al., 1982; Shulman etal., 1990; Simonson etal., 1984).
1.2.2.1. Insulin-resistance
Insulin resistance, or the reduced insulin-stimulated glucose uptake, impedes 
glucose disposal and disrupts lipid metabolism in insulin sensitive tissues particularly 
muscle, the liver and adipose tissue. Most of the resistance has been attributed to a 
decrease in insulin- stimulated glycogen synthesis due to defects in either glycogen 
synthase, hexokinase or glucose transport by glucose transporter 4 (GLUT 4) 
(Shulman, 1999; Shulman et al., 1990). The mechanism of insulin stimulated glucose 
transport in human cells and adipocytes has become more clear in recent years. 
Briefly, the insulin molecule binds with the insulin receptor on the cell surface, this 
initiates a signalling cascade. The first step being the phosphorylation of the receptor 
and insulin-receptor-substrates such as the IRS molecules by tyrosine kinase. These 
substrates form complexes with docking proteins such as phosphoinositide-3 kinase 
(PI3K) (Sheppard and Kahn, 1999) (Fig 1.1). Subsequent steps are less clear, it is 
thought that PI3K induces activation of atypical protein kinase B (Akt or PKB) and 
protein kinase C (PKC), these in turn stimulate the insulin responsive GLUT-4 
containing vesicles to translocate to the cell membrane. It is interesting to note that 
exercise stimulates translocation of the GLUT-4 vesicle to the cell membrane 
independently from the PI3K (Fig 1.1).
0 0  0 0 © ® Extracellular glucoseo 00  o _ •o • e
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Fig 1.1. : S c h e m a tic  re p re se n ta t io n  o f  in su lin  s t im u la te d  g lu c o s e  tra n s p o r t  in  h u m an  
a d ip o s e  o r  m u s c le  c e l ls  (a d a p te d  fro m  (S h e p p a rd  a n d  K a h n , 1 9 99)
G L U T -4  c o n c e n tra tio n s  a re  re d u ce d  in ad ip o c y te s  b u t n o t m u sc le  ce lls , o f  
o b e se  su b je c ts , an d  su b je c ts  w ith  im p a ired  g lu co se  to le ran ce  o r  type  2 d iabe tes. A s 
m u sc le  is th e  m a in  site  fo r  in su lin  s tim u la ted  d isp o sa l o f  g lu co se , red u c tio n s in 
G L U T -4  c o n c e n tra tio n s  c a n n o t ex p la in  the  im p a irm en t o f  w h o le  b o d y  insu lin  
sensitiv ity . D e c re a sed  G L U T -4  p ro d u c tio n  is o b se rv ed  w ith  a g in g  in m u sc le  ce lls  o f  
n o rm al su b je c ts  (K ah n , 1992), w h ic h  m ay  ex p la in  in  p a rt the  o b se rv ed  age-re la ted  
d e c lin e  in  in su lin  se n s itiv ity  .
R e ce n t d a ta  su g g e s t th a t d e fec ts  in  g lu co se  tran sp o rt m ig h t be  re sp o n sib le  fo r 
the  in su lin  re s is ta n c e  o b se rv e d  in type  2 d iab e te s  (C lin e  et a l., 1999). U sin g  a novel 
n u c le a r  m ag n e tic  re so n a n c e  a p p ro a c h  w ith  c a rb o n -13 an d  p h o sp h o ru s-3 1  to  m easu re  
in tra -m u scu la r  g lu co se , g lu co se -6 -p h o sp h a te , and  g ly co g en  c o n ce n tra tio n s  u n d e r
6
hyperglycaemic conditions the investigators were able to demonstrate that the rates of 
whole body glucose metabolism and muscle glycogen synthesis and the glucose-6- 
phosphate concentrations in muscle were approximately 80% lower in patients with 
diabetes (Cline et al., 1999). The rate-limiting step was found to be in the insulin 
signalling pathway that regulates translocation of intracellular GLUT-4 to the cell 
membrane in muscle and adipose tissue (Fig 1.1).
Several other factors have been implicated in the defects in insulin stimulated 
glucose transport. Early in the 1960’s Randle and colleagues introduced the concept 
that NEFA’s interfere with glucose utilization (Randle et al, 1963). NEFA have been 
shown to be chronically elevated in obesity and diabetes presumably due to increased 
lipolytic action (Sheppard and Kahn, 1999; Shulman, 1999). Lipid infusions in 
humans have been shown to inhibit IRS-1-associated phosphatidylinositol 3-kinase 
activity and subsequent reduction in insulin stimulated glucose transport in muscle 
(Dresner et al., 1999), presumably through defective translocation of GLUT-4. The 
defect in signalling may be caused by a NEFA induced diversion of glucose into the 
hexosamine pathway. Incubating isolated hepatocytes with free fatty acids of varying 
chain length reduced insulin binding and insulin internalisation and recycling 
(Svedberg et al., 1992).
NEFA levels have also been related to the diurnal variations in peripheral 
insulin resistance (Morgan et al., 1999). In this study NEFA levels were found to be 
elevated in the evening, corresponding to the increased insulin resistance commonly 
found at that time of the day (Morgan et al., 1999). The entero-insular axis may be 
affected by circulating NEFA levels. Increasing NEFA levels by heparin infusion in 
obese and lean subjects attenuated GIP and GLP-1 secretory responses in the obese 
group (Ranganath et al., 1999).
Insulin resistance is also strongly associated with increased TAG and 
decreased high-density lipoprotein (HDL) levels (Laakso et al., 1990). The multi 
centre study conducted by the European Group for the Study of Insulin Resistance 
studied the association between insulin resistance and lipoprotein concentration by a 
retrospective analysis of euglycaemic hyperinsulinaemic clamp data from 867 
normoglycaemic subjects. There were significant correlations between TAG and
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fasting plasma glucose and insulin levels, and mean glucose infusion rate at steady 
state (Fig 1.2). A positive correlation between suppression of NEFA and insulin 
sensitivity was also shown (Baldeweg et al., 2000).
Measurement of muscle TAG content by biopsy (Johnson et al., 1992) or 
intramyocellular lipid content (Perseghin et al., 1999) have shown strong relationship 
between increased intramuscular fat content and insulin resistance in muscle.
Insulin sen sitiv ity  In quintiles o f  Mew (m icrom o! m in -1 kg-1 bodyw elght)
Fig 1.2 Fasting plasma TAG levels plotted against quintiles of insulin sensitivity 
measured using the hyperinsulinaemic clamp in 867 subjects. (Baldeweg et al., 2000) 
Mbw: mean glucose infusion rate at steady state normalised per kg body weight
“Glucose toxicity” i.e. chronic high blood glucose levels has also been 
implicated in the pathogenesis of insulin resistance. The mechanism proposed is that 
the hexosamine pathway is up-regulated, increasing levels of hexosamine metabolites 
that may interfere with GLUT-4 translocation and glucose transport (Sheppard and 
Kahn, 1999).
Paracrine factors might also play a role in the pathogenesis of insulin 
resistance. The cytokine, tumour necrosis factor a (TNF- a), has been found to be 
over-expressed in muscle and adipose tissue in obese animals and humans 
(Saghizadeh et al., 1996). TNF- a has shown potent inhibitory effects on tyrosine
phosphorylation of insulin receptor substrates in muscle and adipose tissue 
preparations (Svedberg et al., 1992). Although plasma TNF- a levels were negatively 
correlated with insulin stimulated glucose metabolism in humans, administration of 
TNF- a antibodies to humans did not improve insulin sensitivity (Ofie et al., 1996). 
These results were contrary to those previously found in Zucker rats (Hotamisligil and 
Spiegelman, 1994). Other adipocytokines which have also been implicated in the 
development of insulin resistance are leptin, resistin, and adiponectin. Briefly, leptin 
is an afferent signal molecule that interacts with the appetite and satiety centres in the 
brain to regulate body weight. A positive association has been found between leptin, 
BMI, and fasting insulin (Ahren et al, 1997), Conversely, low plasma adiponectin 
concentrations are found in obese individuals and in patients with diabetes and 
ischemic heart disease (Hotta et al., 2000). Lastly, the adipocytokine resistin has been 
proposed to be the link between obesity and insulin resistance as increased amounts of 
resistin mRNA were found in abdominal adipose depots compared to those in the 
thigh, suggesting an increased risk of type 2 diabetes as a result of central obesity and 
higher resistin levels. (McTernan et al., 2002; Steppan et al., 2001).
1.2.2.2. Insulin Sensitivity Measurements
The recognition of insulin resistance has spurred the development of 
measurements which are able to identify subjects at high risk of developing this 
syndrome. The gold standard of measuring insulin sensitivity is the euglycaemic 
insulin clamp technique (DeFronzo et al., 1979). However due to the difficulty of 
performing this test routinely, several other measurements of insulin sensitivity have 
also been developed. The simplest is the Homeostasis Model Assessment (HOMA) 
which uses only the fasting glucose and insulin values, the formula used, is: HOMA= 
22.5/FPGxFPI (Matthews et al., 1985). HOMA has been shown to be a reliable 
measure of in vivo insulin sensitivity in humans when compared with the euglycaemic 
insulin clamp (Bonora et al., 2000). However the Quantitative Insulin Sensitivity 
Check Index (QUICKI), which is based on the logarithmic and the reciprocal of the 
insulin-glucose product, was shown to correlate better than HOMA with insulin 
sensitivity across the entire spectrum of insulin sensitivity except in normal subjects 
(Katz et al., 2000). To correct for this, the modified Quantitative Insulin Sensitivity
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Check Index (QUICKI) was developed which includes fasting NEFA levels according 
to the formula: QUICKI = l/(Log (Gb) +Log (Ib)+ log (NEFAb)). Where Gb, lb and 
NEFAb are the fasting glucose, insulin and NEFA levels respectively. Inclusion of 
NEFA was shown to increase the association with insulin sensitivity in non-obese 
individuals (Perseghin et al., 2001). Finally the insulin sensitivity index (ISI) for 
whole body insulin sensitivity, developed by DeFronzo and colleagues, is calculated 
using OGTT plasma glucose (PG) and insulin (PI) levels, (Matsuda and DeFronzo,
1999): 10 000 divided by the square root of ([FPGxFPI] x ([mean PG x mean PI]), 
where PG is expressed in mg/dl (0.055lmmol/L) and PI in pH/ml (6pmol/L). All 
methods have been validated although, at this point of time, the QUICKI and ISI 
methods are probably preferred
1.2.2.3 Insulin Secretion
It is now well established that hyperinsulinaemia precedes the development of 
type 2 diabetes (DeFronzo et al., 1992). A person with fasting plasma glucose levels 
of 6.6 mmol/L will secrete twice the amount of insulin compared to a person with a 
normal (3.6-6! mmol/L) fasting plasma glucose level. Once the fasting glucose 
exceeds 7.8 mmol/L, a progressive decline is seen in postprandial insulin levels 
(DeFronzo et al., 1989) (Fig 1.3).
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F ig  1.3:. Relationship of fasting blood glucose and fasting plasma insulin levels. As 
the fasting blood glucose levels rises above baseline there is a corresponding increase 
in fasting plasma insulin. Once the fasting blood glucose has reached 7.8 mol/L there 
is a progressive decline in fasting insulin levels. Adapted from DeFronzo et al, 1989.
Normal insulin secretion is biphasic, with an early burst of insulin release 
within the first 10 min, followed by a progressively increasing phase of insulin 
secretion that persists as long as the hyperglycaemic state is present. The early phase 
is important in priming the liver and other insulin target tissues. There are two stages 
in the development of insulin secretory defects: irregular pulsatile insulin secretion 
and decreased absolute insulin secretion. There is evidence that irregular pulsatile 
insulin secretion marks the loss of the first phase insulin secretion. It has been 
suggested that die loss of the first phase insulin release is the first detectable 
abnormality in individuals who will eventually develop diabetes (Efendic et al., 
1988). The incretins such as gastric inhibitory peptide, better known as glucose- 
dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) may 
be important determinants of the early insulin secretory response to a mixed-meal 
intake (Orsakov, 1992).
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1.2.2.3. Glucose-Dependent Insulinotropic Peptide (GIP)
Almost a 100 years ago an anti-diabetogenic effect was reported using an 
extract from the duodenal mucous membranes (Moore et al., 1906). Already at that 
time the authors postulated that using an extract such as this could be used to treat 
diabetes. Purification of extracts which eliminated the presence of cholezystokinin- 
pancreozymine (CCK-PZ) demonstrated inhibitory effects on gastric acid secretion, 
and the purified peptide was therefore called “Gastric Inhibitory Peptide” (Brown et 
al., 1970). However classical experiments performed by Elrick et al. (Elrick et al., 
1964; McIntyre et al., 1965) had demonstrated that intestinal peptides must also be 
involved in the regulation of postprandial insulin secretion. They had found that the 
postprandial insulin response after an oral glucose tolerance was much greater than 
after an intraveneous glucose load which raised blood glucose levels to a level 
equivalent of the oral load. Subsequently, the stimulation of insulin secretion by GIP 
was demonstrated in humans (Dupre et al., 1973) and the alternative name: “Glucose- 
dependent Insulinotropic Polypeptide” was proposed which retained the original 
acronym.
GIP is secreted by the neuroendocrine K-cells of the duodenum and proximal 
jejenum (Buchan et al., 1978) , the highest levels, measured by radioimmunoassay, 
are found in the upper jejunum (Morgan et al., 1978). Ingestion of a carbohydrate and 
lipid rich meal has been shown to be the main stimulus for the secretion of GIP and is 
proportional to the amount of glucose or fat in the meal. Secretion of GIP is therefore 
an indicator of the size o f the meal.. The biological half-life of the intact GIP (1-42 
amide) is estimated to be 7 minutes, it is cleaved by the enzyme dipeptidyl-peptidase 
IV (DPP-IV) at the 1SIH3 terminus to the biologically inactive fragment GIP (3-42 
amide) (Meier et al., 2002).
Physiological effects o f GIP include (Creutzfeldt and Nauck, 1992), increased 
insulin secretion in the presence of glucose (Nauck et al., 1986) and stimulation of B- 
cell proliferation (Trumper et al., 2001). Unique to GIP seems to be its stimulating 
effect on lipoprotein lipase activity and it has been shown to stimulate fatty acid
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synthesis in omental adipose tissue in the rat (Oben et al., 1991). Although the 
secretion of GIP is normal in type 2 diabetes, the insulinotropic effect of GIP is 
markedly decreased (Nauck et al., 1993). It has been postulated that the lack of 
insulinotropic effect is due to a defect of the B-cells to respond to GIP (Meier et al., 
2002). Interestingly, the response to GIP is also muted in first-degree relatives of 
patients with type 2 diabetes which would indicate that the impaired insulinotropic 
effect of GIP may be inherited and be a risk factor for diabetes (Meier et al., 2001).
1.2.2.4. Glucagon Like Peptide-1 (GLP-1)
GIP and GLP-1 share many common physiological properties, a comparison 
of the properties of these two incretins is summ’arised in table 1 .1 .
GLP-1 is a 30 amino acid derivative of proglucagon (PG), a 160 amino acid 
prohormone. PG gives rise to glucagon, GLP-1 and GLP-2 and other peptide 
sequences of yet unknown biological activity (Orsakov, 1992). Post-translational 
processing of PG occurs in the A-cells of the islets of Langerhans in the pancreas and 
produces glucagon, glicentin related pancreatic polypeptide, major PG fragment and a 
small amount of biologically inactive GLP-1. In the ileum, colon and rectum, the 
enteroglucagon-producing cells (L-cells) produce glicentin, oxyntomodulin, GLP-1, 
and GLP-2 (Fig 1.4). The amino acid sequence of GLP-1 is 100% homologous in all 
mammalian species (Holst, 1994; Orsakov, 1992), suggesting that is plays an 
important physiological role.
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Fig 1.4: Schematic representation of post-translational processing of proglucagon in the small 
intestine. The numbers indicate positions of amino acid residues and cleavage sites. 
GRPP=glicentin related polypeptide; GLP-l=glucagon-like peptide. Adapted from (Perfetti and 
Merkel 2000).
GLP-1 is secreted in response to intraluminal glucose (Elliott et al., 1993; 
Ilolst, 1994; Nauck et a l, 1993; Orsakov, 1992). The distribution o f L-cells that 
produce GLP-1 is greatest in the distal small intestine and colon. Nevertheless GLP-1 
is released in the early phase of meal absorption (1999). The proposed mechanism for 
a meal induced GLP-1 stimulation is through neural signals, as it has been shown that 
a vagotomy blocks the GLP-1 response to intestinal lipids.
GLP-1 receptors are highly expressed on the membranes of the B-cells in the 
pancreas. The GLP-1 receptor belongs to the scvcn-transmcmbranc G-protcin-couplcd 
receptor family, which, in turn, belongs to the glucagon/secretin/vasoactive intestinal 
peptide receptor superfamily (Fehmann et al., 1995; Holst, 1994). In addition to 
stimulating the release of insulin, other mechanisms through which GLP-1 regulates 
glucose metabolism include inhibition of glucagon (Holst, 1994; Nauck ct al., 1993; 
Nauck et al., 1997; Orsakov, 1992; Wettergren et al., 1993) and the inhibition of 
gastric motility (Naslund et al., 1999). The half-life of intact circulating GLP-1 is only
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l-2min. The two terminal NH2 amino acids are cleaved from GLP-1 by the same 
protease which degrades GIP, DPP-IV.
The entero-insular axis is estimated to be responsible for 50% of postprandial 
insulin release, of this, GLP-1 and GIP together account for probably more than 80% 
of the intestinal incretin effect (Holst, 1994). In obese women the GLP-1 response has 
been found to be attenuated (Ranganath et al., 1996) but is increased in older women 
(Ranganath et al., 1998). Postprandial GLP-1 levels are also reduced in type 2 
diabetes (Vilsboll et al., 2001). Intravenous administration of GLP-1 will increase 
secretory burst mass and amplitude of pulsatile insulin secretion in both healthy 
individuals and those with type 2 diabetes (Ritzel et al., 2001). GIP, however tends to 
lose its effectiveness in patients with type 2 diabetes (Nauck et al., 1993). Therefore 
increasing postprandial levels of GLP-1 either through stimulating secretion, 
inhibition of DPP-IV, development of analogues or by injection might be a possible 
treatment option for type 2 diabetes.
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T a b le  1 ! :  C o m p ariso n  o f  ph y sio lo g ic  e ffec ts  o f  G lu co se -d ep en d en t Insu lino trop ic  
P o lypep tide  (G IP ) and  G lu cag o n -L ik e  P e p tid e -1 (G L P -1 )
GIP GLP-l Reference
Insulin secretion in 
normal subjects
Stimulation Stimulation (Dupre et al., 1973) 
(Holst, 1994; Nauck et 
al., 1993)
Insulin secretion in 
type 2 diabetes
Reduced stimulation Stimulation (Holst, 1994; Nauck et 
al., 1993)
Insulin extraction Reduction No effect (Kind mark et al., 
2001)
Glucagon secretion No effect Suppression (Nauck et al., 1993; 
Orskov et al., 1988)
B-cell proliferation Stimulation Stimulation (Trumper et al., 2001; 
Zhou et al., 1999)
Gastric emptying (?) Deceleration (Wettergren et al., 
1993)
Gastric acid 
secretion
No effect Slight suppression (Nauck et al., 1992; 
Tolessa et al., 1998)
Lipogenesis Stimulation Stimulation (Beck and Max, 1983; 
Oben et al., 1991)
Satiety ? Enhancement (Flint et al., 1998)
Body weight Enhancement9 Reduction (Zander et al., 2001)
A dap ted  from  M e ie r et al. (M e ier et a l.. 2002).
/. 2.2.4.1 GLP-1 Analogues and DPP-IV Inhibitors
Use of GLP-1 itself as a treatment is limited due to the short half-life of GLP-1.
Development of GLP-1 analogues are of therefore of great interest. Currently two
peptide analogues have advanced to clinical trial: the reptilian peptide exendin-4 and a
derivative of GLP-1, NN2211. Exendin-4 has a 53% sequence homology to GLP-1,
is a agonist to the GLP-1 receptor and is resistant to DPP-IV (Egan et al., 2002).
Single subcutaneous injections of exendin-4 decreased the fasting plasma glucose
levels to the same extent as overnight administration of GLP-1 in type 2 diabetic
subjects. Similar to native GLP-1, this effect was accompanied by increased levels of
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insulin and decreased levels of glucagon (Kolterman et al., 2003). Administration of 
exendin-4 before a meal, resulted in a reduction in the rate of gastric emptying, 
reductions in glucagon levels with resultant reductions in. postprandial glycaemia 
(Kolterman et al., 2003). Two longer term studies (4 weeks) with exendin-4 showed 
significant reductions in HbAlc (Egan et al., 2003; Fineman et al., 2003). No serious 
episodes of hypoglycaemia were reported in either study, however 15-30% of subjects 
experienced nausea.
The second analogue used in clinical studies is a long-acting derivative of GLP- 
1: NN2211. This compound is composed of GLP-1 covalently linked to a 
hexadeconyl residue, this causes it to bind to albumin which extends the half life of 
the GLP-1 NN2211 to approximately 12h (Elbrond et al., 2002). Administration o f a 
single subcutaneous injection increased meal-stimulated insulin levels and lowered 
postprandial glucose levels (Juhl et al., 2002). As with exendin-4, gastrointestinal side 
effects again occurred. Long-term trials will need to be undertaken to assess the 
clinical utility of these products.
To overcome the limitation of the extremely short half-life of GLP-1, DPP-IV 
inhibitors have been developed. The DPP-IV inhibitor NVP-DPP728 has been 
reported to reduce glucose and insulin levels throughout the day, and reduce HbAlc 
and fasting plasma glucose levels after 4wks of treatment in type 2 diabetic subjects 
(Ahren et al., 2002).
Whichever mechanism is used, elevation of GLP-1 levels might therefore be a 
valuable treatment strategy in type 2 diabetes.
1.2.3. Treatment of Type 2 Diabetes
Treatment of diabetes is now more aggressive as tight glucose control has been 
shown to reduce the risk o f microvascular complications in both type 1 and 2 diabetes 
(Diabetes Control Trial, 1996; Turner et al., 1996). Diet remains the cornerstone for 
the treatment of diabetes. Dietary guidelines vary to some extent between countries 
and agencies, a comparison o f recommendations as given by the European
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A sso c ia tio n  fo r  th e  S tu d y  o f  D iab e tes  (E A S D ), the  C a n a d ia n  D iab e tes  A sso c ia tio n  
an d  the  A m e ric an  D ia b e te s  A sso c ia tio n  are  g iv en  in  tab le  1.2.
Table 1.2: C om parison o f  international nutritional guidelines for the treatm ent o f  type 2 
diabetes.
Agency EASD CDA ADA
Year of Publication
2 000 2 0 0 0 2002
Protein 10 -20% 15% 15-20%
• '' vegetable protein 
recommended
' ;]/ 'j:-/ ft. V • •
Fat:
T ota l 2 5 -3 0 % 2 5 -3 0 %
S a tu ra ted < 1 0 %  (incl. trans) < 1 0 % < 7-10%
M o n o u n sa tu ra te d 6 0 -7 0 %  (incl. CHO) 6 0 -7 0 %  (incl. CHO)
P o ly u n sa tu ra ted < 1 0 % < 10% I o ox
T  ra n su n sa tu ra te d
’■ • ' : :
L o w  in take L ow  in take L ow  in take
Carbohydrate: 4 5 -6 0 % 5 0 -6 0 % 6 0 -7 0 %  (incl. MUFA)
F ib re H igh  F ib re 2 5 -3 5 g -
T y p e  o f  C H O L o w  G l L ow  G l -
; 7■ ' • . • f  • ■
Cholesterol < 3 0 0 m g - < 2 0 0 -3 0 0 m g
Reference [EASD , 2000] (W olever et al., [AD A, 2002]
1999)
EASD , E uropean A ssociation for the Study o f  Diabetes; CD A , Canadian Diabetes 
A ssociation; A D A , A m erican A ssociation Diabetes Association.
18
As can be seen from table 1.2, recommendations from the EASD and CDA are 
veiy similar, the notable exception is the ADA, who did not support the concept of the 
glycaemic index (GI) or a high fibre diet. Their position was that, although low 
glycaemic index foods may produce a lower postprandial glycaemic response, there is 
not enough long-term evidence in either type 1 or type 2 diabetes to warrant use of the 
glycaemic index as a treatment strategy. In addition they suggested that the likelihood 
of people adhering to such a diet was low [ADA, 2002]. However a recent statement 
issued by the ADA (Sheard et al., 2004) reversed this position and the ADA now 
allows that the glycaemic index “can provide an additional benefit over that observed 
when total carbohydrate is considered alone”. A meta-analysis of the effect of low 
glycaemic index diets by Brand-Miller et al (Brand-Miller et al., 2003) showed that 
low GI diets had a small but clinically significant effect on medium-term metabolic 
control of diabetes which was comparable to pharmaceutical agents which also lower 
postprandial glycaemia. Currently a multi-centre trial on the effectiveness of the GI is 
underway in Toronto, which hopefully will help establish the usefulness of the GI in 
the treatment of diabetes in tire near future.
Many medications are available for the treatment of diabetes. A brief 
description of the different available drugs is given together with their mechanism of 
action:
S u lp h o n y lu r e a s ,  such as glyburide, glipizide and glimepiride which stimulate the 
secretion of insulin by augmentation of potassium channel activity in the pancreatic 
islet cells.
M e g lit ln id e s , non sulphonylurea agents that are also insulin secretagogues; 
B ig u a n id e s ,  such as metformin, reduces hepatic glucose production in some patients 
and increases peripheral utilization;
A lp lia -g lu c o s id a s e  inhibitors such as acarbose, competitively inhibits the ability of 
enzymes in the small intestinal brush border to break down oligosaccharides and 
disaccharides into monosaccharides. In this way these drugs effectively compensate 
for the defective early-phase insulin release by slowing the absorption of sugars from 
carbohydrate; .
T h ia z o l id in e d io n e s  such as Rosiglitazone and Pioglitazone appear to activate 
peroxisome proliferator-activated receptor gamma, leading to increased glucose
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transporter expression. Improvements in insulin sensitivity have been observed in 
liver, muscle and adipose tissue.
Finally, there is an extensive choice of short, intermediate and long acting 
insulins.
Although all of the above mentioned drugs are of undoubted benefit there are 
also drawbacks: sulphonylureas can induce weight gain and hypoglycaemia, alpha- 
glucosidase inhibitors often are accompanied by gastric symptoms, and adverse 
reactions to metformin are not uncommon. In addition, despite the range of 
medications available, diabetes control often remains sub-optimal, therefore new 
treatments continue to be of interest.
Two new novel treatments we have explored are the viscous fibre, konjac- 
mannan and the root, American ginseng. A description of the properties and studies 
utilising these two compounds follows:
1.3. Viscous Fibres in General and the Viscous Fibre Koniac- 
mannan (Amorphallus Koniac. K Koch) in Particular
1.3 .1  I n t r o d u c t io n
Epidemiological studies have suggested a strong link between intake of dietary 
fibre and reduced risk of heart disease (Bazzano et al., 2003). A recent review 
identified 9 prospective trials which examined the relationship between risk of 
developing coronaiy heart disease (CHD) and dietaiy fibre intake (Kushi et al., 1999). 
Seven out of the 9 trials found a significantly lower risk of CHD in those who 
consumed greater amounts of fibre. Results from studies which specifically looked at 
the effect of soluble fibre, are less consistent (Bazzano et al., 2003; Kushi et al., 1999; 
Liu et al., 2002; Pietinen et al., 1996). Only two of these studies showed a significant, 
inverse relationship between soluble fibre and risk of CHD after adjustments were 
made for multiple confounding risk factors (Bazzano et al., 2003; Pietinen et al.,
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1996). These disappointing results might have been due to the many confounding risk 
factors in epidemiological trials, or alternatively it might be due to the relatively small 
amount of soluble fibre found in a typical, low fibre, “Western” diet, which might be 
insufficient to exert a significant beneficial effect.
Soluble fibre is of interest however as it has been shown to improve 
postprandial glycaemia in acute studies and reduce cardiovascular risk factors such as 
serum cholesterol levels and especially LDL-cholesterol levels in longer-term 
randomised controlled trials.
1 .3 .2 . M e c h a n is m  o f  A c tio n  o f  V isc o u s  F ib r e s
Early work demonstrated that incorporation of viscous, un-absorbable plant 
polysaccharides such as guar and pectin into test meals, reduced postprandial 
glycaemia in healthy and type 2 diabetes subjects (Jenkins et al., 1976; Jenkins et al., 
1977). The effect was independent of endogenous insulin secretory ability (Jenkins et 
al., 1976). It had been observed that fibres with the greatest viscosity caused the 
greatest reduction in postprandial glycaemia (Jenkins et al., 1978). It was 
hypothesised that the reduced postprandial glycaemia observed was due to the ability 
of the fibre to form a gel in the small intestine which slowed the rate of diffusion of 
nutrients from the small intestine (Jenkins et al., 1978). This hypothesis was 
confirmed by a study in pigs which had been fed either a control diet or a diet to 
which guar gum was added at a concentration of either 20 or 40g/kg. Blood samples 
were taken simultaneously from the hepatic portal vein and the mesenteric artery. 
Jejunal digesta was also collected. Absoiption of glucose was significantly reduced by 
both guar concentrations and was directly related to the concentration of the guar in 
the diet. Furthermore there was an inverse relation between the viscosity of the jejunal 
digesta and the rate of glucose absorption (Ellis et al., 1995). Reduction in gastric 
emptying might also play a part in the mechanism of action of viscous fibres (Leeds et 
al., 1981) but not malabsorption (Jenkins et al., 1978).
Guar administration is also associated with a sustained suppression of 3- 
hydroxybutyrate and NEFA production (Jenkins et al., 1980). In addition,
p o stp ran d ia l leve ls o f  G IP  (E llis  e t a l., 1995; Je n k in s  et a l., 1980; M o rg an  e t al., 1979) 
and  en te ro g lu c a g o n  (Je n k in s  e t a l., 1980) a re  red u ced  w h en  g u a r is a d d ed  to  a tes t 
m ea l, d e m o n s tra tin g  th a t th e  g u t e n d o c rin e  re sp o n se  can  be  m an ip u la ted  by  
in te rv en tio n s  w h ich  a lte r  the  pa tte rn  o f  c a rb o h y d ra te  ab so rp tio n .
S everal fac to rs  have  been  im p lica ted  in th e  m ec h an ism  o f  ac tio n  fo r th e  lip id  
lo w erin g  e ffe c t seen  w ith  v isco u s  fib re: in c rease  in faecal n eu tra l s te ro l an d  b ile  ac id  
ex cre tio n  (C h en  e t a l., 20 0 3 ), inh ib ition  o f  c h o le s te ro l a b so rp tio n  in th e  je ju n u m  
(E b ih a ra  and  S ch n eem an , 1989), red u ced  b ile  ac id  a b so rp tio n  in th e  ileu m (K iriy am a  
e t a l., 1974) and  im p ro v em en t in p e rip h e ra l in su lin  sen s itiv ity  (V u k san  e t al., 1999a).
A s v isco sity  h as  been  sh o w n  to  be  im p o rtan t in th e  e ffic a c y  o f  v isc o u s  fib res , 
k o n jac  m annan , a novel so u rce  o f  fib re , is o f  in te res t in th a t it re p re se n ts  a 
p o ly sa cc h a rid e  w ith  o n e  o f  the  h ig h es t v isc o s itie s  (D o i et a l., 1981) (F ig  1.5).
Fig 1.5. Changes in viscosity with tim e o f  pectin, guar gum  and konjac flour (Doi et al., 
1981).
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1.3.3. History and Chemical Structure of Koniac Mannan Fibre
T h e  tu b e r  ro o t o f  th e  k o n jac  p lan t has been 
u sed  fo r  o v e r a  th o u sa n d  y ears  in A s ia  as  a fo o d s tu ff  
an d  a  fo lk  rem ed y . W ritten  e v id e n ce  o f  th e  use  o f  
k o n jac  as  a  food  in C h in a  an d  Jap an  a p p ea rs  in th e  
s ix th  cen tu ry  A D  in an  a n c ien t Ja p a n ese  w o rk  
en titled , “ M a n -y o u -sh u u ” . H isto rica lly , k o n jac  w as 
u sed  to  “ c le an se  o n e 's  d ig es tiv e  trac t o f  irrita ting  
an d  p o iso n o u s  su b s ta n c es  and  k eep  o n e 's  in te rnal 
o rg a n s  c le a n ” [K o n n y ak u  Inc, 2 0 0 4  ].
N*w tulxo
Fig 1.6: D raw ing o f  a konjac plant show ing 
the root from which the viscous fibre is 
extracted
K o n jac , a  p e ren n ia l p lan t, is u n iq u e  to  A s ia  and  
sp ec ia lly  cu ltiv a ted  in Jap an  (F ig  1.6). B y  g r in d in g  th e  roo t, f lo u r  is o b ta in ed  w h ic h  is 
th en  m ade  in to  a  ru b b e ry  gel. K o n jac  f lo u r a lso  has b een  u sed  in th e  U n ited  S ta te s  
s in ce  th e  tu rn  o f  th e  cen tu ry  and  is lis ted  by  th e  F D A  on  th e  “ G e n e ra lly  R e co g n ise d  
as  S a fe ” lis t and  in C a n ad a  it h as  “ novel fo o d ” sta tus .
T h e  f lo u rs  m ain  c o n stitu e n t is a h ig h ly  v isc o u s  m an n a n , a  p o ly sa cc h a rid e  ch a in  
c o n ta in in g  g lu co se  an d  m an n o se  in a  m o la r  ra tio  o f  1:1.6 w ith  B - l - 4  lin k ag es (F ig  
1.7).
CB.OH a OR H «  C H 0 H
c.r~ 0 —  >—-U h/— «
8 OH CR,OX / R  H CK,OX H H C 8 .0H  H OCOCN, CM.OH
/
R H CR.OH /
HO/ 4j< R /
ca,uH h o*i
Fig 1.7: Structure o f  konjac m annan fibre.
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1.3.4 Acute Studies with Koniac Mannan Fibre
When 20g of glucose was fed to healthy subjects alone or with 3 grams of 
fibre added from either psyllium, xanthan or konjac, the results matched the relative 
viscosity of the fibres. In other words, the fibre with the lowest viscosity (psyllium) 
had the highest postprandial glucose results, and konjac, which has the highest 
viscosity, gave the lowest postprandial glucose results. The response after xanthan 
was intermediate between psyllium and konjac (Fig I.8)(Kim et al., 1996). This study 
again confirmed the viscosity hypothesis.
Fig 1.8: Postprandial glycaemic responses to a 20 g oral glucose challenge done alone (O) or 
following 3 g psyllium (O), xanthan (□), or konjac mannan (A). Time points at the same 
time interval with different letters are significantly different (p<0.05). Adapted from (Kim et 
al, 1996)
Combining konjac mannan with another polysaccharide can increases the 
viscosity significantly (Proprietary Technology: Provisional U.S Patent #60/208,090), 
this increase in viscosity is the result of the interaction of the cellulosic backbone of 
other polysaccharides and the mannan backbone of konjac (Kim et al, 1996; Tye, 
1991). The large quantity of fibre needed to cause a significant metabolic effect has 
always been one of the drawbacks of viscous fibre; the advantage of a highly viscous 
fibre blend would be that the dose could be significantly reduced and therefore 
enhance palatability. Our group studied the effect on glycaemic response of 
incorporating a high viscosity konjac mannan polysaccharide blend into a biscuit in
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bo th  hea lthy  su b je c ts  and  su b je c ts  w ith  ty p e  2 d iab e te s  (F ig s  1.9 and  1.10 
re sp ec tiv e ly )(V u k sa n  e t a l., 1992). T h ree  g ra m s o f  th e  k o n jac  fib re  b lend  w a s  a d d ed  
to  50 g ram s o f  av a ilab le  c a rb o h y d ra te  from  th e  b isc u it an d  co m p a red  to  s tan d ard  
w h ite  b read  a lso  c o n ta in in g  50 g  c a rb o h y d ra te . T h e  k o n jac  fib re  b lend  s ig n ific an tly  
re d u ce d  th e  p o stp ran d ia l g ly ca em ia  both  in h e a lth y  su b je c ts  an d  in su b je c ts  w ith  ty p e  
2 d iab e te s . T h e  g ly caem ic  index  o f  th e  fib re  c o n ta in in g  b isc u its  w a s  2 6± 5  and  3 7 ± 6  in 
h ea lth y  and  in ty p e  2 d iab e te s  su b je c ts  re sp ec tiv e ly  (V u k san  e t ah , 1992). T h ese  ve ry  
low  g ly caem ic  index  v a lu es w e re  ach iev ed  u s in g  a lm o s t p h a rm a co lo g ica l d o se s  o f  
k o n jac  m an n an  and  so  im p ro v in g  th e  th e ra p eu tic  po ten tia l o f  th is  fib re .
12.
100
< 1 *
W h i t e  P ro M a n n u riS
B r e a d  B is c u it
Fig 1.9 : Increm ental Changes in G lycaem ia and A rea under the Blood G lucose Curve 
(as glycaem ic index) betw een ProMannan® (konjac fibre blend) Biscuits and W hite 
Bread in 9 healthy subjects. Results are expressed as M ean±SEM , *p<0.05, 
**p<0.001. A dapted from (V uksan et al., 1992)
T im e
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Fig 1.10: Incremental Changes in G lycaem ia and A rea under the Blood G lucose Curve (as 
glycaem ic index) betw een ProMannan® (konjac fibre blend) B iscuits and W hite Bread in 9 
type 2 diabetic subjects. Results are expressed as M ean±SEM , *p<0.05, **p<0.001. (A dapted 
from (Vuksan et al., 1992).
1.3.5 Longer-term Studies with Koniac mannan fibre
L ike  o th e r  v isco u s  fib res , k o n jac  m an n a n  has been  sh o w n  to  lo w er to ta l-  
ch o le s te ro l, L D L -ch o les te ro l and  tr ia cy lg ly ce ro l (A rv ill and  B o d in , 1995; C h en  e t a l., 
2 0 0 3 ; V e n te r  e t a l., 1987), sy s to lic  b lo o d  p re ssu re  (A rv ill an d  B od in , 1995) an d  
g ly caem ia  (D oi e t a l., 1979) w h en  tak e n  as  a  su p p le m e n t. E arlie r, tw o  tr ia ls  w e re  
c o n d u c ted  in o u r  lab o ra to ry , o n e  in ty p e  2 d iab e tic  su b je c ts  an d  th e  seco n d  in 
in d iv id u a ls  w ith  in su lin  re s is tan ce  sy n d ro m e  (V u k san  e t a l., 1999b; V u k san  e t a l., 
2 0 0 0 b ). In the  first s tudy , k o n jac  m an n an  w a s  in co rp o ra ted  in to  b isc u its  and  g iv en  to  
p a tien ts  w ith  type  2 d iab e te s  o v e r  a  th re e -w e e k  pe riod . T h e  p a tien ts  a lso  had  
m ed ica lly  trea ted  h y p e rten sio n  and  h y p e rlip id ae m ia . S erum  fru c to sam in e , se rum  
c h o le s te ro l, L D L /H D L  ra tio , a p o lip o p ro te in  B /A  ra tio , an d  sy s to lic  b lo o d  p re ssu re  
w e re  all s ig n ifican tly  red u ced  fo llo w in g  th e  k o n jac  m an n an  su p p le m e n ted  d ie t 
(V u k san  e t a l., 1999b). In th e  seco n d  stu d y , a 3 w e e k  c ro ss  o v e r, p laceb o  c o n tro lled  
m etab o lic  tria l, in d iv id u a ls  w ith  in su lin  re s is tan c e  sy n d ro m e  w e re  trea ted  w ith  k o n jac  
(V u k san  e t a l., 2 0 0 0 b ). A ga in , s ig n if ic an t re d u c tio n s  in se ru m  fru c to sam in e , to ta l 
c h o le s te ro k H D L -ch o le s te ro l ra tio , and  a p o lip o p ro te in  B w e re  o b se rv ed  (F ig  1 .11). In 
ad d itio n , an im p ro v em en t in in su lin  sen s itiv ity  u sin g  th e  ISI m eth o d  (M a tsu d a  and  
D eF ro n zo , 1999), w a s  o b se rv ed  a fte r  3 w e ek s  on  th e  fib re  b len d .
30 60 90 120
Time (min)
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P<0.001
Total-C LDL
P<0.001
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Fig 1.11: Percent change in serum  cholesterol (Total-C), LD L-cholesterol, Total:H D L- 
cholesterol, LDL:H DL-cholesteroI and A polipoprotein A-1:B after 3 w eeks o f  
supplem entation w ith either a konjac fibre blend (Prom annan® ) or w heat bran (control) 
biscuits in 11 subjects with impaired glucose tolerance. (V uksan et al., 1992)
C o m p are d  to  fo u r o th e r  so lu b le  fib res  (g u a r, p ec tin , p sy lliu m  an d  o a t) th e  lip id  
lo w erin g  ab ility  o f  k o n jac  w a s  sh o w n  to  be  2 -4  tim e s  g re a te r  (B ro w n  e t a l., 1999). 
T h e  d e g ree  to  w h ich  the  k o n jac  fib re  b lend  im p ro v ed  lo n g -te rm  g ly ca em ic  co n tro l 
w as co m p a rab le  to  tr ia ls  u sing  A carb o se .
1.3.6 Viscous fibre and the Second Meal Effect
V isc o u s  fib re , w h en  tak en  w ith  b re ak fa s t, h a s  b een  sh o w n  to  in flu e n ce  th e  
su b se q u e n t m ea l. W hen  h ea lth y  su b je c ts  c o n su m e d  tw o  80  g  o ra l g lu co se  loads, 4 h  
ap art. A d d itio n  o f  2 2 .3 g  o f  g u a r to  th e  firs t load  d e c re ased  th e  rise  in b lood  g lu co se  
an d  insu lin  a f te r  th e  fib re  free  seco n d  m eal by  5 0 %  and  3 1 %  re sp ec tiv e ly  (Je n k in s  et 
a l., 1980). B o th  3 -h y d ro x y b u ty ra te  and  N E F A  ten d e d  to  rise  b e fo re  th e  seco n d  m ea l 
w h en  th e  b re ak fa s t co n ta in ed  no  fib re . N o  c h a n g e s  in GIP an d  e n te ro g lu c a g o n  w e re  
o b se rv ed  (Je n k in s  e t a l., 1980).
V isc o u s  fib re  m ig h t th e re fo re  h av e  a p o ten tia l th e ra p e u tic  ro le  in th e  trea tm e n t 
o f  ty p e  2 d iab e te s  p ro v id in g  a  su itab le  a n d  e ffe c tiv e  m o d e  o f  a d m in is tra tio n  is 
av a ilab le .
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1.4. American Ginseng (Panax quinquefolius L)
A n in cre as in g  n u m b er o f  p e o p le  a re  tu rn in g  to  
a lte rn a tiv e  th e ra p ie s  such  as d ie t su p p le m e n ts  an d  herbs.
In th e  case  o f  he rba l rem ed ies , th e ir  co n su m p tio n  has 
in creased  by  a p p ro x im a te ly  3 8 0 %  from  1990 -1 9 9 7  in the  
U S w ith  an n u a l sa les  e x ce ed in g  $ 3 0 0  m illion  (E isen b e rg  
e t al., 1998). T h is  in c rease  has been  o b se rv ed  d e sp ite  lack 
o f  e v id en ce  to  su p p o rt th e  th e ra p eu tic  v a lu e  o f  m any  o f  
th e  he rba l rem ed ies . A s  o n e  o f  th e  m o st p o p u la r  herbal 
re m e d ie s  is g in se n g  (E isen b e rg  e t a l., 1998), tria ls  
e s tab lish in g  the  m ed ica l e ffic ac y  an d  sa fe ty  o f  g in sen g  
a re  u rg en tly  need ed .
E arlie r s tu d ies  w h ich  h av e  been  c a rried  o u t on  g in se n g  o ften  d o  n o t sp e c ify  
type , age , w h a t pa rt o f  th e  ro o t has  been  u sed , p rep ara tio n , g in se n o s id e  p ro file  e tc  
(V o g le r  e t a l., 1999). T h ere  a re  th irteen  d is tin c t sp e c ie s  o f  g in sen g , th e  m o st 
co m m o n ly  used  sp e c ie s  are: A m erican  g in se n g  (Panax quinquefolius L .), A s ian  
(Panax ginseng C .A . M eyer), Ja p a n ese  (Panax Japonicus C .A . M ey er), san -ch i 
(Panax Notoginseng B u rke  F .H . C h e n ), an d  th e  n o n -p a n ax  sp ec ie s  S ib e rian  
(Eleutherococcus Senticosus). A m e ric an  g ise n g  is in d ig e n o u s  to  O n ta rio , Q u e b e c , 
B ritish  C o lo m b ia  and  W isco n sin , w h ile  th e  o th e r  sp e c ie s  a re  in d ig e n o u s  to  A s ia . 
M an y  b en efic ia l e ffe c ts  a re  a sc rib e d  to  g in sen g , it is o ften  d e sc rib e d  as an 
“ a d ap to g e n ” in th a t it is su p p o sed  to  “ in c rease  th e  re s is tan c e  a g a in s t n o x io u s  o r  
s tre ssfu l in flu e n ce s  w ith o u t im p a irin g  p h y sio lo g ica l fu n c tio n s” (C h o n g  and  
O b erh o lze r, 1988). In trad itio n a l C h in e se  m ed ic in e  it is u sed  a s  a to n ic  an d  to  
g en era lly  en h an c e  w ell be ing . A t th e  p re se n t tim e  c la im s fo r  g in se n g  in c lu d e: 
im p ro v em en t o f  im m u n e  fu n c tio n , e x e rc ise  e n d u ran c e , sex u a l fu n c tio n , g lu co se  
m etab o lism  and  red u ced  risk  o f  c a n c e r  an d  c a rd io v a sc u la r  d ise a se  (V o g le r  e t a l.,
1999). E v id en ce  is e m erg in g  su g g e stin g  a  ro le  fo r g in se n g  in th e  tre a tm e n t o f  
d iab e te s .
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1.4.1. Mechanism of Action of Ginseng on Glucose Metabolism
The mechanism of action of ginseng has been largely unexplored. However, 
based on animal studies, several mechanisms of action of ginseng have been 
suggested: 1 . increase in insulin secretion, 2. changes in glucose transport and 
disposal and 3. slowing of gastric emptying (Hashimoto et al., 2003).
1.4.1.1. Increase in insulin secretion
We observed that administration of 6g of American ginseng increased the 
insulin secretion twofold in the first 45min after a 75g oral glucose challenge (Vuksan 
et al., 2000a). Although it was not possible to measure the first phase insulin response
i.e. the response over the first 5-10min, the relatively early increase of insulin 
suggests that ginseng might be able to influence, if not the first phase, but certainly 
the early phase of insulin secretion. Animal studies support these observations. DPG- 
3-2, a component of ginseng radix, the root of Panax ginseng, lowers the blood 
glucose level and stimulates insulin release in diabetic animals, and was shown to 
stimulate insulin biosynthesis in islets from KK-CAy mice (Waki et al., 1982). 
Perfusion of isolated rat pancreas with a ginseng extract from ginseng radix, 
stimulated an increase in insulin release that was similar to the increase seen when 
sulphonylurea was used. Using the same extract in alloxan diabetic rats, the insulin 
response was increased after ginseng to or above the control responses in normal rats 
(Kimura et al., 1981).
1.4.1.2. Changes in glucose transport and disposal
A water extract of Panax ginseng administered to normal and epinephrine- 
induced hyperglycaemic mice increased GLUT-2 protein in the liver (Ohnishi et al., 
1996). In sheep erythrocytes, Panax ginseng extract increased rates of glucose uptake 
and transport in a dose-dependent manner (Hasegawa et al., 1994).
In rat skeletal muscle and adipose tissue, ginseng has been shown to mediate 
the insulin stimulated glucose uptake (Roy et al., 1998). The ginsenoside Rb2, 
increased the activity of the rate limiting glycolytic enzymes, glucokinase and 
phosphofructokinase, while decreasing the activity of the rate limiting gluconeogenic
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enzyme glucose-6-phosphatase in rat liver preparations (Hasegawa et al., 1994; 
Kimura et al, 1981; Yokozawa et al., 1985a).
1.4.1.3. Slowing o f gastric emptying and absorption
Panax ginseng has been shown to reduce carbachol-induced accelerated small 
intestine transit time in mice, the authors suggested that both an inhibitory effect on 
cholinergic nervous system and direct suppressive effect on muscles were involved in 
the attenuation of the hyper peristalsis (Satoh et al., 2001). Another study 
demonstrated a reduction of glucose and maltose absorption in human duodenal 
mucosa but at the same time they also reported an increase in duodenal muscle 
movement (Onomura et al., 1999). However these studies all used Chinese ginseng 
and it is not clear what the effect of American ginseng is, if any, on gastric motility 
and absorption.
The ginseng root contains many potentially active ingredients such as 
ginsenosides, polysaccharides, flavanoids, daucosterin, mucilaginous substances, 
amino acids, vitamins etc. (Wang et al., 1999; Zhang et al., 1979; Zhang et al., 1980). 
The active ingredients of ginseng are generally assumed to be the ginsenosides (Chen, 
1983; Hasegawa et al., 1994; Ng and Yeung, 1985).
1.4.2. Ginsenosides
1.4.2.1. Structure and Concentration
The accepted nomenclature of the individual saponins named Rx (x = o, 
a,bl,c,d,e,f,gl,g2 ...) is based on the sequence of spots detected after silica gel thin 
layer chromatography. Ginsenosides are tri-terpenoid glycosides (saponins) of the 
dammaran series. They can be divided into three types: oleanic acid, panaxadiol and 
panaxatriol types. Twenty-eight ginsenosides have been identified in the root, stems, 
leaves and flowers and flower-buds of the ginseng plant (Cai P.L., 1982; Kuang and 
Xu, 1982; Shao and Xu, 1982; Zhang et al., 1979; Zhang et al., 1980)(Fig 1.13).
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(20S>Protopanaxadiol
(R,=R,=H)
(R,-Rj=Rj=l I)
Ginsanosldo R( ■■ R,
Rh, Glc H
R$h Glc’-GIc HRd Glc’-Gie Glc
Malonyi-Rd Gle'-GSo’-Mn Gtc
Rb, Glc’-GIc Glc'-A/ap
Mnlonyl-Rb, Glc’-Glc'-Ma Gle’-Aroa
Re Glc’-GIc G tf-h-il
Malonyl-Rc Gic’-Gb’-Ma G'c’-Ara,'
Rbt GltAc'c Glc'-GIc
Malonyl-Rb, Glc’-Glc'-Ma Glc'-GIcRb, Gtc*-G!c Gte'-XvlRa, Glc’-GIc G’c'-Vao‘-Xf(
Ra, gsc’-gsc Gle’-A/a/’-XviRa, Glc’-GIc Gle'Glc’-Xvl
Ginsenosldo R, R, R>
Rh, H M GW
Rg, H ‘ Gie Glc
Rf H H Glc’-GIc
20-Glc-Rf H Glc Glc’-GIc
Rg, H H G’c’-Rha
Re H Glc Glc’-flto
R, Rj
Glc’-GIc Glc
Glc= |M)-<jIijcoso Rl\a= (fL-rhamr.ose 
A rap- u-L-arabinoso (pyranose)
Araf= a-l-arablnoso ((uranoso)
Xyl= p-D-xylose Ma= malonyl
Fig 1.13: S tru c tu re  a n d  n a m e s  o f  th e  3 m a in  g in se n o s id e  c la s s e s  a n d  e x a m p le s  o f  th e  
m o s t  c o m m o n  g in s e n o s id e s  iso la te d  fro m  P a n a x  G in se n g .
The amount and proportion of ginsenosides changes with the number of years 
the ginsengs root is left to grow (Zhang et al., 1980) (Table 1.3), with the highest 
concentrations occurring generally at 4-5 years.
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T ab le  1.3: C o m p a r is o n  o f  S a p o n in  c o n te n t  o f  g in se n g  ro o ts , w h ic h  h a v e  b e e n  g ro w n  fo r 2 -9  
y e a rs  (Z h a n g  e t  a l. ,  1 9 80).
Years Total Saponins
(%)
Rb
(%)
Rg
(%)
Ro
(%)
2 1.97 0.88 0.54 0.13
3 2.2 1.03 0.62 0.17
4 4.75 2.27 1.1 0.40
5 4.6 2.08 1.19 0.21
6 3.84 1.94 0.81 0.29
9 3.81 2.32 0.46 0.40
Ginsenoside content and profile varies between species and within species. 
For example American has a higher ginsenoside content than Asian while Siberian 
ginseng has none (Attele et al., 1999). Presence or absence of certain ginsenosides 
can be used to identify the species, e.g. the ginsenoside Rf is found in Asian ginseng 
but not in American ginseng. (Li et al., 2000). Similarly, ratios of ginsenosides can 
also be used to identify species, a ratio smaller than one in the ginsenosides Rgl/Re 
and Rb2/Rc distinguishes American from Asian ginseng (Chan et al., 2000). The 
variability of ginsenoside content and amount between species emphasises the 
importance of specifying the type of ginseng used, it has been estimated that the 
ginsenoside concentration varies as much as 15-fold in capsules (Harkey et al., 2001).
As mentioned earlier, ginsenoside content varies with the age of the root but 
also with the location where it has been grown. Ginsenosides are not only found in the 
root of the plant, but also in the leaves, stem, berries, root and rootlets. The 
ginsenoside content of American leaves has been shown to be 1.4 fold higher than in 
the root of the same plant. Even though traditional Chinese medicine considers 
products made from the small rootlets to be inferior, the ginsenoside content has been 
estimated to be double than in the prized root body (Liu and Xiao, 1992).
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1.4.2.2. Ginsenoside Absorption and Metabolism
A recent study showed that intact ginsenosides in addition to hydrolysates can 
be absorbed from the human digestive tract and be measured in the circulation and in 
the urine (Tawab et al., 2003). Absorption of ginsenosides is estimated to be quite low 
(less than 5%) (Tawab et al., 2003). It has been estimated that the ginsenosides from 
American ginseng have a half life of about 8 hours once they reach the systemic 
circulation in the rabbit (Chen and Staba, 1980).
1.4.2.3. Physiological Role of Individual Ginsenosides
Using individual ginsenosides, hypoglycaemic effects have also been 
observed. Administration of the protopanaxatriol Rgl at 50mg/kg by stomach 
intubation, decreased glycaemia by 17% compared to placebo in resting rats who had 
been fasting for over 24h (Martinez and Staba, 1984). The 20(S)-protopanaxadiol 
ginsenoside Rbl, has been shown to increase glucose uptake into sheep erythrocytes 
in a dose dependent manner (Hasegawa et al., 1994). The protopanaxadiol Rb2 
reduced glycaemia in streptozotocin induced diabetic rats after 6 days (Yokozawa et 
al., 1985c) and has been shown to increase the activity of the rate limiting glycolytic 
enzymes glucokinase and phosphofmctokinase, while decreasing die activity of the 
rate limiting gluconeogenic enzyme glucbse-6-phosphatase in rat liver preparations 
(Ng and Yeung, 1985). However, /zy/?<?rglycaemic effects have also been observed. 
Insulin stimulated 2-deoxy glucose uptake was significantly inhibited in a dose 
dependent manner by a water extract of Asian ginseng when compared to control in 
3T3-L1 adipocytes (Hong et al., 2000).
Considering the intra and inter-species variability of ginsenoside content these 
different effects might to some extent explain the contrary reports in the literature.
1.4.3. Acute Studies with Ginseng
Animal studies have shown significant hypoglycaemic action by a variety of 
ginsengs (e.g. American, Chinese, Siberian and Korean) (Martinez and Staba, 1984; 
Oshima et al., 1987) using either the root or an extract of the root. Dosages used in
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a n im a l  e x p e r im e n ts  a r e  o f te n  m u c h  la rg e r  th a n  u s e d  in  h u m a n  e x p e r im e n ts  a n d  a re  
th e r e f o r e  d i f f ic u l t  to  in te rp re t .  H o w e v e r  s e v e ra l  a c u te  h u m a n  s tu d ie s  w i th  g in s e n g  
h a v e  b e e n  u n d e r ta k e n , in c lu d in g  p r e v io u s  s tu d ie s  b y  o u r  g ro u p . In  a  s e r ie s  o f  4  
s tu d ie s ,  o u r  g ro u p  r e p o r te d  th a t  A m e r ic a n  g in s e n g  r e d u c e d  p o s tp r a n d ia l  g ly c a e m ia  b y  
1 5 -4 5 % , w h e n  a d m in is te r e d  e i th e r  3 0 - 4 0 m in  b e fo re ,  o r  to g e th e r ,  w i th  a  2 5 g  o ra l  
g lu c o s e  c h a l le n g e  in  s u b je c ts  w ith  d ia b e te s ,  a n d  o n ly  w h e n  g iv e n  3 0 - 4 0 m in  b e fo re  th e  
c h a l le n g e  in  n o rm a l  s u b je c ts  (V u k s a n  e t  a l . ,  2 0 0 1 a ) . T o  id e n t i f y  th e  o p t im u m  d o s e  
n e e d e d , d o s e s  r a n g in g  f ro m  l - 9 g  w e re  u s e d , b u t  a l l  w e re  e q u a l ly  e f f ic a c io u s  (V u k s a n  
e t  a l . ,  2 0 0 0 a ;  V u k s a n  e t  a l. ,  2 0 0 0 c )  s u g g e s t in g  th a t  th e  m a x im u m  e f fe c t  h a s  a lr e a d y  
b e e n  r e a c h e d  w ith  th e  l g  d o se .
Fig 1 !  4.Increm en ta l ch an g e  and  a rea  u n d e r th e  cu rv e  (A U C ) fo r p la sm a  g lu co se  and  insu lin  
fo llo w in g  a 75g -O G T T  (o), o r 6g  A m erica  g in sen g  tak e n  4 0 m in  b e fo re  (A )  a  75g  ora l g lucose  
to le ran ce  tes t in  8 no n d iab e tic  sub jects. P  v a lu es a re  fo r  rep ea ted  m ea su re s  A N O V A  ad ju s ted  
w ith  the  N ew m an  K eu ls  p rocedu re , P < 0 .05 . D a ta  are  m ean± S E M . (U n p u b lish ed
observ a tio n s)
U n l ik e  v is c o u s  f ib re ,  w h ic h  r e d u c e s  b o th  p o s tp r a n d ia l  g ly c a e m ia  a n d  
in s u l in a c m ia ,  g in s e n g  d e c r e a s e s  p o s tp r a n d ia l  g ly c a e m ia  b u t  c a u s e s  a  in c r e a s e  in  
p o s tp r a n d ia l  in s u l in a e m ia  (F ig  1 .1 4 ). T h is  c o n f i r m s  o n e  o f  th e  p o s tu la te d  m e c h a n is m s  
o f  a c t io n  f o r  g in s e n g  ( s e e  1 .4 .1 .1 .)  In  a d d i t io n ,  s in c e  th e  e f fe c t  o f  g in s e n g  w a s  s e e n  to  
b e  th e  s a m e  w h e th e r  th e  g in s e n g  w a s  a d m in i s te r e d  to g e th e r  o r  4 0 , 8 0  12 0  m in  p r io r  to  
th e  m e a l  in  ty p e  2 d ia b e te s ,  th e y  c o n c lu d e d  th a t  g in s e n g  m ig h t  th e r e f o r e  a c t  b y  
in c r e a s in g  th e  g lu c o s e -d e p e n d e n t  in s u l in  r e s p o n s e  (V u k s a n  e t  a l . ,  2 0 0 0 c ) .
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The ability of other ginsengs types to influence postprandial glycaemia and 
insulineamia was also investigated. Eight different ginseng types were studied: 
American, wild-American, Asian, Korean red, Siberian, Japanese, Sanchi and 
Vietnamese ginseng (Sievenpiper et al., 2002). There was a significant effect of 
ginseng type on 90min and AUC glycaemia and AUC insulinaemia (p<0.05). 
However the individual results were variable, American ginseng again lowered 
postprandial glycaemia but Asian ginseng and the non-ginseng species, Siberian 
increased postprandial glycaemia. To determine the role of ginsenosides a stepwise 
multiple regression was performed which showed that an increase in protopanaxadiol 
to protopanaxatriol (PPD:PPT) ginsenoside ratio was an independent predictor for 
reductions at 90min in glycaemia (P =1.39, r2=0.07) and insulinaemia (p=0.26, 
r2=0.07) and in glucose AUC (p=0.25, r2=0.06). Nevertheless they concluded that, 
based on the small r2 values, other components are also involved (Sievenpiper et al., 
2002).
1.4.4 Long-term Trials with Ginseng
Limited long-term data are available. Of the three long-term human studies 
conducted with ginseng, the first showed that supplementation for 8 weeks with 
lOOmg or 200mg/daily of a non-specified type of ginseng extract resulted in 
reductions of HbAlc (Sotaniemi et al, 1995). Results of this study are difficult to 
interpret because of weight loss in the subjects taking ginseng. In the second study, 24 
months of treatment of 3-4.5g/day with Korean ginseng in subjects with diabetes 
resulted in reductions in HbAlc, however primary sources for this article could not be 
found and no further details were reported (Tetsutani et al., 2000). The third long-term 
study was conducted by our group. Using an American ginseng extract in an 8-week 
double-blind placebo controlled crossover trial in 24 subjects with diabetes, 
reductions in fasting glucose, HbAlc, blood pressure and lipids were observed. 
Dosage used was lg ginseng extract taken 40 min before each meal to provide a total 
of 3g/day. A non-significant increase of 25% in fasting insulin levels was also 
observed (Vuksan et al., 2001b; Vuksan et al., 2001c) (Fig 1.14).
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■  Placebo □  G inseng
3 0 1
F P G  F P I  II bA 1C
F i g  1 .1 4 . C o m p ariso n  o f  p e rcen t ch an g e  from  base lin e  in  fasting  p la sm a  g lucose , in su lin , and  
H b A lC  be tw een  p laceb o  and  A m erican  g in sen g  fo llo w in g  8 w eek s  o f  su p p lem en ta tio n  in  24  
ty p e  2 d iabe tic  sub jects. P  va lues a re  fo r  the  be tw een  trea tm en t d iffe re n ce  fo r  ab so lu te  v a lu es 
(A N C O V A  G L M ). D ata  a re  m ean± S E M . F P G = fas tin g  p la sm a  g lu co se , F P I= fasting  p la sm a  
insu lin . (V u k san  et al., 2 0 0 1 b )
1.4.5. Ginseng and Adverse Effects
Based on anecdotal evidence, concerns have been raised that ginseng may 
increase blood pressure (Siegel, 1980). Apart from increases in blood pressure this 
study also reported that 14 out of 133 patients who used ginseng regularly 
experienced diarrhoea, nervousness, insomnia, and skin eruptions. However the 
methods used in this report have been criticised. Recently, Han et al (1998) evaluated 
the changes of diurnal blood pressure in essential hypertensive patients prior to and 
after 8-weeks of 4.5g/day Korean red ginseng treatment. The study demonstrated that 
24hr mean systolic blood pressure (SBP) decreased significantly, with the largest 
decreases observed at daytime (8am-6pm) and dawn (5am-7am). Animal data also 
support these results. Kim et al (1999) demonstrated that increasing levels o f a 
ginsenoside extract relaxed contractions of aortic rings in the presence, but not in the 
absence of the endothelium. These vascular relaxations were mediated by the release 
of NO, which enhanced accumulation of cyclic guanosine monophosphate (cGMP) in 
the aortic rings. Rhodes and colleagues (1995) showed that ginseng enhanced 
formation of citrulline from added arginine, implying synthesis of NO. In our long­
term study, 8 weeks of 3g/day of American ginseng reduced SBP by 5.6mmHg 
(p=0.03) and increased nitric oxide (NO) generation by 6.7% (p=0.03) (Xu Z, 2000).
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Mania has also been related to ginseng intake (Engelberg et al., 2001). However most 
of these side effects have been associated with Asian ginseng and no adverse effects 
have been reported with American ginseng (McGuffm, 1997). The WHO continues to 
endorse ginseng as a herb without known side-effects (Health Canada! 999).
1.4.6 Ginseng - Summary
Both acute and long-term studies with American ginseng indicate a possible 
therapeutic role of ginseng in the treatment of type 2 diabetes. Although the exact 
hypoglycaemic mechanism of American ginseng is still elusive, studies from our 
laboratory strongly suggest enhancement of insulin secretion.
1.5. Rationale for Combining Ginseng and Koniac
Our studies indicate that both ginseng and konjac mannan improve diabetes 
control and reduce cardiovascular risk factors such as serum cholesterol and 
hypertension. The most effective treatment of type 2 diabetes includes increasing 
insulin sensitivity and/or B-cell secretion. Potentially ginseng and konjac can do both: 
Ginseng might act through increasing insulin secretion during the early part of the 
meal (Vuksan et al., 2000a). Its action therefore could be compared to sulphonylurea, 
which also has an insulinotropic effect on pancreatic B-cells. The difference between 
ginseng and sulphonylurea however is that ginseng only seems to stimulate insulin 
release in response to a meal (i.e. a glucose-stimulated insulin secretion). This has 
been illustrated by the acute studies which administered American ginseng 40 minutes 
before the meal and showed that neither glucose or insulin levels changed over the 40 
min period (Vuksan et al., 2000a). The advantage for patients taking ginseng would 
be a reduced risk of hypoglycaemic episodes in the case of postponed or missed meals 
in comparison to patients on sulphonylurea treatment.
Koniac acts through slowing carbohydrate absorption, and so decreasing the 
postprandial glycaemia. Thus the effect o f konjac can be compared to other means of 
prolonging carbohydrate absorption including other viscous fibres, low glycaemic
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index starchy foods, increased food frequency and a-glucosidase inhibitors (e.g. 
Acarbose) used therapeutically in the treatment of diabetes. In addition konjac might 
also improve insulin sensitivity, the mechanism of action of metformin.
Combining ginseng and konjac might therefore result in an additive or 
synergistic effect on postprandial metabolic parameters by meeting two major 
physiological requirements in the treatment of type 2 diabetes.
1.6 Aims and Objectives o f Current Research
The aims of this project were first to establish the acute effect of using the 
combination of konjac mannan fibre and American ginseng on postprandial glucose 
metabolism in type 2 diabetes. At the same time the effect of konjac and ginseng on 
Gl hormones, TAG and NEFA will be determined as these might provide additional 
information on the mechanism of action of these two compounds. Guar gum has been 
shown to reduce postprandial glycaemia to a second or subsequent meal, but it is not 
known whether konjac mannan exerts the same effect or whether ginseng affects the 
response to a second meal. The acute study will therefore be extended to include a 
lunch, or “second meal”, which will allow determination of the effect, if any, of a 
breakfast containing konjac and/or ginseng on the metabolic response to this 2nd 
meal.
If the combination of konjac and ginseng is shown to be effective in 
modulating postprandial glycaemia and insulinaemia, a randomised, crossover long­
term study in subjects with type 2 diabetes will be undertaken. Both treatment arms of 
the study (konjac+ginseng vs control) will be of three months duration. The main 
outcome of the long-term study will be HbAlc, but other parameters such as risk 
factors for cardiovascular disease will also be measured. It is anticipated that prior to 
the long-term study, preliminary work will need to be undertaken to establish the 
optimum administration mode of the konjac fibre and effectiveness of any the 
supplements formulated.
38
The objectives of the following series of experiments were therefore as 
follows:
1. To establish the acute effects of konjac mannan and ginseng alone and in 
combination on postprandial glycaemia in subjects with type 2 diabetes.
2. To establish the acute effects of konjac mannan and ginseng on insulin and GI 
hormone secretion in subject with type 2 diabetes
3. To establish the effect konjac and/or ginseng on the postprandial glucose and 
insulin response to a second meal
4. To formulate effective and palatable products containing konjac mannan.
5. To establish the combined effect of konjac mannan and ginseng on metabolic 
control during a three months, randomised crossover trial in subjects with type 
2 diabetes.
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Chapter 2
MATERIALS AND METHODS
This chapter describes the materials and methods used in the experimental 
work. Protocols for individual experiments will be described in the relevant chapters.
2.1 Equipment and M aterials
2 .1 .1 . E q u ip m e n t
Company Equipment
D .W . B ro o k f ie ld  L td ,  C o o k sv il le , O N Synchro-electric Viscometer
F is h e r  S c ie n tif ic , C a n a d a Thermix Stirrer Model 1205
B e c to n  D ic k in s o n , F r a n k l in  L a k e s ,  NJ Vacutainers:
Sodium Fluoride Potassium Oxalate (2,5&7ml) 
Potassium EDTA (5ml)
Buffered Sodium Citrate (4.5ml)
SSY Gel and clot activator (6ml)
No additives (10ml)
M e d e x , O h io Injector adapter (catheter)
F u t r e x  In c . G a i th e r s b u r g ,  LISA Futrex 5000, total body fat measurements
S a r s te d t  In c , S t  L e o n a r d ,  Q u e b e c Plastic tubes with caps, 7mL
4 0
Owen, Mumford, Oxford, United 
Kingdom
Autolet lancet
Sherwood, Davis & Geek, St Louis, Mo, 
USA
Monolet, sterile lancets
InterScience, Yellow Springs, Ohio, USA YSI 2300 STAT PLUS glucose analyser
Omron Healthcare Inc Omron HEM-907 digital blood pressure device
W.A. Baum Inc Co., Copiague, NY Stanby model sphygmomanometer
Beckman, Palo Alto, CA, USA Refrigerated centrifuge GS-6KR
DiaMed Lab Supplies, Mississauga, ON Eppindorf 1.5ml microtubes
Randox Laboratories Inc, Crumlin, 
United Kingdom
Randox Colorimeter for TAG and NEFA analysis
Alfa Wasserman BV, Woerden, The 
Netherlands
Ace Triglycerides Reagent kit
Randox, Crumlin, United Kingdom NEFA analysis kit
Black and Decker, Towson, Maryland 
USA
Automated breadmaker
2.1.2. Materials:
Company Material
American Association of Cereal Chemists, 
St Paul, MN, USA
Hard Spring Red Wheat (used in day profile 
study, Chapter 4)
International Nutrition Ltd, Markham, 
Ontario
Corn flour
Chai-Na-Ta Corporation, Langley, British 
Colombia
Ginseng capsules
Ensure Abbott Laboratories Limited, 
Saint-Laurent, Quebec, Canada
Ensure liquid meal replacement
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Rougier Inc, Chambly, Quebec Glucodex, 75g glucose drink
SIGMA Chemical Company, St Louis, 
USA
Aprotinin
FiberJohnson, Toronto, On, Canada konjac mannan KJM 3, mesh size unknown
Fiber Tech Co, Gyeouggi, Korea Konjac mannan fibres: KJM1: 100-250 mesh 
size, KJM 2: 40-80 mesh size
Gumix International Inc, Fort Lee, NJ, 
USA
Xanthan gum Type KF, control no 
705/43/18907
Grain Process Enterprises Ltd, 
Scarborough, Ontario
White wheat bran control supplement for 
long term study
Broda Farm, ON Ginseng root
Kensington Bakery,Tor onto, ON Viscous fibre blend bread
Robin Hood, Markham, ON White all purpose flour
Fleischmann’s Yeast, Lasalle, Quebec Fleischmann’s quick rise instant yeast
2.2 Methods
2.2.1. Rheology Measurements
Viscosity was measured using a Synchro-electric Viscometer (D.W. 
Brookfield Ltd, Cooksville, ON), which measures the torque on a rotating spindle by 
means of a calibrated spring. Readings are made from a 0-100 scale on the dial. In this 
study spindle E and shear of 12 rpm was used and a constant temperature of 22°C was 
maintained. Viscosity in poise was calculated by multiplying the dial reading by the 
factor (3.90) corresponding to the viscometer spindle (E) and speed (12rpm) 
combination utilised (Brookfield Helipath Stand Spindle Factors, Stoughton MA,
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USA). The fibres were mixed at a 1% concentration (1.5 g in 150 ml water). 
Measurements were taken at 15, 30, 45, 60, 90, 120, 180 min and 24hr.
2.2.2. Preparation of Fingerprick tubes
Fingerprick blood samples were collected in specially prepared tubes. To 
prepare the tubes, seven ml of distilled water was mixed with the contents of three 
potassium oxalate, sodium fluoride vacutainer tubes, 50pil of this solution was then 
pipetted into 7ml tubes (Sarstedt, St Leonard, Quebec). Seven ml of water was used 
together with 3 potassium oxalate tubes as it corresponds to the volume of blood 
intended for the glucose measurement tubes, i.e. assuming 1 drop of blood is 50p.l, 
addition of 3-4 drops of blood to the 50pl of solution pipetted into the Sarsted tube 
will be at the same concentration of 7ml of blood in the 7ml vacutainer tube. The 
Sarstedt tubes were left to air dry for 24h before capping.
2.2.3 Blood Pressure Measurements
During the acute study all blood pressure measurements were made using a 
conventional mercury sphygmomanometer according to Joint National Council VI 
(N1H,1997) criteria where each measurement was repeated 3 times, separated by 2 
minutes. However for the long-term study a digital blood pressure monitor was 
purchased, the OMRON HEM 907. This blood pressure monitor had been validated 
and satisfies the Association for the Advancement of Medical Instrumentation criteria 
for accuracy for a non-invasive blood pressure monitoring device (White and Anwar, 
2001). The device can be programmed to take 3 blood pressure readings separated by 
a 1 minute interval. The advantages of using this machine are that blood pressure 
measurements can be made easily and are not influenced by the person who collects 
the data.
2.2.4 Body Fat Determination
The Futrex 5000 utilises near-infrared interactance to determine body 
composition. This method has been shown to correlate with hydrostatic densitometry
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(Conway et al., 1984; Elia et al., 1990). The Futrex 5000 emits near-infrared light in 
the range of 938nm and 948nm, at these frequencies body fat absorbs the light and 
lean body mass reflects it. The Futrex measures the amount of light emitted from the 
light wand and reflected back into it, this provides an estimate of the distribution 
between body fat and lean body mass. The measurement is taken at the mid-point of 
the dominant bicep.
2 .2 .5  M e a s u r e m e n t  o f  c i r c u la t in g  m e ta b o li te s  a n d  h o rm o n e s
2.2.5.1 Collection o f blood samples
Blood samples were obtained at regular intervals using an indwelling catheter, 
kept patent with sterile 0,9% (w/v) saline and inserted into a vein in the cubical fossa 
(see study protocols for further details on blood sampling times). For the acute study 
each blood sample consisted of a total of 11ml of blood and collected into 2 mL 
sodium fluoride tubes for glucose and insulin, 4.5 ml EDTA tubes for NEFA and 
TAG, and 4.5 ml heparinised tubes to which aprotinin (SIGMA Chemical Company, 
St Louis, USA) was added at a concentration of 200 ICIU/ml of blood, within 30 
seconds of the sample being drawn. Heparinised samples were kept on ice at all times 
and centrifuged within 15min at 1500g for 10 min at 4 C. For the long-term study 
additional blood samples were collected using standard vacutainers containing EDTA, 
a gel and clot activator, or sodium citrate. All samples were separated, frozen and 
stored at -70°C until analysed.
2.2.5.2. HbAl c measurement:
Prior to the start of the long-term study a method for determining HbAlc had 
to be chosen. There were two possibilities: the HPLC analysis performed by the 
laboratory at St Michael’s Hospital or the desktop method using the DC A 2000 made 
by Bayer. The DC A 2000 is a compact spetrophotometer that carries out all test 
functions of the system once the reagent cartridge has been inserted in the reaction 
chamber. The advantage of this machine is that the results are available within 6 
minutes so that if there was a problem with the sample and a repeat sample was
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req u ired  th e  su b je c t w o u ld  still b e  a v a ilab le . A s  th e  H b A lc  lev e ls  w o u ld  b e  th e  
p rim ary  o u tco m e  o f  th e  lo n g -te rm  s tudy  th is  w a s  an  im p o rta n t a d v a n ta g e  o f  th e  
m eth o d . H o w ev e r, a lth o u g h  th e  d ev ice  had  been  v a lid a ted  in sev e ra l s tu d ie s  (A rs ie  e t 
a l., 2 0 0 0 ; M a tteu cc i e t a l., 1998) an  in terna! c o m p a riso n  w a s  p e rfo rm e d  u s in g  39  
sam p les . T h e  re su lts  w e re  p lo tted  u s in g  a  B lan d -A ltm an  p lo t (B lan d  an d  A ltm an ,
1995)
Comparison of SMH vs DCA 2000 HbAlc 
Analysis (n=39)
5 10
!
Average HbAlc (%)
Fig 2.1: B land-A ltm an plot o f  the difference o f  the m easurem ents against the average o f  the 
tw o m easurem ents o f  39 sam ples
A lth o u g h  th e re  w a s  a  h ig h ly  s ig n if ic an t co rre la tio n  b e tw ee n  th e  tw o  m e th o d s  
(p < 0 .0 0 2 ) th e re  w e re  severa l o u tlie rs  and  a  d is tin c t p o s itiv e  b ia s  a t h ig h e r H B A lc  
leve ls . It w as th e re fo re  d ec id ed  to  c o n tin u e  to  a n a ly se  th e  sa m p le s  th e  co n v en tio n a l 
w ay  u sing  th e  H P L C  m eth o d  (C o le  et a l., 1978). T h e  in te ra ssa y  C V  fo r th e  H P L C  
m eth o d  w as 2 .4 % .
2.2.5.3 Glucose analysis
2.2.5.3.1.Glucose analysis o f whole blood:
F in g e rp ric k  b lood  sa m p le s  w ere  an a ly se d  fo r  g lu co se  u s in g  th e  Y S I 2 3 0 0  
S T A T  P L U S  (Y e llo w  S p rin g s, O h io , U S A ). T h is  m ac h in e  u ses  a g lu co se  o x id ase  
m eth o d  to  a n a ly se  b lo o d  g lu co se  leve ls . T h e  p ro b e  o f  the  m ac h in e  is fitted  w ith  a
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three layer membrane containing immobilized enzyme in the middle layer. When a 
blood sample is aspirated into the buffer-filled chamber, glucose diffuses through the 
membrane. On contact with the immobilised oxidase enzyme, it is rapidly oxidised, 
producing hydrogen peroxide:
GO
G lu c o se +02   G Iu c o n o -5 - la c to n e  +  H 2O
The hydrogen peroxide is then oxidised at the platinum anode, producing 
electrons. A dynamic equilibrium is achieved when the rate of H2O2 leaving the 
immobilized enzyme layer is constant, which is indicated by a steady state response. 
The electron flow is linearly proportional to the steady state H2O2 production and the 
rate at which H2O2 leaves the immobilised enzyme layer are constant.
The instrument was calibrated with a standard glucose solution prior to 
analysis of the samples using a solution of lOmmol/L glucose and this calibration was 
repeated every 5 samples. The inter-assay coefficients of variation for glucose were 
3.3% and 1.8% at 3.9mmol/L and 14.4 mmol/L respectively.
2.2.5.3.2. Glucose analysis on plasma samples
Plasma glucose from the venous samples were analysed by the Banting and 
Best Core Laboratory (Toronto) again using a glucose oxidase method and a Cobas 
Integra Analyser (Roche Diagnostics). The interassay coefficients of variation were 
3.5% and 1.7% at 4.0 mmol/L and 15.5 mmol/L respectively.
2.2.5.4. Analysis o f insulin:
For the acute study the samples were analysed by the Banting and Best Core 
Laboratory using a double antibody radioimmunoassay (Livesey et al., 1980). In this 
analysis the insulin in the samples competes with a fixed amount of 1251-labeled 
insulin for the binding sites on the specific antibodies. Bound and free insulin are 
separated by addition of a second antibody immunoadsorbent followed by
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centrifugation and decanting. The radioactivity in the pellet is then measured. The 
radioactivity is inversely proportional to the quantity of insulin in the sample. The 
inter assay coefficients of variation for the method at different levels were7.2, 6.6 and 
8.8% at insulin concentrations of 72, 316 and 753pmol/L respectively. The lower 
detection limit of the assay was 22pmol/L
While the long term study was in progress the Banting and Best Lab changed 
the insulin analysis from radioimmunoassay to a electrochemiluminescence 
immunoassay (ECLIA) procedure. With this method the insulin in the samples is 
incubated with a biothinylated monoclonal specific antibody and a monoclonal 
insulin-specific antibody labelled with ruthenium complex. Streptavadin-coated 
microparticles are added and the complex becomes bound to the solid phase via 
interaction of biotin and streptavadin. These microparticles are then magnetically 
captured on the surface of the electrode. Application of a voltage to the electrode 
induces chemiluminescent emission which is measured by a photomultiplier. The 
inter assay CV is between 1.5-2.0%. The lower detectable limit of the test is 1.39 
pmol/L.
Unfortunately one of the limitations of this analysis is haemolysis of the 
samples which interferes with the analysis. Our samples had been collected into 
fluoride oxalate tubes and haemolysis of the samples was quite common. This had 
never been a problem with the radioimmunoassay but the insulin results using this 
analysis on our samples were unacceptable with results ranging from -116pmol/L to 
655pmol/L. Another kit (Mercodia Insulin Elisa, Uppsala, Sweden) which claimed 
that haemolysis would not interfere with the analysis was tried to see if better results 
could be obtained. When test runs were done with this kit using plasma samples to 
which haemoglobin had been added (Table 2.1), the results were very encouraging 
with only the higher levels of haemoglobin causing unacceptable decreases in insulin 
levels (table 2.1).
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Table 2 !: Analysis of plasma insulin levels in plasma samples to which 
haemoglobin had been added at 5 different concentrations to estimate the amount of 
interference.
H gb
fl/L W ell 1
A b s o r b a n c e  
W ell 2 M ean
In su lin
m U/L
In su lin
p m o l/L % c h a n g e  (d e c r e a se )
0 0 .1 9 8 0.201 0.200 15.5 1 0 8 .7 0
0 .5 0 .1 9 9 0 .1 8 9 0 .1 9 4 15.0 1 0 5 .0 3 .4
1 0 .1 8 9 0 .1 8 6 0 .1 8 8 14.4 1 0 0 .7 7 .4
2 0 .1 8 9 0 .1 8 6 0 .1 8 8 14.4 1 0 0 .7 7 .4
4 0 .1 8 0 0 .1 7 8 0 .1 7 9 13.6 9 5 .0 12.6
6 0 .1 6 4 0 .1 7 0 0 .1 6 7 12.4 8 7 .0 19.9
Hgb -  haemoglobin
However when samples from the long term study were analysed using the 
Mercodia ELISA kit, the samples which were badly haemolysed again gave negative 
insulin results. It was decided therefore to analyse insulin and glucose levels on 
samples which had been collected into tubes which had sodium citrate as the 
preservative. Unfortunately these samples were only available for the fasting levels 
and plans to analyse insulin levels on the oral glucose tolerances samples which had 
been collected at the beginning and end of each 3 months treatment period had to be 
abandoned.
2.2.5.5. Immunoassays for analysis GIP and GLP-1
2.2.5.5.I. Plasma GIP
Plasma GIP concentrations were measured using a double antibody 
radioimmunoassay developed by Dr. Linda Morgan and colleagues at the University 
of Surrey (Morgan et al., 1978). The actual analysis of both GIP and GLP-1 was 
kindly performed by Dr Kelly Johnston who at that time was a PhD student with Dr 
Morgan.
The antiserum was raised by immunising rabbits against porcine GIP 
conjugated to ovalbumin and crossreacts 100 % with human, rat and mouse GIP, 
exhibiting negligible cross reactivity with secretin, glucagon, GLP-1, VIP, pancreatic 
polypeptide, insulin. Radiolabelled GIP (125I) was prepared at the University of 
Surrey and was used as the tracer in this assay. Biosynthetic human GIP (Sigma-
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Aldrich, Poole, Dorset) was used as the standard, which was diluted into charcoal- 
stripped serum (CSS), produced at the University of Surrey using Norit A charcoal 
and serum collected from fasted volunteers. Anti-rabbit Sac-Cell (IDS, Tyne and 
Wear, UK), a solid second antibody suspended in cellulose was used in the separation 
of the antibody-bound and free GIP. Each sample was counted against the standard 
curve in order to ascertain the concentration of GIP in each sample.
Low and high QC plasma samples were included at the beginning and the end 
of each assay. The intra-assay coefficient of variation for low and high quality 
control samples at and 60 pmol/L and 383 pmol/L were calculated to be 12.08% (low 
QC) and 4.32% (high QC). The interassay coefficients of variation were 20.16% 
(low QC) and 7.89% (high QC).
2.2.5.5.2. Plasma GLP-1 analysis
Plasma GLP-1 concentrations were measured using radioimmunoassay 
methods already established at the University of Surrey (Elliott et al., 1993). 
Antiserum specific for the C-terminal amidated forms of the peptide was raised in 
rabbits against synthetic human GLP-1 (7-36) amide conjugated to bovine serum 
albumin. The percentage cross reactivity of this antiserum is as follows: 100 % cross 
reactivity with GLP-1 from all species tested and is specific for the C-terminal end of 
GLP-1, requiring a C-terminal amide for cross-reactivity. Negligible cross reactivity 
with GLP-1 (7-37), GIP, secretin, glucagon, GLP-2, VIP, pancreatic polypeptide, 
motilin, somatostatin. Radiolabelled GLP-1 (7-36) amide (125I) was prepared at the 
University of Surrey and was used as the tracer in this assay. Biosynthetic human 
GLP-1 (Peninsula, St. Helens, USA) was used as the standard, diluted into CSS which 
was produced at the University of Surrey using Norit A charcoal and serum collected 
from fasted volunteers. Separation of antibody-bound and free antigen was achieved 
by the use of anti-rabbit Sac-Cell, a solid phase second antibody suspended in 
cellulose (IDS, Tyne and Wear, UK).
Low and high QC plasma samples were included at the beginning and the end 
of each assay. The intra-assay coefficients of variation for low and high quality 
control samples at 13 pmol/L and 39 pmol/L were calculated to be were 12.08% (low
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QC) and 4.32% (high QC). The interassay coefficients of variation were 20.16%
(low QC) and 7.89% (high QC).
2.2.5.6.Triacylglycerol (TAG) and Non-Esterified Fatty Acids (NEFA) 
Analysis:
Both TAG and NEFA from the day profile study described in Chapter 4, were 
analysed in Dr Morgan’s laboratory using the Alpha Wasserman SPACE centrifugal 
analyser
2.2.5.6. I.T  AG Analysis
TAG are triesters of glycerol with fatty acids. The method of TAG 
determination is based on the quantitative measurement of the glycerol liberated from 
die hydrolysis of the TAG. The test involves the following reactions:
llD clSSSTriacylglycerol   glycerol + fatty acids
Glycerol + ATP Glycerol kinase Glycerol-3-pliosphate +ADP
 ►
Glvcerol-3-phosphate oxidase
Glycerol-3-phosphate+02 _________^ dihydroxyacetone-phosphate + H2O2
POD
2H2O2 + 4 Aminoantipyrin + 4-chlorophenoj________ ^quinoneimine +HCL + 4H2O
The absorbance of the quinoneimine is measured bichromatically at 505 
nm/692 nm and is directly proportional to the TAG concentration. Each kit (Ace 
Triglycerides Reagent, Alfa Wasserman, Woerden, The Netherlands) contained a- 
buffer solution and enzyme reagent:
Buffer reagent:
Pipes buffer 40 mmol/L, pH 7.5
4-chloro-phenol 5.0 mmol/L
5 0
Magnesium ions 5.0 mmol/L
Adenosine-5 ’-triphosphate 1.0 mmol/L 
Lipases >150 U/ml
Peroxidase >0.5 U/ml
Glycerol kinase >0.4 U/ml
Sodium Azide 0.05%
The inter-assay coefficient of variation for the assay was 0.110.96 (low QC) and 5.6 
(high QC).
2.2.5.6.2. NEFA Analysis
The NEFA analysis is based on the conversion of NEFA to their copper salts, 
which are extracted into an organic solvent. Tire salts are then complexed with a dye, 
which can be measured colorimetrically at 550nm:
Acvl CoA Svnthethase 
NEFA + ATP + CoA Acyl __________________^ CoA + AMP + PPi
a , ^  Acvl CoA Oxidase „ _ ' _  , _ . , TT _Acyl CoA + 0 2  ________________  2,3,-trans-Enoyl-CoA + H2O2
2H20 2 + TOOS + 4-AA Peroxidase Purple adduct + 4 H20
 ►
4-AAP -  4-aminoantipyrine,
TOOS = N-ethyl-N-(2hydroxy-3-sulphopropyl) m-toluidine,
PPi = pyrophosphate.
The Randox NEFA kit was used to analyse the samples in Dr Morgan’s 
laboratory. Each kit consisted of:
Buffer reagent:
Phosphate buffer 0.04 mol/L, pH 6.9
Magnesium Chloride surfactant 3 mmol/L
Enzymes/Coenzymes:
Acyl Coenzymes A synthetase >0.3 U/ml
Ascorbate oxidase >1.5 U/ml
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Coenzyme A 0.9 mmol/L
ATP 5.0 mmol/L
4-aminoantipyrine 
Enzyme diluent: 
Phenoxyehtanol surfactant 
Maleimide
0.3%
1.5 mmol/L
10.6 mmol/L
A calibration curve was established for each new batch of reagents using the 
supplied 1 mmol/L standard. NEFA concentration could then be calculated using the 
formula: Asampie x Concentration of standard/ A standard- The inter-assay coefficient of 
variation for the assay was 5.96 (low QC) and 7.15 (high QC)
2.2.5.7. Analysis ofTotal-cholesterol, LDL-Cholesterol, HDL-cholesterol,
TAG and C-reactiveprotein
All plasma lipid and CRP analyses for the long-term study described in 
Chapter 7 were earned out at the J. Alick Little Lipid Research Laboratory,
University of Toronto. Throughout the study period this laboratory maintained 
certification in part III of standardization for cholesterol, triacylglycerol and HDL 
cholesterol measurement under the National Heart, Lung, and Blood Institute, Centers 
for Disease Control Lipid Standardization Program (1982).
2.2.5.7.1 Total Cholesterol Measurement:
Total cholesterol was measured using the Bayer (Technicon) RA 1000 
Chemistry Analyzer (Bayer, Germany) using the Technicon method No. SM4- 
0139D91, release date April 1991
The principle of the method is that cholesterol esterase completely hydrolyses 
cholesterol esters to free cholesterol. The free cholesterol, in the presence of oxygen 
and cholesterol oxidase, produces hydrogen peroxide which in turn is used to form a 
quinoneimine dye. The concentration of the dye, measured at 500 nm is directly 
proportional to the cholesterol content in the sample. The inter-assay coefficient of 
variation for the assay were 0.69% (low QC) and 0.63% (high QC).
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Reagents used were: Bayer Cholesterol Reagent: Product No. TO 1-1684-02 
and Bayer Wetting Agent Product No. T01-1970-85.
2.2.5.7.2. TAG Measurement
TAG was measured using the Bayer (Technicon) RA 1000 Chemistry 
Analyzer (Bayer, Germany) using the Technicon Method No. SM4-0173D91, release 
date April 1991.
The analysis is based on the conversion of TAG to glycerol and free fatty 
acids by lipoprotein lipase and is the same as described earlier in section 2.2.5.6.I.
Reagents used were: Bayer Triglyceride reagent: Product No. TO 1-1868-02. 
The inter-assay coefficient of variation for the assay were 1.06% (low QC) and 0.90 
(high QC).
2.2.5.7.3. HDL Cholesterol Measurement
HDL can be isolated (Wamick et al., 1982) in serum by selectively precipitating 
low density lipoproteins (LDL) and veiy low density lipoproteins (VLDL) using 
magnetically enhanced reagent containing dextran sulphate (50,000 MW) and 
magnesium chloride. Applying a magnetic field to the mixture pulls away all 
precipitated lipoproteins, leaving only HDL in the supernatant. Using conventional 
methods to measure cholesterol in the supernatant, the specific HDL cholesterol 
content of the serum can be assessed by multiplying the cholesterol result by 1.1.
Reagents used were: dextran sulfate (M 50,000 ±5000) (Dextralip 50, Wamick 
&Co,. Issaquah, WA), M gCL^O reagent grade, sodium azide NaN3, gentamicin 
sulfate, and chloramphenicol. The inter-assay coefficient of variation for the assay 
was 1.54%.
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2.2.5.7.4. Calculation o f  LDL
LDL-cholesterol levels were estimated using the Friedewald equation 
(Friedewald et al., 1972):
LDL-Chol= Total-cholesterol -  (TAG/2.2 +IiDL-Cholesterol)
The equation is a valid estimation as long as the concentration of TAG is less 
than 4.5mmol/L (Friedewald et al., 1972).
2.2.5.7.5. C-Reactive Protein (CRP) Analysis
CRP was measured on the Behring Nephelometer BN 100 (Burladingen, 
Germany).
Polystyrene particles coated with monoclonal antibodies to CRP were 
agglutinated when mixed with samples containing CRP. The intensity of the scattered 
light in the nephelometer is proportional to the CRP concentration in the sample. 
Result were evaluated by comparison with a standard curve of known concentration 
(Rifai and Ridker, 2001).
The reagents used were: N Reaction buffer, product code: OUMS 61, N Latex 
CRP Mono, Product code: OQIY21, N Latex CRP Mono, Product code: OQIY13, 
N/T Rheumatology Control level 1, product code OQDB13, N/T Rheumatology 
Control level 2, product code OQDC13, N/T Apolipoprotein Serum Control, Product 
code: OUPH07, Reference range: less than 3.8mg/L, sensitivity 0.19 mg/L. The inter­
assay coefficient of variation for the assay were 3.31% (low QC and 3.31% (high 
QC).
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2.2.5.8. Estimation o fLD L  oxidation in serum:
Estimation of DDL oxidation was carried out in the laboratory of Dr David 
Jenkins. LDL oxidation in serum samples was estimated using the procedure by 
Ahotupa et al (Ahotupa et al., 1996). The first step in the estimation ofLDL oxidation 
is the isolation ofLDL by precipitation using buffered heparin. The precipitation 
buffer consisted of 0.064 M trisodium citrate, adjusted to pH 5.0. and contained
50,000 IU/L heparin. Prior to the precipitation, 50pl of EDTA solution was added to
0.5ml of the serum samples and the samples and precipitation reagents were allowed 
to equilibrate to room temperature. After the addition of 3.5ml buffer, the tubes were 
incubated for 1 Omin. The insoluble lipoproteins were then sedimented by 
centrifugation at lOOOg (2100rpm) for 10 min. The pellet re-suspended in 0.5ml of 
saline. The level ofLDL in the samples was estimated using a Sigma Cholesterol kit. 
LDL oxidation was estimated by the baseline levels of diene conjugation in lipid 
fraction of the LDL. Lipids were extracted from 100pi of the LDL suspension using a 
chloroform-methanol reagent, dried under nitrogen and then re-dissolved immediately 
in 900pi cyclohexane. Absorbance was read spectrophotometrically at 234nm. 
Conversion to mM was made using the molar extinction coefficient of 29.5 mM'1.
The CV was 4.4% and 4.5% for within and between-assay precision respectively.
2.3 Ginseng Analysis
Analysis of 4 different ginseng samples, using standard techniques, was 
performed by Dr Amason at the University of Ottawa. A following HPLC-UV 
technique developed for the American Botanical Council Ginseng Evaluation 
Program (Fitzloff et al., 1998) was used.. The levels of three 20(S)-protopanaxatriols 
(Rgi, Rf, Re) and four 20(S)-protopanaxadiols (Rbi, Rb2, Rc, Rd) were identified. The 
HPLC conditions included: chromatograph, Beckman HPLC system; column, reverse- 
phase Beckman ultrasphere C-18, 5 pm octadecylsilane, 250x4.6 mm column; mobile 
phase, de-ionised water and acetonitrile; flow rate, 1.3 ml/min ; UV detection, a 
module 168 diode-array detector set at 203 11m. The ginsenoside standards for Rgi and
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Re were provided by Dr H Fong, University of Illinois and the Rf, Rbi, Rc, Rb2, Rd 
standards were provided by Indofme Chemical Co., Somerville, NJ, USA.
2.4 Data H andling and Statistical Analysis
2.4.1 Area calculation
Incremental areas under the curve were analysed geometrically using the method by 
Wolever et al (Wolever et al., 1991). The area under the curve is based on the blood 
glucose-response curve above the baseline only using the formula:
At/2 + At + (B-A)t/2 + Bt + (C-B)t/2 + Ct + (D-C)t/2 + Dt etc
A, B, C and D represent positive glucose increments, t is the time interval between 
blood samples.
2.4.2. Statistical Analysis
Number Cruncher Statistical Software (Kaysville, Utah) was used for all acute 
studies. For the long term study statistical analyses was performed using the SAS 
software (SAS version 8.2, 2001; SAS Institute). Details of analysis are described in 
each chapter.
2.4.3. Insulin sensitivity calculations:
2.4.3.1 Homeostasis Model Assessment (HOMA):
HOMA was calculated according to the formula: 22.5/FPGxFPI (Matthews et 
al., 1985) were FPG is the fasting the plasma glucose value and FPI is fasting plasma 
insulin value.
2.4.3.2. Quantitative Insulin Sensitivity Index (QUICKI):
The modified QUICKI was calculated according to the formula l/log(fasting 
glucose)+log(fasting insulin)+log(fasting NEFA) (Perseghin et al., 2001).
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2.4.3.3.The insulin sensitivity index (ISI):
The ISI for whole body insulin sensitivity was calculated using OGTT plasma 
glucose (PG) and insulin (PI) outcome, according to the formula by Matsuda et al. 
(Matsuda and DeFronzo, 1999): 10 000 divided by the square root of ([FPGxFPI] x 
([mean PG x mean PI]), where PG is expressed in mg/dl (0.0551 mmol/L) and PI in 
fiU/ml (6pmol/L).
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Chapter 3
SELECTION OF EFFECTIVE TREATMENT 
MATERIALS
3 ! . Chapter Synopsis
Neither ginseng or konjac-mannan are standardised products, therefore 
variability in their composition can occur. Consequently physiological effects can 
vary depending on the preparation used. To ensure that both the ginseng and konjac- 
mannan to be used in the studies were physiologically active, preliminary tests were. 
performed:
3.1! Selection of effective Koniac-mannau fibre
Effectiveness of viscous fibre in lowering post-prandial glycaemia has been 
related to viscosity, therefore rheology measurements were taken to select the most 
viscous of 3 different konjac-mannan fibres available. All 3 fibres increased viscosity 
of the liquid over time, the fibre which increased the viscosity to the greatest extent 
over the first 3 hours was selected to be used in future experiments.
3.1.2. Selection of effective American ginseng preparation
Prior studies have shown that the ginseng extracts supplied by the Chai-Na- 
Tai company lowered post-prandial glycaemia both in healthy (Vuksan et al., 2000a; 
Vuksan et al., 2001a; Vuksan et al., 2000d) and diabetic volunteers(Vuksan et al., 
2000a; Vuksan et al., 2001b). However as there were insufficient capsules left for 
further studies the company supplied a new batch of the extract. In addition, capsules 
containing whole ground ginseng root were also supplied. To compare these new 
products with the previous ones, the ginsenoside content was analysed. All samples 
showed the typical ginsenoside profile associated with American ginseng, however 
the replacement extract contained substantially lower ginsenoside levels than the other 
samples. The whole ground ginseng root was therefore selected for use in future 
experiments.
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3.2. Introduction:
Both ginseng and konjac-mannan have been shown to reduce post-prandial 
glycaemia, however effectiveness of these materials is dependent on different factors: 
Viscous fibres have been shown to reduce the rate of glucose absorption 
(Jenkins et al., 1978) and lower serum cholesterol (Anderson et al., 2000; Brown et 
al., 1999; Olson et al, 1997). Panel III of the US National Cholesterol Program for the 
first time, specifically mentioned the term “viscous” to define more precisely the sub 
class of soluble fibres which lowers serum lipids(NCEP, 2001). It has been clearly 
demonstrated that viscosity is an important attribute of fibre required to flatten the 
post-prandial glycaemia (Jenkins et al, 1978), although the data are not as clear in 
relation to the need for high viscosity in order to lower serum cholesterol (Blake et al., 
1997). Commercially available sources of viscous fibre may vary greatly in viscosity 
and this could account for the lack of effect on post-prandial glycaemia of viscous 
fibres in some studies (Simpson et al., 1981; Williams and James, 1979).
As described in the literature review, it has been suggested that the glycosidal 
saponins called ginsenosides present in the ginseng root are the active components of 
ginseng. As with viscosity in commercial fibre sources so also there is great 
variability in the level of ginsenosides in commercial ginseng sources and 
preparations. Interspecies variation in ginsenosides has been reported to be as high as 
15-fold in dried powder and 36-fold in liquid preparations (Harkey et al., 2001).
A simplified method to assess viscosity was used to select the konjac-mamian 
fibre. This method has proved to be a useful way to select the most physiologically 
active viscous fibres in previous studies (personal communication, V.Vuksan). A 
Synchro-electric viscometer was used to assess the relative in vitro viscosity of three 
sources of konjac mannan to determine the most viscous source. Ginsenoside content 
in four different types of ginseng was analysed and the ginseng with the highest total 
ginsenoside level was selected for use in the study.
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3 . 3  S e l e c t i o n  o f  e f f e c t i v e  K o n i a c - m a n n a n  f i b r e :
3.3.Methods
Viscosity measurements were taken of three different konjac mannan fibres 
(see Chapter 2, section 2,1.2) and compared to die wheat bran control (AACC 
certified hard red spring wheat). The fibres were mixed at a 1% concentration (1.5 g 
in 150 ml water). Viscosity was measured using the Synchro-electric Viscometer as 
described in the methods section. In this study spindle E and shear of 12 was used and 
a constant ambient temperature of 22°C (room temperature) was maintained. 
Measurements were taken at 15, 30, 45, 60, 90, 120, 180 min and 24hr. Results are 
tabulated in Table 3.1 and graphed in figure 3.1 and represent the mean of two 
experiments.
3.3.2. Results
There was no change in viscosity in the solution containing wheat bran. All 
konjac mannan fibres increased the viscosity of the solution over time. At 30min 
KJM1 had the highest viscosity when compared to KJM2 and KJM3 (296 vs 35 and 
228 poise respectively). Peak viscosity was reached at 60 min by KJM1, 24hr by 
KJM3 and 120min by KJM3. KJM 1 achieved the highest viscosity absolute level of 
viscosity throughout the 24h measured.
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Table 3.1: V is c o s i ty  m e a s u r e m e n t s  o f  w h e a t  b r a n  a n d  th r e e  k o n ja c  m a n n a n  f ib r e s .  
M e a n  o f  tw o  m e a s u r e m e n t s
Viscosity (p)+
Time (min) 15 30 45 60 90 120 180 24hr
Wheat Bran
1 2 2 2 4 3 2 2
KJM 1 2 1 4 2 9 6 2 9 8 2 9 3 291 2 7 4 2 7 9 2 7 9
KJM 2 2 9 35 82 127 150 193 2 2 4 2 7 7
KJM 3 20 3 2 2 8 2 3 2 2 3 2 2 4 8 2 5 2 2 4 6 2 5 2
*KJM=konjac-mannan fibre; +viscosity ( poise) was calculated by multiplying the dial reading by the 
factor (3.90) corresponding to the viscometer spindle (E) and speed (12rpm) combination utilised 
(Brookfield Helipath Stand Spindle Factors, Stoughton MA, USA)
 ----------- . ---------X
0 15 30 45 60 75 90 105 120 135 150 165 180 
Time (min) Time (h)
-*
24
— ♦— W heat Bran 
---- - KJM 1 
—a—  KJM 2
- -x- - KJM 3
Fig 3!: C om parison o f  viscosity levels in poise over 24h o f  w heat bran and three different 
konjac-m annan fibres.
3.3.3.Discussion
V is c o s i ty  c a n  b e  a l t e r e d  b y  a  v a r ie ty  o f  f a c to r s  in c lu d in g  t e m p e r a tu r e ,  
m o le c u la r  w e ig h t ,  a n d  p H  ( Y o s h im a r a  a n d  N i s h i n a r i ,  1 9 9 9 ) .  T h i s  e x p e r i m e n t  u s e s  a  
s im p l i f i e d  p r o to c o l  to  s c r e e n  th e  d i f f e r e n t  f ib r e s ,  it d o e s  n o t  t r y  to  m im ic
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physiological conditions such body temperature and pH. The temperature was chosen 
for convenience and because konjac-mannan fibre is generally very stable at 
temperatures below 70°C. Similarly we could have chosen to vary the pH levels to 
correspond to levels found in the stomach and small intestine, however as pH levels 
ranging from 2.5-6 also do not change konjac viscosity of readings significantly, this 
was not deemed to be necessary (manufacturers specifications, Fibre Tech Co.). In 
addition, previous experiments utilising this simple experimental protocol correlated 
well with physiological effectiveness of the fibre. Therefore the fibre which attained 
the highest viscosity in the shortest time, and maintained this over 3h, was selected for 
use in further studies.
3 .4 .  S e l e c t i o n  o f  e f f e c t i v e  A m e r i c a n  g i n s e n g  p r e p a r a t i o n :
3 . 4 .1 . M e t h o d s
Analysis of 4 different ginseng samples, using standard techniques, was 
performed by Dr Amason at the University of Ottawa. The following HPLC-UV 
technique, developed for the American Botanical Council Ginseng Evaluation 
Program (Fitzloff et al., 1998), was used. Details of the method have been described 
earlier. The levels of three 20(S)-protopanaxatriols (Rgi, Rf, Re) and four 20(S)- 
protopanaxadiols (Rbj, Rb2, Rc, Rd) were identified. The four samples of American 
ginseng analysed included the original extract (A) used in earlier, acute, studies 
(Vuksan et al., 2000a; Vuksan et al., 2001a; Vuksan et al., 2000c; Vuksan et al., 
2000d), the extract (B) used in a previous, long term study, CNT 2000 (Vuksan et al., 
200 lbj, the new batch of extract (C), and a whole ground ginseng (D). All samples 
were provided by the Chai-Na-Ta Company. Results are presented in Table 3.2.
T a b l e  3 . 2 :  A n a l y s i s  o f  f o u r  s a m p l e s  o f  A m e r i c a n  g i n s e n g :
Ginsenosides (% w/w) A B C D
( 2 0 S ) - p r o t o p a n a x a d io l s :
R b i 1.53 1.34 0.65 1.71
R b 2 0.06 0.08 0.02 0.16
R c 0.24 0.46 0.11 0.84
R d 0.44 0.62 0.12 0.86
( 2 0 S ) - p r o to p a n a x a t r io l s :
• -r. .
R g i 0.10 0.13 0.08 0.17
R e 0.83 0.91 0.67 1.46
R f 0 0 0 0
■
Total ginsenosides 3.21 3.54 1.66 5.20
4 . , . - - 
Ratios:
P P D : P P T
. . . 2.44 2.40 1.20 2.19
R b i :R g i 15.30 10.31 8.13 10.06
R b 2:R c 0.25 0.17 0.18 0.19
R g i iR e 0.12 0.14 0.11 0.11
■
A -  ginseng used in prior studies (Vuksan et al., 2000a; V uksan et al., 2001a; V uksan et al., 
2000c; V uksan et al., 2000d); B - ginseng extract used in the long term  study with type 2 
diabetes, (V uksan et al., 2001b); C - new batch o f  ginseng to replace extract B ; D  - whole 
ground ginseng. P P D  = (20S)-protopanxadiols; PPT= (20S)-protopanaxatriols
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3.5 Chapter Discussion
The composition of all 4 samples are consistent with Panax quinquefolius L. 
Presence and/or absence of various ginsenosides and their ratios are used in the 
authentication of die ginseng species. A ratio of Rbr. Rgi>3 (Awang, 2000; Ma et al.,
1996) and ratios of Rgj:Re<l and Rb2:Rc<l have been shown to be indicative of 
Panax quinquefolius L. (Chan et al., 2000; Wang et al., 1999). However the presence 
or absence of the ginsenoside Rf is the most significant marker, as it is absent in 
Panax quinquefolius altogether (Awang, 2000; Chan et al, 2000; Li et al., 2000; Ma 
et al., 1996). These criteria were met by all ginseng samples. Ginseng samples A and 
B showed similar ginsenosides profiles with totals of 3.21 and 3.54% w/w 
respectively. Sample D had the highest total level of ginsenosides (5.2% w/w). 
However sample C, with a total ginsenoside level of 1.66 % w/w, had 47% less total 
ginsenosides, and a 51% lower PPD:PPT ratio, the differences mainly due to lower 
PPD levels.
The two samples, A and B, which have been shown to be effective in 
improving glycaemic control in type 2 diabetes(Vuksan et al., 2000a; Vuksan et al., 
2001a; Vuksan et al., 2001b), had similar ginsenoside profiles. Although the new 
ginseng extract C was supposed to be a replacement for B, it had a much lower total 
ginsenoside level than the original extract (1.66% vs 3.54%).
The lower level of ginsenosides in sample B stresses the importance of quality 
control and analysis not only of different samples of ginseng, but also of different 
batches. As sample D contained the highest level of ginsenosides, it was decided to 
use this ginseng in future studies.
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Chapter 4
DAY PROFILE STUDY IN TYPE 2 DIABETES
4 .1  C h a p t e r  S y n o p s i s
With the selection of a potentially physiologically active ginseng and fibre 
samples, the in vivo testing could now be undertaken. In previous in vivo studies 
ginseng (AG) had been shown to reduce postprandial blood glucose levels through 
raising insulin levels, while konjac mannan fibre (KJM) had been shown to increase 
insulin sensitivity.
4 .1 .1  S t u d y  D e s i g n :
The study employed a two-by-two factorial, partially blinded, controlled 
randomised cross-over design. Subjects were given a standard breakfast on four 
different occasions to which had been added either: 1. placebo, 2. ginseng, 3. konjac 
mannan or 4. konjac mannan and ginseng. In addition a standard lunch (second meal) 
was consumed on all four days. Blood samples were collected over 7.5 hours.
4 .1 .2  S t u d y  H y p o t h e s i s
A . D u r i n g  t h e  f i r s t  4  h o u r s  o f  t h e  t e s t  ( a f t e r  b r e a k f a s t ) :
1 . G i n s e n g  w i l l :
□ increase GIP and GLP-1
2. K o n j a c  m a n n a n  f i b r e  w i l l :
□ suppress postprandial NEFA levels and reduce postprandial GIP and 
GLP-1 levels
3 .  G i n s e n g  a n d  k o n j a c  f i b r e ,  w h e n  u s e d  i n  c o m b i n a t i o n  w i l l :
□ reduce postprandial glycaemia, and suppress postprandial NEFA levels
65
B .  D u r i n g  t h e  s e c o n d  3 , 5  h o u r s  o f  t h e  t e s t  ( a f t e r  l u n c h ) :
G i n s e n g  a n d  k o n j a c  m a n n a n  w i l l :
□ improve postprandial glycaemia and insulinaemia
4 .1 .3  M e t h o d s
Ten individuals with type 2 diabetes (age 66±6y, BMI 28.7±9.2 kg/m2, Ale 
6.8+1.1%) participated in the study. Four sets of breakfasts, matched for energy and 
fibre content, containing 50g available carbohydrate from Ensure™, were 
administered in random order. 1: Control (7g of wheat bran); 2: AG (3g of American 
ginseng + 7g of wheat bran); 3: KJM (4g of Konjac mannan); 4: AG+KJM (3g of 
Amercian ginseng + 4g of Konjac mannan). This was followed by a second meal, a 
standard lunch, 4h later. Blood samples were obtained at -30, 0, 15, 30, 60, 90, 120, 
150, 180, 240, 270, 300, 360 and 420 min.
4 .1 .4  R e s u l t s
At 15 min the incremental plasma glucose levels after AG were significantly 
lower than the control (p<0.02). Incremental area calculations of the second meal ie 
240-420min showed a reduction in glucose area after KJM and AG+KJM when 
compared to control and AG alone (p<0.03). Incremental insulin levels were 
significantly lower after AG+KJM at 30 min when compared to AG: (p<0.03). At 
120min insulin levels were significantly lower after both KJM and AG+KJM than AG 
(p<0.03), and at 420min AG was significantly higher than control, KJM and 
AG+KJM (p<0.01). There were no significant differences in insulin areas or in the 
insulin sensitivity index. Incremental GIP levels were decreased after KJM and 
AG+KJM at 30min when compared to AG (p<0.04). At 90 and 120min, GIP levels 
after KJM were significantly lower than both control and AG (p<0.02), at 150min 
KJM was significantly lower than AG (p<0.04). The Control incremental GIP area 
was significantly higher than the KJM GIP area, while the area for AG was 
significantly higher than both the KJM and AG+KJM areas (p<0.01). There were no 
differences in the incremental GLP-1 response between control and AG, however
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after KJM, GLP-1 was significantly lower at 60 and 90min when compared to control 
(p<0.04 and p<0.03 respectively). After AG+KJM, GLP-1 was lower at 90min when 
compared to control (p<0.03). The total areas for KJM and AG+KJM were 
significantly lower than the control (p<0.08), there were no significant differences 
between the incremental areas. There were no significant differences between the 
meals in NEFA, TAG, blood pressure levels, and satiety.
4 .1 .6  C o n c l u s i o n :
The ginseng used in this study showed a small but significant reduction in 
postprandial glycaemia, the lack of a more sustained effect on both glucose and 
insulin might have been due to its composition. This emphasises the importance of the 
development of a standardised, effective ginseng preparation. Konjac-mannan 
decreased postprandial insulin, GLP-1 and GIP levels. Lack of effect on glucose 
might be due to lack of the viscosity of the meal. Using konjac-mannan and ginseng 
in combination did not, in this study, improve the metabolic profile more than when 
konjac-mannan was used alone.
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4.2 Introduction
Both ginseng and konjac mannan have been shown to reduce postprandial 
glycaemia (Kim et al., 1996; Vuksan et al., 2000a)(fig 4.1 and 4.2), however the 
mechanisms of action to achieve this reduction is different for each substance (see 
Literature Review). Consequently, it has been postulated that using ginseng and 
konjac-mannan in combination, in the treatment of diabetes, may have additive 
beneficial effects. This would be similar to the current practice of combining oral 
hypoglycaemic agents in the treatment of diabetes.
o  P la c e b o  (T ogeth er) A  G in s e n g  (T o g e th e r)
•  P la c e b o  (B efo re) A  G in s e n g  (B efo re)
T im e , m in
F ig  4 .1 :  Comparison of incremental changes in glycaemia in type 2 diabetes between 
American ginseng and a matched corn flour placebo administered either 40 minutes before or 
together with a 25g g oral glucose challenge. Incremental glycaemia at individual time points 
with different lowercase letters are significantly different (p<0.05). From: (Vuksan et al., 
2 0 0 0 a).
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Fig 4.2: Postprandial glycaemic responses to a 20g oral glucose challenge done alone (o) or 
following 3g of psyllium (O), xanthan (□) and konjac-mannan (A). Points with different 
letters are significantly different (p<0.05). From:(Kim et al., 1996).
In order to study the possible additive effects of ginseng and konjac mannan a 
study was designed which would compare the acute metabolic effects of ginseng and 
konjac mannan alone and in combination in type 2 diabetes. From previous studies 
with ginseng we would expect a reduction of postprandial glycaemia together with an 
increase of postprandial insulin levels (Vuksan et a l, 2000a; Vuksan et al, 2001b). It 
is not known if ginseng affects postprandial levels of NEFA, TAG, GIP and GLP-1. 
Both GIP and GLP-1 are incretins which increase the early insulin response to a 
mixed meal and as ginseng increases postprandial insulineamia, we hypothesised that 
this increase may be modulated through GIP and/or GLP-1.
Viscous fibres have been shown to flatten the postprandial glucose, insulin, 
GIP, and enteroglucagon levels (Jenkins et a l, 1977; Morgan et al, 1979). In 
addition, viscous fibre administration has also been associated with sustained 
suppression of NEFA (Jenkins et a l, 1980). It was expected that konjac mannan 
would elicit a similar postprandial metabolic profile. It is not known what effect, if 
any, konjac mannan would have on GLP-1.
Previous studies with guar gum have shown that addition of guar to a first 
meal, flattens the glycaemic and insulinaemic response not only to the first meal but
also to a fibre free second meal (Jenkins et al., 1980). In part this effect was attributed 
to the suppression of NEFA (Jenkins et al., 1980). It is not known whether konjac- 
mannan will have the same effect as guar 011 the second meal or whether the presence 
of ginseng will affect the metabolic response to subsequent meals. This might be of 
interest with respect to timing of administration i.e. whether it is necessary to take the 
fibre/ginseng with each meal or if it can be taken less frequently. The acute study 
therefore proposed to study the metabolic response to ginseng and konjac mannan not 
only over breakfast but also over a subsequent, standard second meal.
Doses of ginseng and konjac used in the study were based on previous work 
earned out in our laboratory (Vuksan et al., 2000a). Therefore 3g of Ginseng or com 
flour (control) capsules were administered 30min prior to the breakfast. Capsules 
were administered before breakfast because previous work showed that ginseng only 
lowered postprandial glycaemia in healthy volunteers when given 30~40min before a 
meal (Vuksan et al., 2001a; Vuksan et al., 2000c). Although timing of the ginseng 
dose may not be as important in diabetic subjects (Vuksan et al., 2000c)(Fig 4.1), it 
was decided nevertheless to follow the healthy volunteer protocol and capsules were 
therefore given thirty minutes before breakfast. Similarly the dose of konjac mannan 
was based on our previous experience with konjac fibre in acute tests and we 
estimated that addition of 4g of Konjac-mannan (3.5g of soluble fibre) to 50g 
available carbohydrate will reduce the postprandial glycaemia in type 2 diabetes, 
approximately 45-50% (Vuksan et al., 1992)(Fig 4.2.). To simulate a meal, Ensure™ 
(Abbott Laboratories Limited, Saint-Laurent, Quebec, Canada), a liquid meal 
replacement, was used instead of glucose. Ensure™ was chosen as it was felt to be 
more physiological representative of a meal than glucose, it contains protein and fat in 
addition to carbohydrate. A further advantage of Ensure™ is that, although it 
constitutes a meal, it can be consumed in a relatively short time and the konjac 
mannan fibre can easily be mixed into it. This is important as viscous fibre has been 
shown to be more effective when mixed intimately with the carbohydrate portion of 
the meal (Wolever et al., 1979).
Blood samples were analysed for plasma glucose, insulin, GIP, GLP-1, NEFA 
and TAG. In addition, blood pressure measurements were taken throughout the day as 
both ginseng (Stavro et al, 2000b) and konjac (Vuksan et al., 1999b) have been
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shown to reduce blood pressure in long-term studies, and there is some suggestion 
that certain ginsengs may effect blood pressure acutely (Stavro et al., 2002).
4 .2 .1  H y p o t h e s i s
A. During the first 4 hours of the test (after breakfast):
1. Ginseng will:
□ Reduce postprandial glycaemia
□ Increase postprandial insulaemia
□ increase glucose-dependent insulinotropic secretagogue hormones: 
GIP and GLP-1
2 . K o n j a c  m a n n a n  f i b r e  w i l l :
□ decrease postprandial glycaemia and insulinaemia
□ suppress postprandial NEFA levels
□ reduce postprandial GIP and GLP-1 levels
3. Ginseng and konjac fibre, when used in combination will:
4. reduce postprandial glycaemia, and
5. suppress postprandial NEFA levels
6. not change postprandial insulinaemia
B . D u r i n g  t h e  s e c o n d  3 .5  h o u r s  o f  t h e  t e s t  ( a f t e r  l u n c h ) :
Ginseng and konjac mannan will:
□ improve postprandial glycaemia and insulinaemia
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4.3 Research Design and Methods
4 .3 .1 .  V o l u n t e e r s :
4.3.1.1. Power Calculation
It was assumed that the tests were conducted at a significance level of 
alpha=0.05 and the power to detect a significant difference was 90%. Based on 
previous studies with Konjac and ginseng, it was assumed that the expected standard 
deviation for plasma glucose (area under the curve) would be 73 min.mmol/L and for 
insulin, at 15 min, 32 pmol/L. The minimal detectable significant differences for these 
parameters were 110 min.mmol/L and 55 pmol/L respectively. From this set of 
assumptions, the minimum sample size calculated was 12. Assuming a 15-20% 
attrition rate, the final sample size was calculated to be 14.
4.3.1.2 Subjects
Thirteen volunteers with type 2 diabetes completed the study. However 3 
subjects had to be eliminated because of a change in oral hypoglycaemic medication 
during the study period (subjects #1, #4 and #15). Therefore a total of 10 subjects 
were included in the final data analysis, age (mean±SD) 66+6 y, BMI 28.7+9.2 kg/m2, 
duration of diabetes 8.4±5y, HbAlc 6.8+1%, 2 treated with diet alone, 8 treated with 
oral hypoglycaemic agents. Exclusion criteria included: diagnosis of type 2 diabetes 
o f  less than 6 months duration, Alc>9%, use of ginseng within the past 2 months, 
women taking hormone replacement therapy; gastrointestinal disease; cigarette 
smoking or heavy alcohol intake (>2 drinks/day). All volunteers gave written 
informed consent to participate in the study. The study was approved by the St 
Michael’s Hospital Ethics Committee.
4 .3 .2  P r o t o c o l
Participants attended the Risk Factor Modification Centre at St Michael’s 
Hospital on four separate occasions following a 10-12 hour overnight fast. They were
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instructed to maintain the same dietary and exercise patterns the evening before each 
test and ensure adequate carbohydrate intake. Participants were asked to complete a 
questionnaire detailing pre-session information regarding their diet and lifestyle 
patterns and record the previous night’s dietaiy intake. Subjects adhered to their usual 
medication regime during each test day.
The study utilized a two-by-two factorial, controlled randomised crossover, 
partially blinded, design. Four sets of breakfasts were administered in random order. 
All breakfasts used Ensure™ (Abbott Laboratories Limited, Saint-Laurent, Quebec, 
Canada) as the source of carbohydrate. Ginseng and control (com flour, International 
Nutrition Ltd, Markham, Ontario) capsules were administered 30min before breakfast 
while konjac mannan and the fibre control (certified hard red spring wheat bran, 
American Association of Cereal Chemists, St Paul, USA) were mixed into the 
Ensure™. The four breakfasts which were administered were:
1. Control: Ensure+ control capsules + wheat bran,
2. KJM: Ensure + control capsules + konjac mannan fibre
3. AG: Ensure + Ginseng capsules + wheat bran
4. AG+KJM: Ensure + Ginseng capsules + konjac mannan fibre.
Lunch was a standard meal of soup, sandwich and fruit (see tables 4.4 and 
4.5). The test days were randomised for each subject and were scheduled at least one 
week apart. The total test day spanned 7.5 hours. Blood samples were obtained using 
an indwelling catheter, kept patent with sterile 0.9% saline and inserted into a vein in 
the cubical fossa. Blood pressure was measured using a conventional mercury 
sphygmomanometer according to Joint National Council VI (NIH,1997) criteria 
where each measurement was repeated 3 times, separated by 2 minutes. Subjects were 
asked to record their satiety levels throughout the day using a bipolar scale ranging 
from -3 (extremely hungry), 0 (neutral), to +3 (uncomfortably full). The palatability 
of the meals was recorded on a scale from 1 to 10, where 1 was "dislike extremely”, 5 
"neutral” and 10 “delicious”. At each visit, weight was measured using a beam scale 
and total body fat was measured with the Futrex 5000 (Futrex Inc. Gaithersburg, 
USA), using infrared technology. Table 4.1 shows the times when meals and 
measurement were taken.
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T a b l e  4 ! :  S ch ed u le  o f  m e a su re m e n ts  tak e n  d u rin g  
M e a s u r e m e n t
Oh l h
-30 0 15 30 60 90
V e n o u s  B lo o d X X X X X X
B lo o d X X X X
P r e s s u r e
S a t ie ty X X X X X X
P a la ta b i l i ty X
C a p s u le s X
M e a ls X
W e ig h t x
B o d y  F a t X
the d ay  p ro file  s tu d y  
T im e
2h 3 h 4 h 5 h 6h 7 h
120 150 180 240 270 300 360 420
X X X X X X X X
X X X X
X X X X X X X X
x
X
4.3.3 Materials and Meals
C o n tro l c ap su le s , c o n ta in in g  c o m  flo u r (In te rn a tio n a l N u tritio n  L td, 
M ark h am , O n ta rio ) , w e re  d e v e lo p ed  to b a lan ce  the  m a c ro n u tr ie n t co n ten t o f  the  
g in se n g  c ap su le s  (C h a i-N a -T a  C o rp o ra tio n , L an g ley , B ritish  C o lo m b ia )  (see  tab le
4 .2 ). E ach  d o se  c o n s is te d  o f  3g  (6 cap su le s)  o f  e ith e r  g in se n g  o r  c o m  flour. A ll 
b re a k fa s ts  c o n ta in e d  5 0 g  c a rb o h y d ra te  su p p lied  b y  3 5 6 g  o f  E n su re ™  (see  tab le  4 .3  fo r 
n u tritio n a l c o m p o s itio n ) an d  2 0 0 m l o f  w ater. W h ea t b ra n  (C e rtif ie d  H ard  R ed  W h ea t 
B ran , A m e ric an  A sso c ia tio n  o f  C e rea l C h e m is ts , S t P au l, M in n e so ta , U S A ) w as used  
as the  fib re  c o n tro l fo r  k o n jac  m an n a n  (F ib e rJo h n so n , T o ro n to , O n , C an ad a )(T ab le
4 .3 ). D ue  to  th e  n a tu re  o f  th e  fib res  it w as n o t p o ss ib le  to  b lin d  th e  su b je c ts  to  the  type 
o f  fib re  th ey  rece iv ed .
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T a b l e  4 .2 :  Macronutrient content of 1 gram of either com flour (control) or American 
ginseng
Corn Flour (Control) American Ginseng
Energy (kcal) 3.51 3.44
Carbohydrate (g) 0.73 0.57
Fat (g) 0.039 0.013
Protein (g) 0.069 0.26
Macronutrient analysis determined by the Association o f  Official Analytical Chemists methods for 
macronutrients analysis (1980).
T a b l e  4 .3 :  Composition of Ensure™, Konjac and Wheat bran fibre used in t e s ts  
meals
. Ensure™* Konjac** Wheat Bran**
(356g) (4g) (7g)
Carbohydrate (g) 50 NA 0.9
Protein (g) 12.4 NA 1.1
Fat (g) 8.8 NA 0.3
Fibre - total 0 3.5 3.5
- soluble NA 0.2
insoluble NA 3.3
*Nutrient information obtained from manufacturer: Abbott Laboratories Limited, Saint-Laurent, 
Quebec, Canada
**Macronutrient analysis determined by the Association o f  Official Analytical Chemists methods 
for macronutrients analysis (1980).
After the -30min blood sample, subjects swallowed the control or ginseng 
capsules with 200ml of water. At Omin another blood sample was drawn, the f ib re  
was mixed with the Ensure™ and subjects were instructed to consume the mixture 
over 5 min. Four hours after the start of breakfast a standard lunch was offered, 
macronutrient composition and details of the meals are given in tables 4.4 and 4.5. In 
addition each subject had a choice of beverage (coffee, tea or water) at lunch. The 
type and amount of beverages selected were kept constant for each test day.
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Table 4.4: Macronutrient composition of test meals
Meal Energy Protein Carbohydrate Fat Fibre in 
meal
Added
Fibre
Breakfast: 1487 KJ 12g 50g 13g 0g 3.5g**
(Ensure™) (354kcal) (14%) (55%) (32%)
Lunch* 2284 KJ 24 g 75g 19g 5g 0g
(544kcal) (17%) (53%) (30%)
* beverage not included; ** fibre from either wheat bran or konjac mannan fibre
Table 4.5: Foods consumed during breakfast and lunch on each test day
Time Test 1 
(Control)
Test 2 
(KJM)
Test 3 
(AG)
Test 4 
(AG+KJM)
Capsules -30’ Com flour + 250 
ml water
Com flour + 250 
ml water
Ginseng + 250 ml 
water
Ginseng + 250 ml 
water
B’fast 0’ EnsureI M (356g)+ 
wheat bran (7 g) + 
200ml water
Ensure™ (356g)+ 
Konjac (4g) + 
200ml water
Ensure ™ (356g)+ 
wheat bran + 200m 
water
EnsureI M (356g)+ 
Konjac + 200ml 
water
Lunch 240’ Lipton’s instant 
vegetable soup
Lipton’s instant 
vegetable soup
Lipton’s instant 
vegetable soup
Lipton’s instant 
vegetable soup
3 si white bread 
(84g)
3 si white bread 
(84g)
3 si white bread 
(84g)
3 si white bread 
(84g)
2 tsp Canola 
margarine (8g)
2 tsp Canola 
margarine (8g)
2 tsp Canola 
margarine (8g)
2 tsp Canola 
margarine (8g)
3 si cheese (57g) 3 si cheese (57g) 3 si cheese (57g) 3 si cheese (57g)
' ■ /•'f' ;
Tomato slices 
(80g)
Tomato slices (80g) Tomato slices
(80g)
Tomato slices
(80g)
r
Apple slices (lOOg) Apple slices (lOOg) Apple slices 
(lOOg)
Apple slices 
(lOOg)
Beverage of choice Beverage of choice Beverage of 
choice
Beverage of choice
Abbreviations: AG - American ginseng, KJM -  konjac mannan fibre
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4 . 3 . 4  H o r m o n e  a n d  M e t a b o l i t e  M e a s u r e m e n t s
Each blood sample consisted of a total of 11ml of blood and collected into 
sodium fluoride tubes for glucose and insulin, EDTA tubes for NEFA and TAG, and 
heparinised. tubes to which aprotinin (SIGMA Chemical Company, St Louis, USA) 
was added at a concentration of 200 KlU/ml of blood, within 30 seconds of the 
sample being drawn. Heparinised samples were kept on ice at all times and 
centrifuged within 15min at 1500g for 10 min. All samples were separated, frozen and 
stored at -70°C until analysis.
The glucose concentration of each sample was determined by a glucose 
oxidase method (Kadish and Hall, 1965). A double antibody radioimmunoassay was 
used to determine insulin concentrations (Livesey et al., 1980) (see Chapter 2). The 
inter-assay coefficients of variation for glucose was 3.3 and 1.8% at 3.9 and 14.4 
mmol/L respectively; for insulin 7.2, 6.6 and 8.8% at 72, 316 and 753 pmol/L 
respectively,
The whole body insulin secretion index (ISI) was calculated using the method 
described by (Matsuda and DeFronzo, 1999), using the formula:
10,000
ISI =_________________________
' V (FPG x FPI x mean PG x mean PI)
where plasma glucose (PG) and fasting plasma glucose (FPG) are expressed in mg/dl 
(0.0551 mmol/L) and plasma insulin (PI) and fasting plasma insulin (FPI) in pU/ml 
(6pmol/L). The mean PG and PI are calculated using the results from the first 2 hours 
of the OGTT.
GIP and GLP-1 were analysed using in-house radioimmunoassay methods 
(Elliott et al., 1993; Morgan et al., 1978). NEFA and TAGs, were analysed using 
standard colorimetric analytical techniques (Randox Colorimeter, Randox 
Laboratories Inc, Crumlin, UK)(See Chapter 2).
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The NEFA analysis is based on the conversion of NEFA to their copper salts, 
which are extracted into an organic solvent. The salts are then complexed with a dye, 
which can be measured calorimetrically. TAG analysis is based on the quantitative 
measurement of the glycerol liberated enzymatically from the hydrolysis of TAG. See 
Chapter 2 for more detailed descriptions of analytical methods.
4.3.5 Statistical analysis
Plasma glucose, insulin, GIP, and GLP-1, NEFA and TAG were graphed, and 
the positive incremental area under the curve (AUC) was calculated geometrically for 
each participant (Wolever et al., 1991)(see Chapter 2 for details of area calculation). 
AUC was calculated separately for the first 4 hours and the last 3.5hours. 
Between the four types of test meals, differences in AUC were assessed by one-way 
repeated measures ANOVA, and adjusted for multiple pair-wise comparisons with the 
Newman Keuls procedure. The same statistical method was used to assess the 
independent effect at the individual time points. As the major effect seemed to reside 
with konjac mannan, a test of contrast was also performed. This allowed comparison 
of those tests which contained konjac with those that did not. Body fat and weight was 
analysed using two-way ANOVA to test for differences between treatments and to 
test for treatment-by-time interaction. All statistical analyses were performed using 
the Number Cruncher Statistical System 2000 software (NCSS statistical software, 
Kaysville, UT, USA). Results are expressed as mean ± SEM and significant at p<
0.05.
4.5 RESULTS
4.4.1 Fasting Levels
There were no statistical differences between the fasting levels of any of the
metabolites measured (table 4.6).
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T a b l e  4 .6 :  F a stin g  lev e ls  a t -3 0 m in  and  Omin fo r 10 su b je c ts  w ith  d iab e tes  b e fo re  
tak in g  4 d iffe re n t te s t m ea ls . T h ere  w ere  no s ta tis tica lly  s ig n if ic an t d iffe ren ces
b e tw ee n  fa s tin g  leve ls .
F a s t i n g  a t  - 3 0 m i n F a s t i n g  a t  O m in
C o n t r o l A G K J M A G + K J M C o n t r o l A G K J M A G + K J M
G lu c o s e
m m o l/L
8 .7 ± 0 .7 9 .1 ± 1 .0 9 .0 ± 0 .8 8 .9 ± 1 .8 8 .5 ± 0 .7 9 .2 ± 1 .1 8.8± 0.8 8 .9 1 1 .7
I n s u l in
p m o l/L
6 2 ± 1 7 6 6 ± 1 7 7 4 ± 2 0 7 1 ± 1 6 6 0 ± 1 3 7 3 ± 1 9 7 8 1 2 2 7 2 1 1 7
N E F A
m m o l/L
0 .5 8 ± 0 .2 4 0 .6 1 ± .0 .2 1 0.6± 0.22 0 .6 1 ± 0 .14 0 .5 9 ± 0 .1 8 0.66± .0.21 0 .6 4 1 0 .2 1 0 .6 1 0 .1 4
T A G
m m o l/L
1 .7 7 ± 0 .1 5 2 .0 5 ± 0 .3 1 .9 8 ± 0 .2 0 1 .9 8 ± 0 .2 6 1 .76± 0 .1 2 .0 5 ± 0 .3 1 .8 1 1 0 .1 6 1 .8 6 1 0 .2 4
G I P
p m o l/L
N /A N /A N /A N /A 52.1 ± 1 3 .0 5 4 .3 ± 1 5 .5 5 2 .3 1 1 3 .8 3 9 .3 1 1 0 .8
G L P -1
p m o l/L
N /A N /A N /A N /A 1 3 .8 ± 2 .9 1 2 .7 ± 3 .6 1 4 .3 1 2 .8 10. 112.8
S y s t  B P  
m m H g
1 2 0± 3 1 2 2 ± 4 1 28± 5 1 2 4 ± 4 117 ± 4 1 1 8 .6 ± 4 125 1 5 1 2 4 1 3
D ia s t
B P
m m H g
7 4 ± 2 73 ± 2 7 8 ± 3 7 3 ± 2 7 3 ± 2 7 1 ± 2 7 6 1 3 7 2 1 2
4 .4 .2  W e i g h t  a n d  B o d y  F a t
T h ere  w e re  n o  s ig n if ic a n t ch an g es  in to ta l b o d y  w e ig h t an d  b o d y  fat 
th ro u g h o u t th e  te s t p e rio d  (T ab le  4 .7 ).
T a b l e  4 .7 :  T o ta l b o d y  w e ig h t an d  b o d y  fa t v a lu es fo r 10 su b je c ts  d u rin g  the  day
p ro file  s tu d y  ( m e a n iS D )
C o n t r o l  + W h e a t  
B r a n
G i n s e n g  +  W h e a t  
B r a n
C o n t r o l  +  
K o n j a c
G i n s e n g  +  
K o n j a c
W e i g h t  ( k g ) 88.4116.4 88.3116.5 88.2116.5 88.5116.4
B o d y  F a t  ( % ) 28.817.3 29.117.1 28.516.7 29.217.0
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4.4.3 Glucose and Insulin
At 15 min the incremental plasma glucose levels after AG were significantly lower 
than the control: 0.8+0.3 vs. 1.76+0.3 mmol/L respectively (p<0.02)(Fig 4.3). There were 
no significant differences in the areas under the curve between 0-240min. Incremental area 
calculations of the second meal ie 240-420min, and using 240min values as the baseline, 
showed a reduction in glucose area after KJM and AG+KJM when compared to control and 
AG alone (p<0.03) (Fig 4.4 and Table 4.8 ).
Fig 4.3 : I n c r e m e n ta l  p l a s m a  g lu c o s e  d a y  p r o f i l e  r e s u l t s  o f  10 s u b je c t s  w i th  t y p e  2  d i a b e t e s  a f te r  
e i t h e r  c o n tr o l ,  g in s e n g  ( A G ) ,  K o n ja c  m a n n a n  ( K J M )  o r  a  c o m b in a t io n  o f  g in s e n g  a n d  k o n ja c  
m a n n a n  ( A G + K J M )  f o l lo w e d  b y  a  s ta n d a r d  lu n c h  a t  2 4 0 m in .  R e s u l ts  a r e  e x p r e s s e d  a s  m e a n  ±  S E M ; 
* A G  s ig n i f ic a n t ly  lo w e r  th a n  c o n tr o l  ( p < 0 .0 2 ) .
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Control AG KJM AG+KJM
Glucose Area during the 2nd meal
Fig 4.4: I n c r e m e n ta l  a r e a s  u n d e r  t h e  c u r v e  f o r  g lu c o s e  in  1 0  s u b je c t s  w i th  ty p e  2  d ia b e te s  
o v e r  t h e  2 n d  m e a l  a f t e r  c o n tr o l ,  g in s e n g  ( A G ) ,  k o n j a c - m a n n a n  ( K J M )  a n d  th e  c o m b in a t io n  o f  
g in s e n g  a n d  k o n ja c  m a n n a n  ( A G + K J M ) .  R e s u l t s  a r e  e x p r e s s e d  a s  m e a n  ±  S E M . B a r s  w i th  
d i f f e r e n t  l e t t e r s  a r e  s ig n i f ic a n t ly  d i f f e r e n t  ( p < 0 .0 5 ) .
Incremental insulin levels were significantly lower after AG+KJM at 30 min 
when compared to AG: 82.4+25.3, 127.7+40!pmol/L respectively (p<0.03). At 
120min both KJM and AG+KJM were significantly lower than AG (173.9+43.6, 
167.5+43.7 and 254.7+65.2pmol/L respectively) (p<0.03), and at 420min AG 
(154.2±41.2pmol/L) was significantly higher than control, KJM and AG+KJM 
(166.7+45.1, 138.8+32.7 and 154.2+41.2pmol/L respectively)(p<0.01)(Fig4.5). There 
were no significant differences in insulin areas (Table 4.8) or in the insulin sensitivity 
index.
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Incremental Insulin Day Profile
o
EQ.
3</>c
Isco
E
2oc
- 3 § o  0 3 0  6 0  9 0  1 2 0  1 6 0  1 8 0  2 1 0  2 4 0  2 7 0  3 0 0  3 3 0  3 6 0  3 9 0  4 2 0
Time (min)
Fig 4.5 : I n c re m e n ta l  p la s m a  in s u l in  d a y  p r o f i le  r e s u l t s  o f  10  s u b je c t s  w i th  ty p e  2 d ia b e te s  a f t e r  
e i th e r  c o n tr o l ,  g in s e n g  ( A G ) ,  K o n ja c  m a n n a n  ( K J M )  o r  a  c o m b in a t io n  o f  g in s e n g  a n d  k o n ja c  
m a n n a n  ( A G + K J M )  f o l lo w e d  b y  a  s t a n d a r d  lu n c h  a t  2 4 0 m in .  R e s u l ts  a r e  e x p r e s s e d  a s  m e a n  ±  S E M . 
T im e  p o in ts  w i th  d i f f e r e n t  le t t e r s  a r e  s ig n i f ic a n t ly  d i f f e r e n t .
4.4.3.1. Contrast Test
W h e n  a  c o n tr a s t  t e s t  w a s  p e r fo r m e d  ie  a  c o m p a r is o n  o f  th e  g lu c o s e  a n d  in s u l in  
le v e ls  b e tw e e n  th e  te s ts  w h ic h  c o n ta in e d  k o n ja c  m a n n a n  ( K J M  a n d  A G  i K J M )  a n d  th o s e  
th a t  d id  n o t  (C o n tro l  a n d  A G ), o n ly  th e  in c re m e n ta l  g lu c o s e  a re a  u n d e r  th e  c u rv e  w a s  a g a in  
s ig n i f ic a n t  f o r  th e  2 nd m e a l. T h e  s a m e  te s t  a p p l ie d  to  th e  in s u l in  r e s u l ts  s h o w e d  c o n s is te n t  
s ig n if ic a n t ly  lo w e r  in s u l in  le v e ls  a t  3 0 , 9 0  a n d  1 2 0 m in  (P < 0 .0 5 ) .  T h e  in c re m e n ta l  in s u l in  
a r e a  a f te r  th e  k o n ja c  m a n n a n  c o n ta in in g  m e a ls  w a s  s ig n if ic a n t ly  d e c r e a s e d  o v e r  th e  f i r s t  4  
h o u r s  o f  th e  t e s t  (p < 0 .0 1 ) . T h e  in c r e m e n ta l  in s u l in  a r e a  o v e r  th e  2 nd m e a l  w a s  n o t  
s ig n i f ic a n t ly  d i f f e re n t.  T h e  s a m e  te s t  a p p l ie d  to  g in s e n g  c o n ta in in g  m e a ls  d id  a g a in  s h o w  a  
s ig n i f ic a n t  lo w e r  g lu c o s e  v a lu e  a t 3 0 m in  a n d  a t  3 0 0 m in  ( p < 0 .0 4 )  b u t  n o  d i f f e r e n c e s  in  
in c re m e n ta l  a re a s .
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4.4.4 NEFA and TAG
There were no significant differences between the meals in NEFA or TAG levels. 
(Fig 4.6 and 4.7).
Incremental NEFA Day Profile
—♦ —Control 
-•-AG  
-A -KJM 
—X—AG+KJM
Fig 4.6: Increm en ta l p lasm a  N E F A  day  p ro file  re su lts  o f  10 sub jects w ith  type  2 d iab e tes  a fte r e ith e r 
con tro l, g in sen g  (A G ), K on jac  m annan  (K JM ) o r a  c o m b in a tio n  o f  g in se n g  and  k o n jac  m annan  
(A G + K JM ) fo llo w ed  by  a  standard  lunch  a t 240m in . R esu lts  a re  e x p ressed  as m ean  ±  SE M .
INCREMENTAL DAY PROFILE TAG
(n=10)
o
E
S
O
-60 -0.2 0
CONTROL 
AG 
KJM 
-X-AG+KJM
60 120 180 240 300 360
Time (min)
420
Fig 4.7: Inc rem en ta l p lasm a  T A G  d ay  p ro file  re su lts  o f  10 sub jects w ith  ty p e  2 d iabe tes a fte r e ith er 
con tro l, g in sen g  (A G ), K on jac  m annan  (K JM ) o r a  c o m b in a tio n  o f  g in sen g  and  k o n jac  m annan  
(A G + K JM ) fo llow ed  b y  a standard  lunch  a t 240m in . R esu lts  a re  e x p ressed  as m ean  ±  SE M .
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4 . 4 . 5  G I P  a n d  G L P - 1
Only the first 4 hours of the day profile were analysed for GIP and GLP-1. As 
starting GIP levels for subject #9 were not available, this subject was excluded from 
the analysis. Incremental GIP levels were decreased after KJM and AG+KJM at 
30min when compared to AG (174131, 149134 and 174131 pmol/L respectively) 
(p<0.04). At 90 and 120min (134122 and 92118pmol/L), KJM was significantly 
lower than both control (217135 and 157131 pmol/L) and AG (223144and 
181143pmol/L) (p<0.02), at 150min KJM (76il9pmol/L) was significantly lower 
than AG (131133pmol/L) (p<0.04), (Fig 4.8). The incremental GIP area for KJM was 
significantly lower than both the Control and AG areas (2328613708, 349531 6010 vs 
378301 6809pmol/L respectively)(p<0.01) and the AG+KJM area was significantly 
lower than the AG area (2618415771 vs 378301 6809pmol/L) (Fig 4.9).
GLP-1 was significantly reduced at 60 and 90min after KJM when compared 
to control (10.416.6, and 2.614.4 vs 30.9111 and 25.011 Opmol/L, p<0.04 and p<0.03 
respectively). GLP-1 was significantly lower at 90min after AG+KJM when 
compared to control (13.013.9 vs 2614.4pmol/L, p<0.03). There were no differences 
in the incremental GLP-1 response between AG and control (Fig 4.10).
Although there were no significant differences in starting levels, when absolute GLP- 
1 levels were used in the statistical analysis the differences were more marked: when 
compared to the control values KJM was significantly lower at 60, 90, 120, and 180 
min (p<0.05) and after AG+KJM at 60, 90,150 and 180min (p<0.05). Similarly the 
total areas for KJM and AG+KJM (412711041 and 37551 668min.pmol/L) were 
significantly lower than the control (658311137 min.pmol/L, p<0.008), whereas with 
the incremental areas, only the konjac was significantly different from the control (Fig 
4.9 and Table 4.8).
4.4.5.1. Contrast Test
When incremental areas of GIP and GLP-1 of the konjac containing meals 
(KJM and AG+KJM) where compared to the non-konjac containing meals (Control 
and AG), konjac containing meals were significantly lower than those which did not 
contain konjac (15851427 vs 32421681 min.pmol/L, p<0.01), there was no difference
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in  in c re m e n ta l  a r e a s  b e tw e e n  th e  g in s e n g  c o n ta in in g  m e a ls  a n d  th o s e  w h ic h  d id  n o t  
c o n ta in  g in se n g .
Day Profile - Incremental GIP
n=9 ,—  ------
A - ♦ “ Control
-■ “ Ginseng 
Konjac 
G+K
1 2 0  180  
Time (min)
Q_ 3 0 0
O  J
5  o  200 E c
j r e  ^  1 0 0a.
0 
0
F i g  4 .8  : In c rem en ta l p lasm a  G IP  day  p ro file  re su lts  o f  10 sub jec ts  w ith  ty p e  2 d iab e tes  a fte r 
e ith er con tro l, g in seng  (A G ), K on jac  m an n an  (K JM ) o r  a  com b in a tio n  o f  g in sen g  and  k o n jac  
m an n an  (A G + K JM ). R esu lts  are  e x p ressed  as m ean  ±  SE M . T im e  p o in ts  w ith  d iffe re n t le tters 
a re  s ig n ifican tly  d ifferen t.
Day profile -GIP Area 240 min (n=9)
5  40000 - o A,BE
a
c  30000 -
E, +•. . *
£  20000 - 
<
c  10000 - a>
E
£rt a
I § f l
if'; '
o u c
Control AG KJM AG+KJM
F ig  4 .9: G IP  Increm en ta l a reas  fo r con tro l, g inseng , k o n jac  m an n an  an d  th e  c o m b in a tio n  o f  
g in sen g  an d  kon jac . B a rs  w ith  d iffe ren t le tte rs  a re  s ig n ifican tly  d iffe re n t (p < 0 .0 1 )
AG: American ginseng, KJM: Konjac-mannan fibre, AG+KJM: American ginseng and konjac 
combination
Day Profile - Incremental GLP-1
Time (min)
—♦ — CONTROL  
- ■ - A G  
KJM 
—X —AG+KJM
F ig  4 .10 : Increm en ta l p la sm a  G L P-1 day  p ro file  re su lts  o f  10 sub jects  w ith  type  2 d iab e tes  
a fte r e ith e r  con tro l, g in sen g  (A G ), K on jac  m an n an  (K JM ) o r a  c o m b in a tio n  o f  g in sen g  an d  
ko n jac  m annan  (A G + K JM ). R esu lts  a re  ex p ressed  as  m ean  ±  SE M . T im e  p o in ts  w ith  d iffe ren t 
le tters are  sign ifican tly  d ifferen t.
Day Profile Study - GLP-1
A T o ta l  AUC
A,B
KJM AG+KJM
Incremental AUC
I
CONTROL
Fig 4.11: T ota l a n d  increm en ta l a reas o f  G L P-1 fo r  con tro l, g inseng , k o n jac  m annan  a n d  the  
com bination  o f  g inseng  and  konjac. B ars w ith  d iffe re n t le tte rs a re  s ig n ifican tly  d ifferen t.
AG: American ginseng, KJM: Konjac-mannan fibre, AG+KJM: American ginseng and konjac 
combination
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4.4.6 Blood Pressure
S y s to l ic  a n d  d ia s to l ic  b lo o d  p r e s s u re  r e s u l ts  a re  p r e s e n te d  in  F ig  4 .1 2  a n d  
4 .1 3 . T h e  s y s to l ic  b lo o d  p re s s u re  s h o w s  th e  g r e a te s t  fa ll  o n  th e  K J M  te s t  m e a l ,  
h o w e v e r  i t  a ls o  h a s  th e  h ig h e s t  s ta r t in g  v a lu e  1 2 9 ± 5 m m H g  c o m p a r e d  to  1 1 9 ± 4  m m H g  
a l th o u g h  th is  w a s  n o t  s ta t is t ic a l ly  s ig n i f ic a n t ly  d i f f e re n t .  S ta t is t ic a l  a n a ly s is  u s in g  
tw o -w a y  A n o v a , d id  n o t  s h o w  a n y  s ig n i f ic a n t  d if fe re n c e s .
Control
— — AG+KJM
Day Profile - Change in Systolic BP
10.0
5 .0
% - 10.0
-5,0
-15.0 -30 0  3 0  6 0  120 24 0  3 6 0  42 0
Time (min)
F ig  4 .12 : Increm en ta l S ysto lic  b lo o d  p re ssu re  d ay  p ro file  re su lts  o f  10 sub jec ts w ith  type  2 
d iab e te s  a fte r e ith e r con tro l, g in sen g  (A G ), K on jac  m an n a n  (K JM ) o r a  c o m b in a tio n  o f  
g in sen g  an d  k o n jac  m annan  (A G + K JM ). R esu lts  a re  ex p ressed  as m ea n  ±  SE M .
—♦ —Control 
—• —AG 
—A—KJM 
—*-A G +K JM
Day Profile Study - Change in Diastolic BP
a>o>c10£O
4
2
0
-2
-4
-6
-8
■10  1 1 1 1 1 1 1 1
-30 0 30 60 120 240 360 420
Time (min)
F ig  4 .1 3 :  In c re m e n ta l  D ia s to lic  b lo o d  p r e s s u re  r e s u l ts  o f  10 s u b je c ts  w i th  ty p e  2 
d ia b e te s  a f te r  e i th e r  c o n tro l ,  g in s e n g  (A G ) , K o n ja c  m a n n a n  (K J M )  o r  a  c o m b in a t io n  
o f  g in s e n g  a n d  k o n ja c  m a n n a n  (A G + K J M ) . R e s u l ts  a re  e x p r e s s e d  a s  m e a n  ±  S E M .
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4.4.7 Satiety. Palatabilitv and Eating Time
There were no significant differences in satiety, palatability or eating time 
between the different meals over either breakfast of lunch.
Fig 4 .14 : T o ta l sa tie ty  sco re  over b reak fa st and  lunch  o f  10 sub jec ts  w ith  ty p e  2 d iab e te s  a fte r 
e ith e r con tro l, g in seng  (A G ), K on jac  m an n an  (K JM ) o r a  co m b in a tio n  o f  g in sen g  an d  k o n jac  
m annan  (A G + K JM ). R esu lts  are  ex p ressed  as m ean  ±  SE M .
Patatabiiity of Breakfast and Lunch
18 .0  -I
16 .0  -
g 14.0 -
8  12.0 -  V)
*  10.0 - 
2  8.0 -  
«  6.0 -
4.0 -
2.0
0.0 -
CO NTR O L AG  KJM AG+KJM
Fig 4 .1 5 :  T o ta l p a la tab ility  sco res fo r b reak fast an d  lunch  o f  10 sub jec ts w ith  type  2 d iab e tes  
a fte r e ith e r con tro l, g in se n g  (A G ), K on jac  m an n an  (K JM ) o r  a  co m b in a tio n  o f  g in sen g  an d  
k o n jac  m annan  (A G + K JM ). R esu lts  a re  ex p ressed  as m ean  +  SE M
T a b le  4 .8  : Means of incremental areas under the curve (AUC) for glucose, insulin, 
GIP, GLP-1, and TAG over breakfast (0-240min) and the second meal (240-420min). 
AG=American Ginseng, KJM=konjac mannan fibre, N/A=not analysed.
I n c re m e n ta l  A U C  0 -2 4 0 m in
T es t C o n t r o l A G K J M A G + K J M
G lu c o se  
(m in .m m o l/L )
757±112 708±113 820±96 759195
In su lin
(m in .p m o l/L )
33111±6659 34612±7629 27267±6240 2770817321
G IP
(m in .p m o l/L )
34953±6016 37830±6809 23286±3708 2618415771
G L P-1
m in .p m o l/L )
6016±959 6808±694 3709±684 57711352
T A G
(m in .m m o l/L )
92±17 86±21 90±17 77114
I n c re m e n ta l  A U C  2 4 0 -4 2 0 m in
T es t C o n t r o l A G K J M A G + K J M
G lu c o se
(m in .m m o l/L )
389±47 410±75 233139 238151
In su lin
(m in .p m o l/L )
24986±7346 31524±12548 2328618697 2006614999
G IP
(m in .p m o l/L )
N/A N/A N/A N/A
G L P-1
(m in .p m o l/L )
N/A N/A N/A N/A
T A G
(m in .m m o l/L )
60±13 54±14 48111 5219
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4.5 Chapter Discussion
Previous acute studies with ginseng have shown postprandial glucose lowering 
with concomitant increases in postprandial insulin levels (Vuksan et al.5 2000a) aswel 
as decreases in blood pressure (Stavro et al., 2000a). However the physiological 
effectiveness of ginseng can be variable and is dependent on the ginseng preparation 
(Sievenpiper et al., 2003). In this study the ginseng preparation used, was only shown 
to decrease glucose levels at 15min. Insulin levels tended to be higher both during the 
first and second meal but this did not reach significance when compared to the 
control. Several factors might be responsible for these results: First, the study may be 
underpowered after having to eliminate 3 subjects, secondly there is still controversy 
regarding what constitutes the physiologically active component(s) of ginseng. The 
ginseng used in the study was selected on the basis of total ginsenosides, however the 
ratio of key ginsenosides might be of greater importance (Hong et al., 2000). Low 
protopanaxadiols (PPD) to protopanaxatriols (PPT) ratios have been shown to inhibit 
non-insulin stimulated glucose uptake in adipocytes at the highest dose of 
10,000]ng/ml and significantly inhibited insulin stimulated glucose uptake compared 
to control in a dose related manner (Hong et al., 2000). This particular batch of 
ginseng had a slightly lower ratio of PPD: PPT than a previous, more effective, batch. 
Alternatively, other components such as peptidoglycans, polysaccharides and 
quinqefolians also present in ginseng might be responsible for the glucose lowering 
seen with some batches of ginseng.
As ginseng has been shown to increase postprandial insulin levels (Vuksan et 
al., 2001b) it was hypothesised that this was achieved by increased levels of the 
insulinotropic hormones GLP-1 and GIP, however no such increases were seen in this 
study. Another mechanism of action must therefore be responsible for the increase in 
insulin levels seen after ginseng administration.
Konjac-mannan fibre too has been shown to decrease postprandial glucose 
levels but, unlike ginseng, this is accompanied by decreased postprandial levels of 
insulin. In this study, although no effect on glucose was seen, the postprandial insulin 
levels were decreased significantly. Similarly GLP-1 and GIP were decreased after
9 0
the meals containing konjac-mannan. Previous studies with guar showed reductions in 
postprandial GIP levels (Ellis et al., 1995; Jenkins et al., 1988; Morgan et al., 1979). 
These results therefore support the hypothesised slow release mechanism of action of 
viscous fibres.
Guar has been shown to also decrease the postprandial glycaemic and 
insulinaemic response to a second, standard meal, after the fibre was administered in 
the first meal. It was expected that konjac-mannan would have a similar effect. It was 
not known if ginseng would affect the metabolic response to a second meal. In this 
study konjac-mannan did decrease the incremental glucose area of the second meal, 
however this effect was mainly due to higher starting levels present before the second 
meals was consumed. These higher levels seen 4 hours after consuming a viscous- 
fibre rich meal, although not significantly different, again support the slower release 
carbohydrate hypothesis where one of the beneficial effects of fibre is ascribed to its 
ability to smooth out the glucose and insulin curves thereby preventing the shaip 
increase and concomitant undershoot of both glucose and insulin levels seen after 
fibre free meals.
In spite of the differences in insulin levels there were no significant 
differences in NEFA levels. NEFA levels did not go back to baseline, which might 
explain the lack of effect as NEFA levels may have already been maximally 
suppressed.
There was a tendency for TAG levels to be higher after the control meal over 
the first 2 hours but this only reached significance when incremental levels were 
calculated from -30min rather than Omin and might be therefore be related to starting 
levels.
Although konjac mannan affected postprandial insulin, GIP and GLP-1 levels 
there was no effect on postprandial glucose levels. Similar reductions in GIP and 
GLP-1 have been observed without affecting postprandial glucose levels after coffee 
or chlorogenic acid administration (Johnston et al., 2003). This might be a reflection 
of a relatively small gut effect and that plasma glucose levels are less sensitive to 
small changes in gut hormones than plasma insulin.
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The general lack of effect of konjac-mannan in this study on glucose levels 
might also be due to the mode of administration. Subsequent tests showed that 
addition of konjac-mannan to Ensure did not result in the expected increase of 
viscosity of the liquid (see Chapter 5). The lack of viscosity of the meal could explain 
the lack of effect on glucose. In addition, it is possible that viscosity of the meal 
developed after ingestion and that the reduced levels of insulin, GIP and GLP-1 might 
be due an increase of viscosity lower down in the gastrointestinal tract.
Although shown in previous studies, (Stavro et al., 2002; Stavro et al., 2000b) 
(Vuksan et al., 1999b) in this study, no effect of either ginseng or konjac-mannan was 
seen on blood pressure. Again, effectiveness of this particular ginseng preparation 
might have been responsible for the lack of effect. Konjac-mannan has been shown to 
reduce blood pressure in longer term trials (Vuksan et al., 1999b), however acute 
reductions have not been reported. It is possible blood pressure reductions seen with 
konjac mannan might be die result of a general improvement in metabolic control 
rather than a direct, acute effect.
It has been suggested that fibre may play an important role in weight 
maintenance through increasing satiety (Blundell and Burley, 1987). The proposed 
mechanisms of action are delayed gastric emptying and intestinal transit time and/or 
reduction of postprandial glucose, insulin and Gl peptide and hormone levels. Some 
studies have reported increases in satiety and/or suppression of appetite with soluble 
fibre (Kovacs et al., 2002; Pasman et al., 1997) but results vary (Ellis et al., 1981; 
Heini et al., 1998). One of the confounding factors might be GLP-1, which promotes 
satiety (Verdich et al., 2001), but which is generally reduced after the ingestion of 
fibre rich meals. In this study there were no differences in perception of satiety. 
Factors which may have been responsible for this result, may have been the reduced 
levels of GLP-1, the lack of gelling of the konjac mannan and the insensitivity of the 
bi-polar scale.
Although it had been expected that the combination of konjac-mannan and 
ginseng would further improve the metabolic response to a meal, in this study no 
additive effect was seen. The contrast tests performed on the data indicate the major
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effective component was the konjac mannan fibre, therefore the lack of additive effect 
seen here may have been due to the overall small physiological activity of the ginseng 
preparation used in this study. Further studies will need to be undertaken to study 
possible additive effects.
4.6 Conclusion
The ginseng used in this study showed a small but significant reduction in 
postprandial glycaemia, the lack of a more sustained effect on both glucose and 
insulin might have been due to its composition. This emphasises the importance of the 
development of a standardised, effective ginseng preparation.. Konjac-mannan 
decreased postprandial insulin, GLP-1 and GIP levels. Lack of effect on glucose 
might be due to lack of the viscosity of the meal. Using konjac-mannan and ginseng 
in combination did not, in this study, improve the metabolic profile more than when 
konjac-mannan was used alone.
9 3
Chapter 5
SUPPLEMENTARY STUDIES TO EXPLORE RESULTS 
FROM ACUTE STUDY
5.1. Chapter Synopsis
Studies were initiated to explore reasons for the failure of konjac and ginseng 
to exert the expected effect on circulating glucose and insulin levels seen in prior 
studies.
First the viscosity measurements were repeated with the konjac fibres to test 
whether the viscosity of the three konjac fibres maintain the same relationship when 
mixed with Ensure™ instead of water.
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Secondly, in vivo tests were undertaken to test, in healthy volunteers, whether 
the konjac when taken with Ensure ™, showed the same lack of effect as seen with 
the Day Profile.
Thirdly, test meal studies were undertaken to compare the ginseng used in the 
day profile with a ginseng preparation which was known to be effective in lowering 
postprandial blood glucose levels. Test meals were given with and without konjac to 
evaluate again the effect of the combination of ginseng and konjac on postprandial 
glucose.
5.1.1 Results:
Rheology:
1. Viscosity of Three Konjac Fibres when Mixed with Ensure™: when 
konjac was mixed with Ensure the expected rise in viscosity was not 
observed
In Vivo:
2. Postprandial Blood Glucose Response to Two Konjac Fibres showed a 
significant 29 and 32% reduction in incremental areas when konjac was 
added to Ensure™ (p<0.01).
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3. Postprandial Blood Glucose Responses to Three Ginsengs With or 
Without Konjac Fibre. The ginseng used in the acute study, again showed 
no beneficial effect on blood glucose. The ginseng which had previously 
shown to be effective, signficantly reduced the incremental glucose level at 
90min (p<0.05) and reduced the AUC by 24% when compared to control 
but this did not reach significance. Addition of konjac did not show any 
additional benefit. Two way ANOYA analysis of konjac containing meals 
vs non-konjac containing meals showed a AUC reduction of 14% (p<0.02) 
by konjac.
5.1.2 Conclusion
Despite the use of viscous konjac fibre and high ginsenoside containing 
ginseng, no significant effect on post-prandial glucose or insulin levels were seen in 
subjects with type 2 diabetes (chapter 4). Supplementary studies in healthy volunteers 
also showed a relative lack of effect on post-prandial glycaemia and indicate that 
further studies are required to determine the optimal dose, source and nature of the 
supplements to maximise the effectiveness of konjac and ginseng for use in further 
studies.
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5.2. Introduction
Effectiveness of viscous fibre has been related to its ability to increase the 
viscosity of the intra-luminal contents of the small intestine (Ellis et al., 1995). Prior 
to the acute study the relative viscosity of three konjac-mannan fibres had been 
determined to select the most viscous of the three fibres available. However in this 
determination the fibres were mixed with water, in the acute, in vivo test, the fibres 
were mixed with the meal replacement Ensure™. As the post-prandial glucose 
reductions by konjac-mannan were less than expected it was hypothesised that the 
ability of the konjac-mannan fibre to form a viscous gel in Ensure™ was reduced. To 
test this hypothesis, the viscosity experiment performed in Chapter 3 was repeated 
using Ensure™ as the base rather than water.
Although viscous fibre lowers post-prandial glycaemia when incorporated 
into solid mixed meals (Ellis et al., 1981; Jenkins et al., 1976; Kovacs et al., 2001; 
Kovacs et al., 2002) the effects are generally larger when the fibre is incorporated into 
liquid test meals such as water (Jenkins et al., 1978) or soup (Wolever et al., 1979). 
The results from the acute study and in vitro results were therefore unexpected. 
Additional in vivo studies with the konjac and Ensure™ combination were carried out 
because it was not understood whether the effect was due to the presence of diabetes 
or whether it was truly because the fibre is ineffectual when mixed with Ensure™. 
The two fibres (KJM1 and KJM 3), which achieved peak viscosity in the shortest time 
in the first theology experiment, were used for in vivo testing.
In the acute day profile study carried out in chapter 4, the effect of ginseng on 
post-prandial glucose and insulin levels was also less than expected. It was therefore 
decided to repeat the study in healthy volunteers using the ginseng from the acute 
study (whole root ginseng) and compare it with a ginseng extract (CNT2000) which 
had been shown to be effective in previous studies in diabetic subjects (Vuksan et al., 
2000a; Vuksan et al., 2001a). A third ginseng (Mary ginseng) was added to allow 
further comparison.
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To evaluate whether addition of konjac to ginseng had an additive effect on blood 
glucose, all test meals were given either with or without konjac mannan fibre (see 
table 5.2).
5.3. In Vitro Experiment: Rheology: Viscosity of Three Konjac Fibres 
when Mixed with Ensure™
5.3.1 Methods
The earlier rheology experiment was repeated (see Chapter 3) using the same 
methods and materials with the exception that 150ml of Ensure™ was substituted for 
150ml of water.
5.3.2 Results
The viscosity results are tabulated in table 5.1. The peak viscosity of the wheat 
bran was 6 poise, which is similar to the earlier results where the peak viscosity of 
wheat bran was 8 poise (table 3.1). However the viscosity of the konjac fibres this 
time, did not go higher than 14 poise compared to 246-335 poise when the fibres were 
mixed with water (Fig 5.1).
Table 5.1: Viscosity measurements of wheat bran and 3 different konjac fibres
with EnsurerM as the medium.
Viscosity (p)+
Time 15 30 45 60 90 120 180 24hr
Wheat Bran 4 6 4 6 6 4 4 4
KJM 1 6 8 10 12 12 12 14 14
KJM 2 6 6 10 10 10 10 10 12
KJM 3 8 8 10 8 6 8 6 8
+viscosity (poise) was calculated by multiplying the dial reading by the factor (3.90) corresponding to 
the viscometer spindle (E) and speed (12rpm) combination utilised (Brookfield Helipath Stand Spindle 
Factors, Stoughton MA, USA).
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5.3.3. Interim Discussion
T h e  re s u l ts  w e re  u n e x p e c te d ,  a s  th e  v is c o s i ty  b a r e ly  c h a n g e d  w h e n  th e  k o n ja c  
f ib r e  w a s  a d d e d  to  th e  E n s u re . T h e  r e a s o n  f o r  th is  is  n o t  c le a r . A c c o rd in g  to  
m a n u fa c tu r e r s  s p e c if ic a t io n s  k o n ja c  f ib re  f o rm s  a  v e ry  s ta b le  g e l u n d e r  m o s t  
c o n d it io n s .  T h e y  s ta te  th a t  g e l l in g  o f  th e  f ib re  is  n o t  a f fe c te d  b y  o th e r  in g re d ie n ts  
in c lu d in g  m ilk  p ro te in s ,  a n d  is  c o n s ta n t  w i th  a  p H  b e tw e e n  4 -1 0 . H o w e v e r  h y d r a t io n  
a n d  d i s p e r s io n  a re  k e y  f a c to r s  ( E l l i s  a n d  M o r r is ,  1 9 9 1 ) , b o th  o f  w h ic h  m ig h t  h a v e  
b e e n  a f fe c te d  b y  th e  E n s u re . T h e  f ib r e  w a s  h a n d  m ix e d  in to  th e  E n s u re ,  a n d  a l th o u g h  
n o  c lu m p s  w e re  v is ib le ,  it is  p o s s ib le  th a t  th e  f ib re  w a s  n o t  d is p e r s e d  su f f ic ie n tly . D u e  
to  th e  h ig h  c o n c e n tr a t io n  o f  p r o te in ,  fa t,  g lu c o s e  a n d  m in e ra ls  in  E n s u re ,  i t  is  p o s s ib le  
th a t  th e  w a te r  p r e s e n t  is  n o t  a v a i la b le  to  h y d ra te  th e  k o n ja c  f ib re  s u f f ic ie n t ly  to  fo rm  a  
ge l.
T h e  la c k  o f  v is c o s i ty  o b s e rv e d  m ig h t  in  p a r t  e x p la in  th e  n e g a t iv e  r e s u l ts  o b s e r v e d  
in  th e  d a y  p ro f i le  e x p e r im e n t .  T o  c o n f irm  th is ,  in vivo e x p e r im e n ts  in  h e a l th y  
v o lu n te e r s  w e re  c a r r ie d  o u t.
» KJM 1 
a - -  KJM 2 
«- - KJM 3 
WB+E 
K1+E 
-*— K2+E 
 K3+E
*
30 60 90 . 120 1 50 180 24Time (min)
Fig 5 !.: Comparison of previous viscosity measurements of 4 different fibres (WB, KJM1, 
KJM2, KJM3) mixed with water, and the same fibres (WB+E, Kl+E, K2+E, K3+E) mixed 
with Ensure.
Abbreviations: WB= wheat bran, KJM=konjac mannan, K=konjac mannan, E=Ensure
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5.4. In Vivo Studies
Two different studies were performed in healthy volunteers, the first (“konjac 
experiment”) tried to evaluate whether it was the presence of diabetes which made the 
konjac ineffective in lowering postprandial glycaemia in the acute experiment. The 
second study (“ginseng experiment”) compared the ginseng used in the acute study 
with a previously shown, effective ginseng. In addition this study also evaluated the 
effect of adding konjac to ginseng on blood glucose in healthy volunteers.
5.4.1. Methods
5.4.1 J . Power Analysis
The sample size was determined by power analysis. It was assumed that the 
tests were to be conducted at a significance level of alpha=0.05 and the power to 
detect a significant difference was 90%. Based on previous studies with konjac and 
ginseng, it was assumed that the expected standard deviation for the 90min area under 
the curve for plasma glucose was 60 min.mmol/L. and the minimal detectable 
significant differences 72 min.mmol/L. From this set of assumptions, the minimum 
sample size calculated was 9 for both studies. Assuming a 15% attrition rate, the final 
sample size was calculated to be a minimum of 10.
5.4.1.2. Volunteers
1. Konjac experiment: Eleven healthy volunteers participated in the study 
and all completed the study protocol (4 men, 7 women, age (mean ±SD) 36 ±13 y., 
body mass index 23.5±3.4kg/m2).
2. Ginseng experiment: Ten volunteers were recruited for the study but two 
volunteers were unable to finish the test series, due to time constraints. Due to the 
limited supply of CNT2000 we were unable to enrol further subjects. Therefore eight 
healthy volunteers participated in the study (4 men, 4 women), age (mean +SD) 
(28.4±12.Q y, BMI 23.4±3.9 kg/m2).
The studies were approved by the Ethics Committee of St. Michael’s Hospital. 
Informed written consent was obtained from all volunteers.
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5.4.1.3. Protocol
The studies had 3 and 8 treatment segments for the konjac and ginseng 
experiments respectively and were given in a randomised order. Tests were performed 
at the Clinical Nutrition and Risk factor Modification Centre of St Michael’s Hospital. 
The standard fmgerprick protocol was followed for both studies (see Chapter 2). In 
the konjac experiment, after a fasting fmger-prick blood sample was obtained, KJM1, 
KJM3 or wheat bran was mixed with the Ensure™ Subjects were instructed to 
consume the Ensure™ over a 5 min period. For the ginseng experiment, a fasting 
finger-prick blood sample was obtained (-40min), after which the subjects swallowed 
the capsules with 200 ml o f water. After 40 min, an additional fasting sample was 
obtained (Omin) after which the subjects consume the Ensure™ and fibre mixture 
over a 5 min period. Immediately after the Ensure™ and fibre mixture was consumed, 
subjects consumed an additional 200 ml water (table 5.2).
5.4.1.4. Test Meals
All test meals consisted of 50 g available carbohydrate from 365g Ensure1 M 
(Ross Products Division, Abbott Laboratories, Saint-Laurent, Canada) to which in the 
konjac experiment, 3.5g of fibre was added either as 7g wheat bran (control) or 4g of 
KJM1 or KJM3 was added. After the Ensure™ and fibre mixture was consumed, 
subjects drank 250 ml water. In the ginseng experiment, the three ginseng products 
used were: 1) Whole root ginseng (“Premium'North American Ginseng “ (Chai-Na- 
Tai, NF Formulas Inc, Canada) which was the ginseng used in the acute study; 2) 
CNT 2000 (Chai Na Tai, NF Formulas Inc, Canada) an extract of ginseng, which had 
been shown previously to be effective and finally 3) “Mary ginseng” (Mary Ginseng 
House, Toronto, Canada) a locally produced, whole ground, ginseng. Each dose 
consisted of 3 grams (6 capsules) of either com flour or ginseng, 200ml of water was 
given to swallow the capsules. The fibre used was either 7g of wheat bran (control) or 
4g of KJM1 and was mixed with the Ensure just prior to consumption. Immediately 
after consuming the Ensure and fibre mixture, subjects consumed an additional 200ml 
of water (table 5.2.
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T a b le  5.2: Ginseng experiment: Description o f the 8 Test meals o f the ginseng
experiment comparing the effect o f 3 different ginsengs with or without added 
konjac mannan fibre.
C a p s u le s E n s u r e 1' 1 3 .5 g  F ib r e  S o u rc e W a te r*
C + W B Control 356 g 7g o f Wheat bran 200ml+200ml
C + K JM Control 356 g 4 g o f Konjac 200ml+200ml
C N T + W B CNT 2000 356 g 7g o f Wheat bran 200ml+200ml
C N T + K JM CNT 2000 356 g 4 g o f Konjac 200ml+200ml
M G + W B Mary Ginseng 356 g 7g o f Wheat bran 200ml+200ml
M G + K JM Mary Ginseng 356 g 4 g o f Konjac 200ml+200ml
G + W B Whole root ginseng 356 g 7g o f Wheat bran 200ml+200ml
G + K JM Whole root Ginseng 356 g 4 g o f Konjac 200ml+200ml
C=control capsules, WB=wheat bran, KJM=konjac mannan, CNT= ginseng capsules containing 
CNT2000 ginseng extract, MG=ginseng capsules containing ginseng from Mary Ginseng, G=whole 
root ginseng capsules.*Water -  200ml of water was consumed with the capsules at —40min and again at 
Omin immediately after the Ensure was consumed
5.4.1.4. Sample Analysis
The blood glucose samples were analysed using a glucose oxidase method 
(Yellow Spring Instruments, 2300 Stat glucose/L-lactate analyser, model 115)(see 
Chapter 2).
5.4.1.5. Statistical Analysis
The results are expressed as means ± SEM. The incremental areas under the 
blood glucose response curve (0 to 90min), ignoring the area below the fasting level, 
were calculated geometrically (Wolever et al, 1991). A two-factor repeated measures 
ANOVA was used to assess differences in glucose levels between treatments. 
Between the meals, differences in AUC were assessed by one-way repeated measures 
ANOVA, and adjusted for multiple pair-wise comparisons with the Newman Keuls 
procedure. In all cases, differences were considered statistically significant if p<0.05. 
A further 2-way ANOVA was perfonned on the ginseng study to compare the glucose 
response to konjac containing meals with those without konjac.
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5.4.2 Results
Konjac experiment: A repeated measures ANOVA over the time course of 
the experiment showed a significant difference in absolute glucose values between 
treatments (p<0.01). A comparison of individual time points showed that at 15 and 
30min both KJM1 and KJM3 were significantly lower than the wheat bran (p<0.02), 
and at 45min KJM3 was significantly lower than the wheat bran (p<0.04)(Fig 5.2). 
The areas under the curve (AUC) for KJM1 and KJM3 were (MeanlSEM) 79.7117.8 
and 83.8±20.8 min.mmol/L respectively; both were significantly lower than the AUC 
for wheat bran of 117.7±18.1 min.mmol/L (p<0.01) (Fig 5.3). This represents 
respectively a 32 and 29% reduction in the incremental areas for KJM 1 and 3 when 
compared to the control.
Incremental Glucose
* \ t — ♦“ control
- ■ - K J M  1
—♦ —KJM 3
30  6 0
T im e  (m in )
90
F ig  5 .2 : Increm en ta l g lucose  lev e ls  in  11 h ea lth y  su b jec ts  a fte r 3 5 6 g  E nsure  m ix e d  
w ith  e ith e r 7g  w h ea t b ran  (con tro l), o r 4 g  o f  tw o  ko n jac -m an n an  fib res  w ith  d iffe ren t 
v isco sitie s  (K JM 1 and  K JM 3). P o in ts w ith  d iffe ren t le tte r a re  s ign ifican tly  d ifferen t.
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Fig 5.3: Incremental areas under the glucose tolerance curve after 356g Ensure 
mixed with either 7g of wheat bran (control), or 4g of two konjac-mannan fibres with 
different viscosities (KJM1 and KJM3). Bars with different letters arc significantly 
different p< 0.01.
Ginseng experiment: A repeated measures ANOVA over the time course of 
the experiment showed no significant differences in absolute glucose values between 
treatments. A comparison of individual time points showed that at 90min CNT2000 
was significantly lower than all other values (p<0.05) (Fig 5.4). There were no 
significant differences in the areas under the curve (Table 5.3, Fig 5.5). Comparing all 
the meals containing konjac with those which did not, showed significant differences 
in glucose concentrations and treatment (p<0.03). The AUC for konjac containing 
meals was reduced by 14% (p<0.01) when compared to the non konjac containing 
meals.
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Table 5.3: Incremental glucose areas under the curve of three different ginseng 
preparations with or without konjac mannan fibre, tested in 8 healthy subjects
C = con tro l capsu les, W B = w h ea t b ran , K JM = k o n jac  m an n an  fib re, G =  w h o le  g ro u n d  ro o t 
g in sen g  capsu les, C N T = C N T 2 0 0 0  g in se n g  capsu les , M G =  “M ary  G in se n g ” capsu les.
Incremental Blood Glucose
o
E
E,
0)
§0
3
e>
1  
m
—A— C + W B  
— C + K J M 
G + W B  
- X —G + K JM  
•H * -C N T + W B  
-" • - -C N T + K J M  
—I— M G + W B  
 M G +K JM
F ig  5.4: Increm en ta l g lu co se  leve ls  o f  th ree  d iffe ren t g in sen g  p re p ara tio n s  w ith  o r  w ith o u t 
k o n jac  m an n an  fib re, te s ted  in  8 hea lthy  sub jects. C = con tro l c ap su le s , W B = w h ea t b ran , 
K JM = k o n jac  m an n an  fib re, G =  w ho le  g ro u n d  ro o t g in seng  capsu les, C N T = C N T 2 0 0 0  g in seng  
capsu les, M G =  “M ary  G in sen g ” capsu les. * p < 0 .0 5
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3 Ginsengs with or without Konjac
(n=8)
200.0 n
Fig 5.5: Glucose AUC (90min) results of three different brands of American ginseng taken 
with or without konjac fibre. C=control capsules, WB=wheat bran, KJM=konjac mannan 
fibre, G= whole ground root ginseng capsules, CNT=CNT2000 ginseng capsules, MG= 
“Mary7 Ginseng” capsules. Mean + SEM, n=8
When comparing the previously used, effective ginseng (CNT2000) with the 
new ginseng (whole root) used in the acute study, there were no significant 
differences in incremental blood glucose values when compared to control (Fig 5.6). 
Although the 90min incremental area under the curve for CNT 2000 was lower (102.4 
± 15.6 min.mmol/L) than either the control (135! ± 17.2 mmol/L) or the whole root 
ginseng (144.2 ± 28.6 mmol/L) il did not reach significance (p -0 .16).
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Fig 5.6: Incremental blood glucose levels after control (C+WB), previously used 
ginseng (CNT+WB) and the new ginseng (G+WB) in 8 healthy subjects.
5.5. Chapter Discussion
In the acute study in diabetes, konjac mannan fibre failed to reduce the post­
prandial glucose levels. It was postulated that the lack or delay in viscosity of the 
meal was the cause of the lack of effect observed. The rheological experiment seemed 
to confirm these results as the konjac did not increase the viscosity of the Ensure. 
Similarly, in the ginseng experiment, the added konjac had only a small effect on 
incremental glucose area, which only reached significance when all the konjac meals 
were pooled. However in the in vivo konjac experiment, the konjac fibre did show a 
significant, 29-32% decrease in incremental glucose areas. These reductions, although 
substantial, are still less than the 40-50% reported in the literature (Vuksan et al,, 
1992). These experiments therefore show that Ensure seems to inhibit gel formation 
of konjac fibre and this reduces the glucose lowering potential of the fibre in vivo. 
This effect might be less pronounced in a healthy population. One of the reasons for 
this might be that in the diabetic population even a mild sub-clinical degree of 
autonomic neuropathy is reflected in slower gastric emptying which might negate the 
effect of the viscous fibre as the slower gastric emptying will in turn reduce the rate of 
glucose absorption in the small intestine (Levitt et al., 1980).
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The ginseng experiment again showed that the ginseng used in the acute study 
had no effect on the glucose tolerance of healthy subjects. However the CNT 2000 
ginseng, which had previously shown to be effective, also showed no significant 
reduction in AUC. A lack of power might be the reason for not finding a significant 
effect of any of the ginsengs tested, however insufficient supplies of CNT2000 
prohibited inclusion of more subjects.
These data therefore suggested that, prior to the start of the long-term trial, a 
proven, effective ginseng preparation needed to be selected and that the vehicle of 
konjac administration was of great importance and needed to be investigated further. 
The next chapter describes the selection of the most effective ginseng from 5 different 
samples and explores different, effective and palatable means of incorporating konjac 
fibre into food.
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Chapter 6
SELECTION OF EFFECTIVE GINSENG AND METHOD 
OF KONJAC ADMINISTRATION
6 !. Chapter Synopsis
The experiments performed in Chapter 5 made it clear that, prior to the start of 
the long-term study, an effective ginseng preparation was urgently needed. In addition 
the effective type, dose and mode of administration of konjac mannan fibre also 
needed to be established.
A. Ginseng
As the company, which had in the past supplied us with ginseng, was not in a 
position to supply new material, ginseng fanners were contacted and 5 batches of 
different American ginsengs were set aside for in vivo testing and analysis. The 
ginseng which lowered the postprandial glycaemia to the greatest extent was to be 
used in further studies.
B. Koniac mannan
To determine die most effective mode and dose of konjac three experiments were 
undertaken using the standard glycaemic testing protocol. The most viscous form of 
soluble fibre was used which was a mixture of konjac and xanthan fibre (Viscous 
Fibre Blend, VFB):
1, To establish most effective mode of incorporation, VFB was incorporated into 
capsules, bread, or margarine.
2. To establish the minimum effective dose, 1,2,and 4g of VFB were tested. The 
VFB was baked into bread or mixed into margarine
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3. As time of ingestion of VFB capsules might influence its effect on 
postprandial glycaemia, in this experiment the capsules were given either at 
30min before, immediately before, during or after the meal was consumed.
6.1.1. Results
All five ginsengs tended to lower postprandial glycaemia, the American ginseng 
from the Broda farm was selected for future studies as it lowered the AUC to the 
greatest extent.
Incorporation of VFB into capsules and bread had no significant effect on 
postprandial glycaemia, however mixing of the VFB into margarine reduced the area 
under the curve by 34% (p<0.001). A repeat of this experiment, but using different 
levels of the VFB, again showed that incorporation of the VFB into margarine was the 
most effective in lowering postprandial glycaemia. All doses of VFB when 
incorporated into margarine reduced the mean postprandial glucose AUC but this only 
reached statistical significance with the 4g dose. Ingestion of VFB capsules at 
different times had no effect on postprandial glycaemia.
6.1.2. Conclusion
It was unexpected that die VFB, when incorporated into bread, had no effect, the 
experiment was therefore repeated and at the same time a dose response was 
established. This experiment again showed that incorporation of the VFB into 
margarine was more effective dian baking it into bread.
In preparation for the long-term study, the selected ginseng and its control 
(cornstarch) were sent off to be encapsulated.
A decision needed to be made on how to administer the VFB. When baked into 
bread it did not seem to be effective. When mixed witii margarine it did seem to be 
effective and a margarine spread could easily be prepared however its limiting factor 
would be acceptability and the limited amount of VFB which could be incorporated 
into the margarine. It was therefore decided to use a VFB sprinkle in addition to the 
margarine spread. Unlike other fibres, sprinkling of VFB on to carbohydrate foods 
had been shown to be effective previously (personal communication, Dr Vuksan). In
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addition, it was decided to also use VFB capsules as some studies had shown that, in 
the long-term, capsules might be effective in lowering lipid levels (Khan et al, 1981)
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6.2. Introduction
The company which had provided us in the past with ginseng capsules, was no 
longer able to do so. As this was quite unexpected, a reliable, effective preparation of 
ginseng was therefore urgently needed for my long-term study and other studies 
planned at the Risk Factor Centre. Although a major part of the work was performed 
by Dr John Sievenpiper, who was at that time a PhD student with Dr Vuksan, because 
of the urgency, the selection process was a group effort of Dr Vuksan’s students and 
staff. Accordingly, in cooperation with the Ontario Ginseng Growers Association, 5 
ginseng farms in Simcoe County were contacted. The owners agreed to set aside one 
batch of 180kg of whole ginseng root each, which allowed us to select the most 
effective ginseng through in vivo testing and be assured that sufficient quantity from 
the same batch would be available for future studies.
In preparation for the long-term study, a decision needed to be made on which 
fibre to use and how to best incorporate it into the diet. At that time one of Dr 
Vuksan’s students was using a viscous fibre blend, consisting of 75% konjac mannan 
and 25% xanthan. Using a combination of konjac mannan fibre and xanthan produces 
a fibre with a much higher viscosity (Table 6.1). In vivo studies confirmed the 
effectiveness of using the konjac and xanthan viscous fibre blend (VFB) (Vuksan, 
Unpublished data). To determine the most effective and palatable way of 
incorporating fibre into the diet, in vivo studies were undertaken in which fibre was 
administered either in capsules, baked into bread or mixed into margarine.
I l l
Table 6.1. Viscosity measurements of three different konjac mannan fibres alone or blended 
with xanthan gum at two different concentrations. Measurements were taken 120min after 
mixing with water (Vuksan, unpublished data)
Viscosity at Different Levels of Xanthan 
(cps)
0% Xanthan 25% Xanthan 40% Xanthan
KJM-1 5,850 21,060 26,910
KJM-2 6,630 20,670 28,080
KJM-3 8,580 19,110 26,520
*KJM=konjac-mannan fibre; +viscosity (cps) was calculated by multiplying the dial reading by 
the factor (390) corresponding to the viscometer spindle (E) and speed (12rpm) combination 
utilised (Brookfield Helipath Stand Spindle Factors, Stoughton MA, USA)
6 .2 !  Subjective assessment of appetite
It has been suggested that fibre may play a role in weight maintenance through 
increasing satiety levels. Several studies using guar gum have shown an increase in 
satiety levels (Kovacs et al., 2001; Kovacs et al., 2002; Pasman et al., 1997) following 
guar administration but not all (Ellis et al., 1981; Heini et al., 1998). Discrepancies 
between these results might be because of the different dosages used, study design 
and the difficulty in quantifying satiety.
As konjac mannan is a viscous fibre it might also be able to influence appetite 
and satiety (desire to eat, feeling of fullness etc). In previous studies, as part of the 
standard glycaemic response protocol, subjects were asked to rate their satiety using a 
bi-polar scale ranging from -3 (extremely hungry) to +3 (uncomfortably full). 
However interval scales are more powerful instruments because the interval or 
distance between points on the scale is assumed to be equal (Hetherington and Rolls, 
1987). Therefore parametric tests can be applied to the data. The visual analogue scale 
(VAS) is such a scale. The V A S  is a straight line usually measuring 100mm with 
bipolar anchors of adjectives or descriptive phrases. One end of the scale represents 
the lowest rating of the variable and the other end the highest rating, e.g. “not at all 
hungry” and “extremely hungry”. V A S  are easy to administer and sensitive to small
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changes (Maxwell, 1978). It was therefore decided to replace the old scale and use the 
VAS instead in future experiments. VAS was used in VFB study 2 and 3.
6 .3 .1 .  S e l e c t i o n  o f  G i n s e n g
Five ginsengs were collected from a range of farms (Broda, Shaw, Duca, 
Spreit and John Farm) to ensure that varying growing conditions (location, soil type, 
age at harvest, etc) and physical characteristics such as body shape (short, long, thin, 
etc.) and the ratio of rootlets to body were included. These differences were verified 
using a standard questionnaire. The ratio of rootlets-to-body was determined by hand 
sorting with a 1cm gauge mesh. Expressed as % rootlets, it was 14% for Duca farm,
19% for Shaw Farm, 22% for Broda Farm, 24% for Spreit Farm, and 24% for John 
Farm. Representative (by rootlets-to-body ratio) 11.5kg samples were taken from 
each of the five 180kg batches for grinding, ginsenoside analyses, and subsequent 
clinical screening. The remainder was stored in a central location awaiting the 
screening outcome. We found that the 5 batches were distinct yet still authentic AG 
by their ginsenoside profile (Table 6.1).
T a b le  6 .2  - G in s e n o s id e  c o n te n t of 5 b a tc h e s  o f A m erican  g inseng(% w t/w t)
Farm P ro to o an axad io ls P ro top an axatrio ls To ta l R atios
Rb1 ~Rb2 Rc Rd PPD Rd1 “  Rf Re P P T P P D :P P  Rh1:Rn Rb2:Rc Rb2:Rb
Shaw 3.245 0.040 0.238 0.241 3.764 0.110 0.000 1.285 1.395 5.159 2.698 29.500 0.168 0.012
Duca 4.149 0.037 0 .224 0 .269 4.679 0.077 0.000 1.524 1.601 . 6 .280 2.923 53.883 0.165 0.009
John 4.191 0.039 0 .2 52 0.358 4.840 0.108 0.000 1.394 1.502 6.342 3 .222 38 .806 0.155 0.009
Broda 4.087 0.056 0.334 0 .2 52 4.729 0.165 0.000 1.665 1.830 6.559 2 .584 24.770 0.168 0.014
Spreit 3.294 0.047 0 .2 86 0.317 3.944 0.131 0.000 1.252 1.383 5.327 2.852 25.145 0.164 0.014
Applying the same 75g-OGTT protocol as had been used previously and using 
9g doses of the 5 AG batches, 2-way ANOVA showed a significant effect of time 
(P0.0001) but not treatment (P=0.098) with significant interaction (P=0.026) on 
plasma glucose. Exploring the interaction with 1-way ANOVAs, it was found that 
there was a significant effect of treatment at 60min (P=0.015) and on AUC (P=0.046). 
Comparisons with control showed that all the ginsengs reduced postprandial glucose 
levels but this only reached significance with the ginsengs from the Broda, John and 
Spreit Farms (Figure 6.1). Insulin was not measured. Broda Farm ginseng which 
reduced the AUC to the greatest extent was concluded to have the greatest lowering
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effect compared with control. In view of these results, the whole 180kg batch of 
Broda Ginseng was reserved for the proposed studies.
Figure 6.1 — Differential effects of American ginseng (AG) batches from 5 different Ontario farms: 
The line plots and bars represent the incremental change and AUC for plasma glucose and insulin 
following control (fl) or 9g AG (O) taken 40min before a 75g-OGTT in 12 healthy subjects (sex: 
5m:7f, age: 27±2y, BMI: 24±lkg/m2). P values are for repeated measures ANOVA with non- 
ortliogonal contrasts comparing treatment with placebo
6.4. Effective and Palatable Incorporation of VFB
During the long-term study subjects would be required to take 7g of viscous fibre 
a day for a three month period. To ensure compliance it was therefore cmcial that 
palatable and effective viscous fibre products would be available. In order to be effective 
in lowering postprandial glycaemia, the viscous fibre needs to be intimately mixed with 
the food (Jenkins et al., 1979). However preparation of palatable formulations is a 
challenge.
1 1 4
To investigate the most effective and palatable mode of VFB incorporation 
three studies were undertaken:
VFB study 1: Different methods of VFB incorporation: It was decided that 
three different methods of VFB incorporation would be tested. Traditionally, 
incorporation of viscous fibre has been with the carbohydrate portion of the food to 
ensure adequate mixing. Therefore the first product to be tested was a white bread 
with added VFB. The disadvantage of white bread is that it limits the choice of 
carbohydrate source, a spread containing viscous fibre would have the advantage that 
it could potentially be added to any carbohydrate portion. Tire second product 
formulated therefore was a margarine with added fibre. The third product to be tested 
was VFB in capsules.
VFB study 2: Dose response: To establish a minimum effective dose of VFB, 
a dose response study with 1, 2 and 4g of VFB was undertaken.
VFB study 3: Timing of capsules: The possibility that the time of ingestion of 
VFB capsules would influence its effect on postprandial glycaemia was explored.
6.4.1 Protocol
VFB study l:Eight healthy subjects were recruited from the Risk Factor 
Modification Centre, 3 men and 5 females, (Mean±SD), age 28±7y, BMI 22±4 kg/m2. 
Control and VFB breads were prepared by the Kensington Bakery (Toronto, ON). 
Test meals consisted of white bread, margarine and capsules with VFB either added to 
the bread, margarine or capsules with control capsules containing cornstarch (see 
Table 6.3). Capsules were taken immediately before the white bread test meal. 
Palatability data were collected using a scale from 1 to 10 where 1 was “extremely 
dislike” and 10 “delicious”.
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Table 6.3. YTB study l:Test meals consumed for the study indicating where the VFB 
is incorporated
. Control;'.-wviyvS:.'V.K/L ■ VFB-Margo VFB-Bread VFB-Caps
White bread. 50g CHO 50g CHO 50g CHO 50g CHO
; v (H  lg) (H lg ) (147g) (H lg )
Margarine 10 g 10g 10 g 10 g
Capsules (8) 4g 4g 4g 4g
cornstarch cornstarch cornstarch VFB
VFB 0 g 4 g 4 g 4 g
Incorporation 
of VFB
None In margarine In bread In capsules
VFB -  viscous fibre blend
VFB study 2: Twelve healthy subjects 4M, 8F (Mean±SD) BMI 27+4 kg/m2, 
age 36±13y, consumed white bread and margarine (50g of carbohydrate, iOg of 
margarine) on 8 different occasions. Six test meals had either 1, 2, or 4g of viscous 
fibre either mixed into the bread or into the margarine; the other 2 test meals had no 
fibre added and acted as control (Table 6.4).
Table 6.4: VFB study 2: Composition of the eight different test meals which were 
consumed, including two controls, indicating amount of viscous fibre blend (VFB) in 
each test meal and whether it was incorporated into the bread or margarine.
Testmeal Control
(x2)
Bread-lg Bread-2g Bread-4g M arg-lg Marg-2g Marg-4g
XMXxYxx- -• v
White bread
.
50g CHO 50g CHO 50g CHO 50g CHO 50g CHO 50g CHO 50g CHO
Margarine
'■;‘V'.Vv ■' ■
10 g 10 g 10 g 10 g 10 g 10 g 10 g
VFB 0g lg 2g 4g lg 2g 4g
Incorporation 
Of VFB
Into bread Into bread Into bread Into
Margarine
Into
Margarine
Into
Margarine
VFB -  viscous fibre blend
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VFB study 3: The aim of this study was to explore whether the postprandial 
glucose response to a meal would differ if VFB capsules were taken at different times 
with respect to a meal i.e. some time before a meal immediately before a meal 
during the meal or after the meal was consumed. Therefore thirteen healthy subjects 
5M, 8F (Mean±SD), BMI 25+5 kg/m2, age 39±17y, consumed 50g of carbohydrate 
from white bread and i 8 capsules on 6 different occasions. Each capsule contained 
either 500mg of cornstarch or 500mg of VFB, the 18 capsules were divided as 
follows: six capsules were given 30min before the white bread, six capsules 
immediately before the white bread, and six capsules 15min after white bread 
ingestion with the exception of one meal where the six capsules were consumed 
together with the white bread. Two test meals acted as control and all 18 capsules 
contained only cornstarch . During the other tests meals, 6 VFB capsules (3g of VFB) 
were substituted for 6 cornstarch capsules and were taken at either -30min (VFB at -  
30), immediately before (VFB at 0), during the meal (VFB with meal) or 15 min after 
the white bread was eaten (VFB at 15)(see figure 6.2 and table 6.5).
Whit^Bread
6 caps 6 caps 6 caps
j i i
T - ---------1--------- 1-------- t----------- 1----------- 1----------------- 1------------- 1
-30 0 15 30 45 60 90 120
Fig 6.2. S chem atic  rep re sen ta tio n  o f  study p ro to co l u sed  in  th e  V F B  s tudy  3 -  T im in g  o f  
C apsu les . F ingerp rick  b lo o d  sam p les w ere  taken  a t a ll tim e  po in ts. C ap su les  w ere  tak en  a t  -  
30m in , Omin and  15m in w ith  2 00m l o f  w ater. W hite  b read  w as co n su m ed  a fte r the  Omin 
b lo o d  sam ple.
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Table 6.5.: Table illustrating the content of the 6 capsules given at each time point during 
the different test meals. Each capsules contains either 500mg of cornstarch (CS) or viscous 
fibre blend (VFB).
CS-comstarch, VFB-viscous fibre blend
The standard finger prick protocol was used for all three studies (see chapter 
2). For VFB studies 2 and 3, a visual analogue scale (VAS) was used to record satiety 
and replaced the bi-polar scale used in previous studies.
6.5. Results
VFB study 1: Different methods of VFB incorporation: All meals were 
well tolerated. There were no significant differences in starting levels (Mcan± 
SEM)(Control 4.4 ± 0.2; VFB-bread 4.6 ± 0.1; VFB-marg 4.5 ± 0.1; VFB-caps 4.7 ± 
0 !  mmol/L, p<0.3). Ad hoc analysis showed a significantly decreased postprandial
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g lu co se  level a t 30 m in  a fte r  th e  m eal w h ic h  had  V F B  m ix ed  in to  th e  m arg a rin e  
(p < 0 .0 0 0 6 )(F ig  6 .2 ), s im ila rly  th e  a rea  u n d e r  th e  cu rv e  w a s  s ig n if ic an tly  d e c re ased  
a f te r  th e  V F B -m a rg a rin e  m eal co m p a red  to  th e  o th e r  m ea ls  (p < 0 .0 3 )  (F ig  6 .3 ).
VFB Incorporation Study
Fig 6.3. Postprandial glucose o f  8 healthy subjects levels after consum ing white bread, 
m argarine and capsules containing 50g o f  carbohydrate and 8g o f  fat. Four gram s o f  VFB w as 
added either to the bread (VFB-bread), m argarine (V FB-m arg) o r capsules (V FB-caps). 
Control capsules contained 4g cornstarch. Data are expressed as m ean±SEM . P values are for 
repeated m easures A N O V A  com paring treatm ent w ith control. **p<0.0006.
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VFB Incorporation Study
A A a
Control VFB-bread VFB-caps VFB-marg
Fig 6.4. P ostp rand ia l g lu co se  a rea s  o f  8 healthy  su b jec ts  a fte r co n su m in g  w h ite  b read , 
m arg a rin e  and  capsu les co n ta in in g  5 0g  o f  carb o h y d ra te  and 8g  o f  fat. F o u r g ram s o f  V F B  w as 
ad d ed  e ither to  th e  b read  (V F B -b read ), m arg a rin e  (V F B -m arg ) o r  cap su le s  (V F B -cap s). 
C on tro l capsu les co n ta in ed  4 g  co rnstarch . D a ta  are  e x p ressed  as m ean ± S E M . R ep ea ted  
m easu res  A N O V A  w as u sed  to  co m p are  trea tm en t w ith  con tro l, b a rs  w ith  d iffe ren t le tte rs  are  
sig n ifican tly  d iffe ren t (p< 0 .03 ).
Palatability of the VFB-margarine meal was significantly lower than the other 
VFB containing meals but did not differ from the control meal (p<0.05) (Fig 6.3). 
Satiety scores, using the bi-polar scale, showed no significant differences between the 
test meals at any time point.
VFB Incorporation Study - Palatibility Score
10 !
Control VFB-bread VFB-caps VFB-marg
Fig 6.5: P a la ta b i l i ty  s c o re s  8 healthy  su b jec ts  a fte r c o n su m in g  w h ite  b read , m arg a rin e  and  
cap su le s  c o n ta in in g  50g  o f  carb o h y d ra te  a n d  8g  o f  fat. F ou r g ram s o f  V F B  w as a d d ed  e ither 
to  the  b read  (V F B -b read ), m argarine  (V F B -m arg ) o r  capsu les (V F B -cap s). C on tro l cap su le s  
co n ta in ed  4 g  co rnstarch . D a ta  are  ex p ressed  as m ean± S E M . R ep ea ted  m easu res  A N O V A  w as 
u sed  to  co m p are  trea tm en ts  w ith  con tro l, b a rs  w ith  d iffe ren t le tte rs  a rc  s ig n ifican tly  d iffe ren t 
(p< 0 .05).
190
V F B  s t u d y  2 :  D o s e  R e s p o n s e :  Two factor repeated measures ANOVA over the time 
course of the experiment showed a significant difference in glucose concentrations 
between treatments using the Newman-Keuls multiple-comparison test a significant 
difference between control and Marg-4g was found. Post-hoc analysis showed that 
there were no significant differences in starting values (Table 6.4), in addition there 
were no diferences in postprandial response between control and Bread-1 g, Bread-2g 
and Bread-4g. However when VFB was mixed with margarine the postprandial 
glycaemia was significantly reduced at 30 and 45min for all three doses (p<0.001)(Fig
6.5). Compared to control, VFB containing meals (Bread-1 g, Bread-2g, Bread-4g, 
Marg-lg, Marg-2g, and Mar-4g) reduced the incremental AUC by 2%, 5%, 20%, 
22%, 24%and 34% respectively, but this only reached statistical significance for the 
Marg-4g test meal (p<0.001)(Fig 6.6).
T a b l e  6 . 6 :  Fasting capillary blood glucose values for each test meal consumed during 
the dose response-VFB study 2.
Testmeal Control
( x 2 )
Bread-lg Bread-2g Bread-4g Marg-lg Marg-2g Marg-4g
Fasting
glucose
(mmol/L)
4.5+0.1 4.4+0.1 4.4+0.2 4.5+0.1 4.6+0.1 4.5+0.1 4.5+0.1
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Fig 6.6: Postprandial glucose o f 12 healthy subjects levels after consuming white bread, and 
m arg a rin e  co n ta in in g  50g  o f  carb o h y d ra te  and  8g  o f  fat. O ne, 2 o r  4 g  o f  V F B  w as ad d ed  
e ith e r to  th e  b read  (B re a d - lg , B read-2g , B read -4 g ) o r  m arg a rin e  (M a rg - lg , M arg-2g , M arg - 
4g). C on tro l is the  m ea n  o f  tw o  con tro l tes tm eals. D a ta  are  e x p ressed  as m ean+ S E M . 
♦ sign ifican tly  d iffe ren t fro m  con tro l p< 0 .001 .
VFB Dose Response Study
Fig 6.7: Increm en ta l g lu co se  A U C  o f  12 h ea lth y  sub jec ts lev e ls  a fte r c o n su m in g  5 0 g  o f  
carb o h y d ra te  fro m  w h ite  b read , an d  8g  o f  fa t fro m  m argarine . O ne, 2  o r  4 g  o f  v isco u s fib re  
b lend  (V F B ) w as a d d ed  e ither to  th e  b re ad  (B re a d - lg , B read -2g , B read -4 g ) o r  m arg a rin e  
(M a rg - lg , M arg-2g , M arg-4g). C on tro l is th e  m ean  o f  tw o  con tro l tes t m eals. D a ta  are  
ex p ressed  as m ean+ S E M . B ars w ith  d iffe ren t le tte r  a re  s ta tis tica lly  d iffe ren t, p <  0 .002 .
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U sin g  th e  V A S , th e re  w e re  n o  s ig n if ic a n t d if fe re n c e s  seen  in e ith e r  h u n g e r, 
d e s ire  to  eat, fu lln e ss  o r  th irs t a t an y  tim e  b e tw ee n  th e  m ea ls . P a la tab ility  sco res  w e re  
8 .9 + 0 .3 , 8 .4+ 0 .4 , 8 .7 + 0 .4 , 8 .9 + 0 .4 , 8 .1 + 0 .6 , 7 .3 + 0 .8 , 7 .0 + 0 .9  fo r  C o n tro l, B re a d - lg ,  
B read -2 g , B read -4 g , M a rg - lg , M arg -2 g , an d  M a rg -4 g  re sp ec tiv e ly  an d  a lth o u g h  th e  
p a la tab ility  sco re  ten d e d  to  be  lo w er fo r  the  m ea ls  w h ich  had  V F B  in co rp o ra ted  in to  
th e  m arg a rin e  th isd id  n o t reach  s ig n if ic a n c e  u s in g  th e  N e w -K e u ls  m u ltip le  
c o m p a riso n  te s t (p = 0 .0 4 ).
VFB study 3: Timing of Capsules: T w o  fa c to r  rep ea ted  m e a su re s  A N O V A  o v e r  th e  
tim e  co u rse  o f  th e  e x p e rim e n t sh o w ed  no  s ig n if ic an t g lu co se  an d  trea tm e n t 
in te rac tion . T h e re  w ere  no  s ig n ific an t d iffe re n c e s  in A U C  (F ig  6 .8 ), p a la tab ility  sc o re  
an d  V A S .
Timing of VFB Capsules
200
|  160 
E
c 120 
E
O
<
80
40 -I-
I
: : : ; 
.
Controls
I
i p f
I
f g P
M l
I
f p
B w
VFB a t -30* VFB at O’ VFB with VFB at 15’
meal
Fig 6.8. Incremental glucose AUC o f  12 healthy subjects levels after consum ing 50g o f  
carbohydrate from white bread and 18 capsules. Six capsules containing cornstarch or VFB w ere 
consum ed either 30m in before, im m ediately before, during or 15m in after bread consum ption. 
Control is the m ean o f  two control test m eals. D ata are expressed as m ean±SEM .
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6.6 Chapter Discussion
Due to the concerted efforts of Dr Vuksan’s team we were able to select a 
ginseng which significantly lowered the postprandial glycaemia. As a consequence of 
these results the Broda batch was ground and encapsulated in readiness for the long-term 
study.
The three konjac/VFB studies confirmed that method of incorporation is an 
important determinant of the ability of viscous fibre to lower postprandial glycaemia. 
The finding that the viscous fibre was more effective when mixed with the margarine 
was unexpected but was again confirmed in the second VFB study. Previous studies 
have demonstrated that just sprinkling the viscous fibre on the meal negates it glucose 
lowering effect (Williams et al., 1980), however the margarine, presumably because it is 
spread over the carbohydrate portion of the meal, allows the viscous fibre to be 
intimately mixed with the carbohydrate. Previous effective konjac preparations used 
biscuits and crackers (Vuksan et al., 1999b), it is interesting that the higher fat cookies 
tended to be more effective than the lower fat crackers. However, the reason that the 
viscous fibre/ margarine method was more effective than baking it in the bread is still 
unclear. One can speculate that the usual separation of the fat and liquid phases in the 
stomach did not take place when the VFB was mixed with the margarine. This 
dispersion may have caused a slowing of gastric emptying and therefore reduced the rate 
of glucose absorption in the small intestine.
It was unfortunate that the most effective meals, i.e. the 4g margarine/VFB meals 
received the lowest palatability scores, again emphasising the difficulty in preparing 
palatable, effective VFB preparations.
In view of these results it was decided that the VFB would be offered to the 
subjects in three different preparations: a margarine spread, a sprinkle and in capsules. 
The drawback of the margarine spread is that not all subjects use margarine routinely 
and introducing it into their diet would alter their nutrient profile. Furthermore, in order 
to ingest 7g of VFB, subjects would be required to ingest approximately 20g of 
margarine which would be more than people habitually consume. It was therefore
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decided to also offer a sprinkle, the reason a VFB sprinkle was selected in that it allowed 
it to be added to all meals and snacks. In addition, contrary to other viscous fibres, 
konjac has been reported to be effective when sprinkled on the carbohydrate part of the 
meal (personal communication, Dr Vuksan).
Capsules are an ideal method of viscous fibre administration as they are highly 
acceptable and therefore compliance rates are high, especially in a diabetic population 
habituated to taking medications on a regular basis. Although viscous fibre capsules do 
not have an acute beneficial effect on blood glucose possible long-term beneficial 
effects may be present, especially on lipid levels. When 9g/day of guar gum was 
administered in capsules to 24 healthy volunteers for four weeks, significant decreases 
in Total, and LDL-cholesterol were observed (Khan et al., 1981). Capsules might 
therefore have beneficial long-term effects which may not be predicted from acute 
studies. It was estimated that the total amount of VFB to be ingested which would be 
acceptable to subjects using the sprinkle and margarine spread, would be approximately 
3-4g/day. Previous studies (Vuksan et al., 1999a; Vuksan et al., 1999b) used doses of 
konjac ranging from 6-13g. Therefore, to increase the total viscous fibre dose , it was 
decided that subjects would also be given VFB capsules.
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Chapter 7 
LONG -TERM STUDY
Both American ginseng and viscous fibre have been shown to improve 
diabetes control, American ginseng by increasing post-prandial insulin levels and 
viscous fibre by improving insulin sensitivity.
7 .1 ! Objectives
To investigate the combined effects of American Ginseng (AG) and a highly 
viscous fibre blend (VFB) on metabolic control in type 2 diabetes.
7.1.2 Methods
A partially blinded, randomised, placebo controlled, crossover design was 
used with a 4 week run-in period, two 12 week treatment phases separated by a 4 
week wash-out period. Thirty subjects with well-controlled type 2 diabetes, 
participated in the study (18M, 12F; age 64±7y; BMI 28±5kg/m2; HbAlc 7.0+1.0%). 
Twenty-three subjects were treated with oral hypoglycaemic agents and 7 with diet 
alone. Medications, dietary intake, and lifestyle were kept constant throughout. 
During the control phase subjects were given 3g of cornstarch (placebo for AG) 
together with 14g wheat bran (fibre matched placebo for VFB) and during the test 
phase 3g of AG together with 7g of VFB .
7.1.3 Results
Compliance was generally good, percentages of the prescribed supplements 
consumed during the Control and Test periods were as follows: cornstarch 90 % (2.7+ 
0.08 g), ginseng 90% (2.7+0.07 g), wheat bran 73% (10.3+0.7 g), VFB 91% (6.4+0.3 
g). Using the GLM repeated measures ANOVA significant differences between
7.1 Chapter Synopsis
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treatments were found for HbAlc (p<0.02), Total cholesterol (p<0.03), LDL- 
cholesterol (p<0.04), and Apliporotein B (p<0.02). There were no significant 
differences between the treatments in fasting glucose and insulin, Quieki, HOMA, 
triacylglycerol, HDL cholesterol, Apolipoprotein A-l, C-reactive protein, oxidized 
LDL, and. blood pressure measurements. The percent difference at 12 week from 
control for HbAlc was (-4.1+1.4%, p<0.01), total cholesterol (-5.7+1.9%, p<0.01), 
LDL cholesterol (-8.2+3.1%, p<0.002, and apolipoprotein B (-9.0+2.3%, p<0.0005).
Both the total amount of the combined supplement and the VFB dose by itself 
correlated negatively with the difference between changes in control and test HbAlc 
levels (i--0.27, n-30, p<0.04).
7.1.4 Conclusion
Addition of American ginseng and viscous fibre to conventional treatment 
significantly decreases HbAlc levels and improves cardiovascular risk factors over 
a 12 week trial in well-controlled individuals with type 2 diabetes.
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7.2 Introduction
The aim of the study was to assess the long-term metabolic and therapeutic 
effects of combining a viscous fibre blend (VFB) and American Ginseng (Panax 
quinquefolius) in die management of type 2 diabetes, the primary and secondary 
objectives were:
□ Primary: To explore the effects of using the combination therapy ginseng 
and konjac mannan for 3 months on HbAlc in type 2 diabetes.
□ Secondary: To evaluate the effect of the treatment on, fasting blood 
glucose, fasting insulin, blood pressure, , insulin sensitivity, total 
cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerol, oxidised 
LDL, apolipoproteins A-l and B, and C-reactive protein.
7.3 Research Design And Methods
7.3!. Subjects
7.3.1.1. Power Calculation
Given that the study employed a crossover design, we wanted to be able to 
detect a 0.8% treatment difference in HbAjC (SD=1.3%). Power analysis calculations 
indicated that approximately 28 individuals were required (a=0.05 and P=0.8), 
assuming a 30% attrition rate a total of 37 subjects were to be recruited. The standard 
deviations and attrition rate used were based on our own previous observations and 
those of other investigators from studies performed in type 2 diabetes.
7.3.1.2.Recruitment
The study was approved by the St Michael’s Hospital Ethics board, and 
informed consent was obtained from all subject prior to the start of the study. Subjects 
were recruited through newspaper advertisements and from patients already attending 
the diabetes clinic at the Risk Factor Modification Centre at St. Michael’s Hospital.
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Inclusion criteria were: presence of type 2 diabetes (at least 1 year) as defined by 
HbAiC between >6.5% and <8.4% (140% of normal) at recruitment; being treated 
with diet or oral hypoglycaemic medication; be between the ages of 40 and 75 years; 
have systolic blood pressure <140 and diastolic blood pressure < 90; be clinically 
euthyroid; have normal renal and liver functions; live within 30 km range from St. 
Michael’s Hospital; and be willing to comply with the study protocol and sign a 
consent form.
Interested volunteers were initially screened by telephone using a simple 
questionnaire and invited to come to the Centre where the exact nature of the study 
was described and volunteers had the opportunity to ask detailed questions about the 
study. If written consent was obtained, potential candidates filled-out a detailed 
questionnaire concerning their medical history, drugs and medication use (including 
ginseng, herbs, vitamin and minerals), smoking habits, alcohol intake and exercise 
pattern, and whether they were already following a specific diet. This visit was 
followed by a screening visit for which the subjects were asked to come to the clinic 
after a 10-12-hour overnight fast. A blood sample was taken and anthropometric and 
clinical blood pressure measurements were collected. Blood was analysed by die St 
Michael’s Hospital laboratory using standard techniques (see Chapter 2) for total 
cholesterol, LDL-cholesterol (calculated), HDL-cholesterol and triacylglycerol, as 
well as for HbAiC and FBG to confirm diagnosis, level of diabetes control and 
eligibility for the study. Those volunteers who were willing to participate in the study 
and met inclusion/exclusion criteria were invited to join the study.
Fifty-two subjects were screened and of those, 39 were recruited. During the 
study period 9 subjects dropped out (23%). Subjects #11 and 18 because of a change 
in their medication, #27 because of gastrointestinal side effects, #22 felt unable to 
continue taking the capsules, #15, 20, 23, 25, and 31 felt they were unable to 
continue the study due to lack of time. Therefore a total of 30 subjects (18 men and 12 
women) completed the study with a mean age (mean+SD) of 64-±7 y, BMI of 
28±5kg/m2, HbAlc 7.0±1.0%, duration of diabetes of 9.0+6.8y. Seven were treated 
with diet alone, 23 with oral hypoglycaemic agents.
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During the screening visit, subjects were instructed on details of the study 
protocol such as completing the dietary record, VAS and other questionnaires. They 
were asked to maintain a consistent level of physical activity, and to continue their 
habitual diet and lifestyle during the course of the study. Every effort was made 
through counselling to ensure subjects did not change body weight. Also, 
medications for the control of diabetes, if taken, were kept unchanged starting at least 
3 months prior to the beginning of the study.
7.3.2. Study Protocol
1.3.2.1. Design
The study used a partially blinded, randomised, placebo controlled, crossover 
design (see Fig 7.1). Due to the nature of the fibre it was impossible to blind the 
subjects to which fibre they were on. (see section 73.2.3. describing the 
supplements). The study was divided into two phases with each phase having a 4 
week run-in period, and a 12 week treatment period, separated by a 4 week wash-out 
period.
Phase 1 Phase 2
<  ► <  ►
Run-in Control Wash-out Run-in Control
 ^  ^  ^  ^
► Ginseng-VFB ^ .  Ginseng-VFB =M m « n n o B H M i m H « S M H M n a a n n n K i e m K
<- 4 W KS - >  < -  12W KS ->  <— 4W K S —> <— 12WKS - >
Fig 7 !  Schematic representation of the study protocol used in the long-term study
The treatments consisted of an ad-libitum Canadian Diabetes Association 
recommended diet supplemented with either cornstarch capsules and wheat bran
no
(Control) or American ginseng capsules and VFB (test). Subjects were asked to attend 
the clinic at weeks -4 , 0, 3, 6, and 12 during each phase. Table 7.1. summarises the 
analysis and measurements performed at each visit, and section 7.3.2.3. describes the 
methods of collection.
Table 7.1: Analysis and measurements collected at each clinic visit during the study.
> > 4 S E 1 >>>:/■' . - ' ' w  .
n* I H .
Screen­ R un- C on tro l/T est
b
R un-in Test/Control
ing in
- A . .. .. .
-4 0 3 6 12 -4 0 3 6 12
Blood sample:
H bA lc X X X X X X X X X
Lipids
FBG
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Fasting insulin X X X X X X X
C-reactive protein X X X X X X X
Oxidised LDL
. , . :>  • ■ 
Liver &
kidney function
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Anthropometric
.
X X X X X X X X X X X
measurements
Clinical Wood 
pressure
X X X X X X X X X X X
3 day Diet record X X X X X X X X
Quality of Life 
Questionnaire
X X X X
O G T T
........._____ ....................
X X X X
  : ______  ______ i________ _________
OGTT -oral glucose tolerance
7.3.2.2. Study details and measurements:
On weeks -4, 0, 3, 6 and 12 of each treatment phase, subjects attended the 
clinic at the Risk Factor Modification Centre (RFMC), at St. Michael’s Hospital after 
a 10 - 12 hour overnight fast. The only exception was on week 3 when subjects did 
not have to come fasting as no blood work was taken that day; this visit was used to
m
review with the subjects their supplement intake and discuss any problems they had 
encountered. To measure compliance, capsules and fibre supplements not consumed 
were returned and capsule number and weight of the spread and sprinkle were 
recorded. Blood samples were drawn at each visit except for visit 3 and were analysed 
for HbAlc, Total, LDL- and HDL-cholesterol, triacylglycerol, NEFA,
Apolipoproteins A and B, fasting blood glucose, fasting insulin, insulin sensitivity, C- 
reactive protein, and oxidised LDL. Blood samples were drawn by trained intra­
venous nurses and analysed according to established methodologies (see Chapter 2).
Anthropometric measurements included body weight and body fat
composition using infra red technology (Futrex 5000). Clinical blood pressure was 
measured at each visit using a digital blood pressure monitor (OMRON, HEM-907, 
Vemon Hills, USA). Three-day food records were collected and weeks 0, 6 and 12 of 
each treatment arm were analysed for macronutrient and fibre content using the Food 
Processor for Windows diet analysis program (ESHA Research, version 6.11, Salem, 
USA). A 75g OGTT was performed at the beginning and end of each phase. This 
would allow an estimation of insulin sensitivity using the formula proposed by 
Matsuda. et al (Matsuda and DeFronzo, 1999). A symptom questionnaire was 
completed at each visit. Electrolytes, urea, creatinine, aspartate aminotransferase 
(AST), alanine amninotransferase (ALT), prothrombin time (PT), international
normalised ratio (INR) and activated partial thromboplastin time (APTT) performed 
to monitor health status of volunteers and analysed in the main hospital laboratory 
(see table 7.1).
7.3.2.3. Supplements:
GINSENG: The ginseng supplement consisted of 3g of ginseng or 3g of 
cornstarch which acted as the placebo. Each supplement was contained in 6 gelatin 
capsules (500mg/capsule). There were no differences in macro-nutrient composition 
between the capsules (Table 7.2). The subjects were instructed to take two capsules 
before each meal (Fig 7.3). The ginseng used came from the Broda Farm (see Chapter 
6) and had been donated by the Ontario Ginseng Growers. Placebo capsules, on the 
other hand, contained cornstarch (International Nutrition Ltd, Markham, Ontario).
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There were no visually detectable differences between the placebo and ginseng 
capsules.
FIBRE: The aim was to supplement the diet with 6g of fibre, therefore 7g of 
VFB and 14g of wheat bran needed to be consumed. Subjects were instructed to 
consume seven grams of VFB per day in the form of capsules (4g), margarine and/or 
powder. The 14g of white wheat bran control supplement (Grain Process Enterprises 
Ltd, Scarborough, Ontario) was supplied in the same manner as the VFB. Subjects 
were instructed to take 2 capsules containing the fibre before each meal with a glass 
of water to ensure that these were swallowed easily. If subjects habitually consumed 
margarine they were offered the spread and instructed to substitute this for their 
regular margarine. One serving (1 tsp of KJM margarine or 1.5 tsp of wheat bran 
margarine) was to be consumed with the meal. If no margarine was taken with a meal, 
subjects were asked to sprinkle one spoonful of the sprinkle on their food using the 
supplied spoon. This ensured that at each meal fibre was supplied in two different 
formats i.e. in a capsule and as a spread/sprinkle. As the volume of the KJM and 
wheat bran differed, different spoons were supplied on each phase to ensure the 
correct dose was used (table 7.3). At the beginning of each treatment phase, subjects 
were advised to introduce the fibre slowly into their diet to avoid gastrointestinal 
symptoms and increase the dose to the recommended level as tolerated. Although the 
capsules looked identical, due to the nature of the fibres, blinding the subjects to 
which fibre they were on was impossible, however they were not told which fibre was 
expected to have a metabolic effect.
T a b l e  7.2: Macronutrient composition of 3g of ginseng and cornstarch supplements.
■ ,  '  •:■. •• ;< - ■ ■ . ■
American Ginseng 
(3g)
Cornstarch
(3g)
Energy (kcai/g)
■
10.5 10.3
Carbohydrates (g) 2.2 1.7
Protein (g) 0.21 0.76
(g) 0.11 0.04
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Table 7.3 : Number of capsules and amount of ginseng, cornstarch and fibre in the 
capsules and sprinkle/spread taken at each meal during the treatment periods.
Breakfast Lunch Dinner Total
Ginseng 2 2 2 6
Capsules (3g)
Test
Konjac 2 2 2 6
Capsules (4g)
Konjac 1 1 1 3g
Sprinkle/Spread
Cornstarch 2 2 2 6
Capsules (3g)
Control
Wheat bran 2 2 2 6
Capsules (3.4g)
Wheat bran 3.5 3.5 3.5 io.5g
Sprinkle/Spread
7.4 Statistical Analysis
Statistical analysis was performed using the SAS software (SAS version 8.2, 
2001; SAS Institute). The GLM was used to perform two-way ANOVA to detect 
differences of outcome variables in treatments and visits, controlling for treatment 
sequence and sex. If the effect of treatment was significant than percent differences 
were calculated between weeks 12 of test and control and analysed using the GLM 
repeated measures one-way ANOVA controlling for sex. Indices of glucose and 
insulin sensitivity were assessed. As the samples from the OGTT were unusable to 
analyse insulin (see Chapter 2), insulin sensitivity was calculated using fasting 
glucose and insulin levels by two different methods: HOMA insulin sensitivity 
according to the formula: 22.5/FPGxFPI (Matthews et al., 1985) and the modified 
QUICK T according to the formula 1/log(fasting g1ucose)+log(fa sting 
insulin)+log(fasting NEFA) (Perseghin et al., 2001). A Pearson regression correlation
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was used to analyse die relationship between dose and metabolic response. All results 
were expressed as mean±SEM and considered statistically significant if p < 0.05.
7.5 Results
7.5.1 Compliance and Anthropometric Measurements
Compliance was generally good, percentages of the prescribed supplements 
during the Control and Test periods were as follows: cornstarch 90 % (2.7± 0.08 g), 
ginseng 90% (2.7+0.07 g), wheat bran 73% (10.3+0.7 g), VFB 91% (6.4+0.3 g). 
Actual daily fibre intake from the supplements during the study was therefore 4.9g 
from wheat bran and 5.5 g from VFB. There were no changes in body weight, % body 
fat or waist to hip ratio over the test or control periods (table 7.4).
7.5.2 Background diet
Three day dietary records were analysed for weeks 0, 6 and 12 of each 
treatment period. No significant changes in macronutrient intake over the treatment 
periods or between treatments were seen (table 7.4).
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Table 7.4: Absolute and percent macronutrient and fibre intake at weeks 0, 6 and 12 
during the control and test periods.
CONTROL TEST
"1- >' ‘
WeekO Week 6 Week 12 WeekO Week 6
| i 0  j --'‘i
Week 12
T * - "
: ;.v ' 0  
■ ‘ % • '  -  . . . f V .
Energy, (kcal/d) 1685±78 1773±120 1776+116 1687+90 1714+72 1755+95
Protein (g/d) 86±6
20%
92±7
20%
91+7
20%
88+6
21%
88+5
20%
88+5
20%
Available 
Carbohydrate (g/d)
208±23
49%
217±17
49%
213+16
48%
213+13
50%
210+10
49%
218+16
49%
Total Fat (g/d)
• V -  - '  " ,  ■■■ . . '  . ■
■ ■ • ■ « ;v. :- - 
•
-SFA• ■ ' .• - 
-MUFA
-PUFA
............. ............ _ _ ..........................................
60±5
32%
6.2+0.7
21.7±1.6
11.1±0.9
64±6
32%
6.5±0.9
24.6+3.0
12.1+1.3
65+6
33%
5.7+0.5
18.9+1.9
10.6+1.1
56+5
30%
5.8+0.5 
18.9+1.6 
10.6+1.0
61+4
32%
5.2+0.4 
22.2+1.9 
10.0+0.7
62+4
32%
5.7+0.6 
22.9+2.2 
11.1+1.0
Dietary Fibre* (g/d)
'
.
. .  . . . . . . .
23±3 22+3 22+2 22+2 21+2 20+2
*Fibre supplied by diet only and does not include t ie fibre in the supplements.
7.5.3. Outcomes
Using the GLM repeated measures ANOVA over the entire treatment period 
showed a significant difference in HbAlc (p<0.02), total cholesterol (p<0.03), LDL- 
cholesterol (p<0.04), and Apolipoprotein B (p<0.02) between treatments. Using the 
same procedure there were no significant differences between treatments in fasting 
plasma glucose or insulin levels, HOMA, QUICKI, triacylglicerides, HDL- 
cholesterol, Total cholesterol:IIDL, apolipoprotein A -l, conjugated dienes/LDL, 
blood pressure, C-reactive protein (table 7.5, and fig 7.3).
Baseline values did not differ significantly between the two treatments (Table
7.5). The percent difference at 12 week from control for HbAlc was (-4.1+1.4%, 
p<0.01), total cholesterol (-5.7+1.9%, p<0.01), LDL cholesterol (-8.2+3.1%, p<0.002, 
and apolipoprotein B (-9.0+2.3%, p<0.0005).
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Table 7.5: A n th ropom etric  , H b A lc , g lucose , insu lin , b lo o d  lip ids, ox id ised  L D L , c -reac tiv e  p ro te in  and  
b lo o d  p re ssu re  d a ta  on  w eeks 0 , 6 , an d  12 o n  th e  co n tro l and  tes t p e rio d s  (m ean+ S E M ).
'
CONTROL
-A',..:’.' /.v: , .
■ TEST
WeekO Week 6 Week 12 WeekO Week 6 Week 12
Body weight (kg) 80.7+3.2 80.5+3.2 80.8+3.3 80.7+3.2 78.5+3.6 80.9+3.3
Body fat ( % )
...........
28.4+1.2 28.7+1.3 31.2+1.8 28.6+1.2 30.9+2.7 29.5+1.2
HbAlc ( % ) 6.94+0.16 6.62+0.17 6.77+0.18 6.89+0.17 6.54+0.15 6.46+0.16***
Glucose
(mmol/L)
7.5+0.4 7.6+0.4 7.5+0.4 6.9+0.4 7.2+0.3 7.3+0.3
Insulin (pmol/L) 65.3+8.0 63.7+7.3 70.9+6.2 65.8+7.8 63.4+7.7 67.0+7.7
NEFA (pmol/L) 0.58+0.04 0.60+0.06 0.50+0.03 0.56+0.04 0.55+0.04 0.56+0.04
HOMA (ratio) 0.070+0.005 0.073+0.010 0.066+0.010 0.081+0.010 0.076+0.010 0.070+0.008
QUICKI (ratio) 0.44+0.02 0.45+0.02 0.45+0.02 0.47+0.02 0.46+0.02 0.44+0.02
(mmol/L)
TOTAL
LDL
HDL
TOTALiHDL
LDL:HDL
4.64+0.18
2.66+0.05
1.26+0.05
3.80+0.18
2.20+0.13
4.63+0.19
2.75+0.14
1.21+0.02
3.89+0.16
2.32+0.13
4.71+0.19
2.77+0.16
1.25+0.04
3.83+0.14
2.24+0.12
4.62+0.19
2.77+0.14
1.21+0.04
3.89+0.16
2.34+0.13
4.42+0.16
2.57+0.13
1.22+0.05
3.74+0.15
2.19+4.4
4.40+0.17**
2.48+0.14*
1.23+0.04
3.67+0.14
2.07+0.12
Oxidised LDL 
LDL conjugated 
dienes (pmol) 
LDL conjugated 
dienes/LDL
(fimol/mmol)
70.5+8.3
26.4+2.8
113.3+10.4
41.7+3.6
61.9+6.7
22.9+2.4
85.1+11.9
29.9+3.3
115.6+10.8
46.8+4.4
58.6+7.4
24.8+3!
TAG (mmol/L)
■
1.55+0.14 1.47+0.10 1.53+0.14 1.42+0.10 1.38+0.10 1.53+0.14
Apolipoproteins 
ApoA-1 (g/L) 
ApoB (g/L)
1.55+0.04
0.94+0.04
1.53+0.04
0.91+0.04
1.54+0.04
0.98+0.04
1.51+0.04
0.94+0.04
1.52+0.04
0.86+0.04
1.51+0.04
0.88+0.04***
CRP (mg/L) 2.03+0.36 2.28+0.44 2.44+0.62 2.31+0.43 2.34+0.50 1.93+0.42
Blood pressure
Systolic (mmHg) 
Diastolic (mmHg)
130+3
76+2
128+3
73+1
133+3
76+2
128+4
74+2
129+3
73+2
130+3
75+2
Waist (cm) 
Hip (cm) 
Waist:HIP
93.5+2.5
102.0+1.9
0.9+0.01
90.7+3!
100.2+1.9
0.9+0.02
93.4+2.6
101.7+2.0
0.9+0.01
93.5+2.4
101.9+2.0
0.9+0.01
89.6+3.6
100.8+1.9
0.89+0.03
91.1+3.6 
101.7+1.8 
0 88+0.03
GLM repeated measures, significant difference between treatments: ***p<0.02, **p<0.03, *p<0.04
7.5.4. Safety Parameters.
Safety factors were measured at the beginning an end of each treatment period to 
monitor possible changes in kidney and liver function. No statistical or clinical significant 
changes were observed over the treatment periods or between treatments (table 7.6).
Table 7.6: Safety param eters m easured at the beginning and end o f  the control and test treatm ent
periods.
CONTROL TEST
WeekO Week 12 Week 0 Week 12
Sodium
(mmol/L)
137.710.4 138.410.5 138.310.5 138.210.5
Potassium
(mmo/L)
4.410.2 4.510.1 4.310.1 4.410.1
Chloride
(mmol/L
100.310.6 10110.6 100.210.7 101.6+0.7
Total C 0 2 
(mmol/L)
27.110.4 27.010.6 27.610.4 26.810.5
Anion Gap 
(mmol/L)
10.310.4 9.910.4 10.510.4 9.810.3
Urea
(mmo/L)
5.910.3 6.010.3 6.210.3 5.810.3
Creatinine
(umol/L)
79.013.0 78.914.4 81.713.3 82.813.3
AST
(U/L)
25.711.7 25.911.4 26.7+2.0 26.211.5
ALT
(U/L)
28.212.7 27.612.0 28.712.6 29.2+2.3
PT
(s)
10.610.1 10.010.2 10.510.2 10.010.1
INR 1.010.0 1.010.0 1.010.0 1.010.0
APTT
(s)
27.510.6 27.010.6 27.210.4 26.610.5
AST: aspartate aminotransferase; ALT: alanine aminotransferase; PT: prothrombin 
time; INR: international normalised ratio: APTT: activated partial thromboplastin 
time. s:seconds
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7.5.5 Symptoms
During each visit to the clinic subjects were asked whether they experienced 
symptoms or conditions such as headaches, flatulence, belching, diarrhoea, nausea, 
joint pain etc. If their response was positive they were asked to rate the severity on a 
scale from 1 to 7. Statistical analysis showed no difference between the severity of the 
symptoms between treatments (fig 7.2).
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Fig 7.2 : Percent symptom occurrence on weeks 0, 6 and 12 during control and test 
periods.
F i g  7 .3 . A bso lu te  v a lu es are  g iven  fo r  H b A lc , to ta l cho lestero l, L D L -ch o les te ro l, and  
A p o lipop ro te in  B  a t w eek s 0 ,6  and  12 o n  con tro l an d  te s t trea tm en ts  in  30  p a tien ts  w ith  
type  2 d iabetes. R esu lts  are  m ean  ± S E M . P  va lues d e n o te  s ig n ifican t d iffe ren ces be tw een  
trea tm en ts  u sing  G L M  A N O V A  rep ea ted  m easu res  m odel.
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7.5.7.0ral Glucose Tolerance Test
There were no statistically significant differences in plasma glucose values at 
any time between the test and control groups either at week 0 or week 12 (Fig 
7.4). As discussed in Chapter 2, the insulin results for the oral glucose tolerance 
test could not be analysed.
F ig  7 .4 : P lasm a  g lucose  lev e ls  d u rin g  th e  o ra l g lu co se  to le ran ce  p e rfo rm ed  a t w eek  
12 a fte r e ith e r th e  te s t o r  th e  con tro l period . R esu lts  a re  ex p ressed  as M e a n lS E M .
7.5.8. Dose response
The relationship between total self-reported intake of either ginseng, VFB or both 
with HbAlc, total cholesterol, LDL-cholcstcrol and Apo B was also investigated. 
Only the difference between changes of treatment and control in HbAlc correlated 
positively with both the total dose (p<0.04) and the VFB (p<0.03) (Fig 7.5).
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F ig  7 .5 : C o rre la tio n  b e tw een  the  to ta l d o se  o f  g in sen g + V F B  an d  the  d iffe re n ce  b e tw een  
ch an g es o f  trea tm en t an d  con tro l in  H b A lc .
7.6 Chapter Discussion
In this group of subjects the compliance with the prescribed dosages of 
ginseng and VFB was very high and the supplements were generally well tolerated. 
Symptoms associated with high fibre diets such as flatulence, bloating, belching all 
increased on the VFB arm of the study, but this did not reach significance. The 
increase in symptoms was especially seen at week 6 but a decrease in symptoms was 
seen at week 12 as presumably adaptation to the higher fibre intake took place.
The expected difference between treatments in HbAlc used in the power 
calculation was 0.8%, a significant difference would therefore not be expected to be 
seen with the actual difference of 0.4% found in this study. However, the SD of the 
subjects in this study was considerably lower than initially estimated: 0.5 versus 1.3% 
used in the power calculation. If these new figures are used the actual number of 
subjects required to detect a significant difference of 0.4% is 16. The study was 
therefore well powered and able to detect a difference of 0.4%.
The reductions in HbAlc seen in this trial are comparable to previous trials 
with both ginseng and konjac mannan. A study with type 2 diabetes using konjac 
mannan fibre, showed a significant reduction in fructosamine over a three week 
period of about 0.19mmol/L which represent about a 6% reduction (Vuksan et al., 
1999b). Similarly when ginseng was taken over a three-month period a reduction of
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0.3% was seen in HbAlc (Vuksan et al., 2001b). In this study a reduction in HbAlc 
was observed of approximately 0.4%. Although this reduction is modest, the subjects 
in the study were well controlled at the start of the study with an average HbAlc level 
of 7%. This is the HbAlc treatment goal of diabetes. At the end of the study their 
average HbAlc levels were reduced to 6.5%, which, at the time of the study, was 
defined as normal. Similarly the reductions seen in total cholesterol and LDL 
cholesterol were modest, but again the subjects baseline values were low with almost 
a third of the patients on statin treatment. Nevertheless a 7% reduction of LDL 
cholesterol was achieved which translates in a 14% risk reduction in coronary heart 
disease (LRC, 1984). Furthermore, although not significant using the GLM repeated 
measures, both the ChofHDL and LDL:Choi ratios decreased by 4 and 6% 
respectively when compared to control at week 12. A recent NCEP report which 
summarised the implications of the recent trials for the National Education Program 
Adult Treatment Panel III Guidelines (Grundy et al., 2004), concluded that these trials 
confirm the benefit o f cholesterol-lowering therapy in high risk patients and support 
the ATP III treatment goal o f LDL< lOOmg/dl (2.6mmol/L). Plotting relative risk for 
coronary heart disease against LDL-cholesterol, supports the concept “ the lower the 
better” for reducing risk for major cardiovascular events is correct (figure 7.6). In this 
study the average LDL-cholesterol levels were reduced from 2.8mmol/L to 2.5mml/L, 
and therefore decreased the average LDL level into the recommended range.
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Fig 7.6 : Log linear relationship between LDL-cholesterol levels and relative risk for 
coronary heart disease ((Grundy et al.. 2004).
Conjugated dienes in the LDL fraction are a marker of LDL oxidation. 
Therefore a reduction in conjugated dienes is an indicator of increased antioxidant 
activity and low levels are related to a reduced risk in cardiovascular disease (Holvoet 
et al., 2001). Reductions in LDL oxidation have been observed after feeding nuts, soy
143
and other vegetable protein diets (Ginsberg et al., 1998; Jenkins et al., 2002; Jenkins 
et al., 2001). In this study the conjugated dienes fell on both the control and treatment 
arms but this was not significant neither was there a significant difference between 
treatments.
HbAlc was the only variable which correlated with the amount of the 
supplements ingested. Both the total amount of supplement and VFB con-elated with 
HbAlc but not ginseng, this fits in with other studies using viscous fibre. It was 
unfortunate that the OGTT data could not be used to calculate insulin sensitivity, as it 
is a more robust method than those which calculate insulin sensitivity using fasting 
levels only. Neither HOMA or QUICKI were significantly different between test and 
control.
It was hoped that the combination of VFB and ginseng would produce an 
additive effect and, although the trial was not designed to answer this question, this 
did not seem to be the case as the total reductions seen in either HbAlc or lipid did 
not seem to be substantially different from the results of previous trials which used 
only one or the other. However, the ginseng/VFB combination caused a small but 
clinically significant improvements in diabetes control and cardiovascular risk factors 
in this group of well-controlled subjects with diabetes and although small may be a 
useful adjunct in the armamentarium of strategies required to achieve the new, much 
lower, recommended treatment goals set for people with diabetes.
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Chapter 8
GENERAL DISCUSSION
The aim of the thesis was to determine whether synergistic or additive benefits 
could be derived with the use of two plant-based components with independent 
physiological benefits and whether the use of these two agents would improve 
diabetes control in the long term. Combination drug therapy to treat chronic disease 
is already common practice, pharmacological agents such as biguanide and 
sulfonylurea or biguanide and thiazolidinedione are now routinely used together in the 
treatment of type 2 diabetes (CDA,2003). Combining dietary components to treat 
chronic disease is another approach which has been used, for example the recent 
“dietary portfolio diet”, which uses an array of nutritionally active components such 
as soy protein, plant sterols, viscous fibre, and almonds, has been shown to be as 
effective at reducing LDL- cholesterol levels as a first generation statin (Jenkins et al.,
2003).
If dietaiy components and so-called natural health products (plant derived 
nutraceuticals) are to have clinical relevance it is likely they will have to be used in 
combination since singly their effects are often small. This issue has taken on an even 
greater significance as the levels of risk factors considered acceptable, be it blood 
pressure control, glycaemic control or LDL-cholesterol are progressively reduced. 
Thus acceptable levels for blood pressure have been reduced from 140/90 to 130/85 
mmHg (Grundy et al., 2004), HbAlc from 7.0 to 6.0% (CDA,2003), and now for high 
risk individuals, which includes diabetes, it has been suggested that LDL-cholesterol 
should be reduced from 2.5 mmol/L to less than 1.8 mmol/L (Grundy et al., 2004). It 
is in this context that our studies may be of use since even small effects may benefit 
those on the borderline of the range. Furthermore, in view of the pleiotropic effects 
now looked for in drugs such as statins, using a combination of natural products may 
also have value.
8.1 Introduction
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Individually both American ginseng and konjac mannan have been shown to 
improve metabolic control in healthy and diabetic individuals. Acute studies with 
American ginseng (AG) have demonstrated reductions in postprandial glucose levels 
(Vuksan et al., 2000a), these were accompanied by increases in the early phase of 
insulin secretion (Vuksan et al., 2001b). Long term studies with AG in type 2 diabetes 
have confirmed the possible benefits of this substance with reductions in HbAlc and 
blood pressure (Vuksan et al., 2001b). Viscous fibre too has been shown to reduce 
postprandial glucose levels (Jenkins et al., 1977), however these reductions have been 
associated with decreases in postprandial insulin and GIP (Jenkins et al, 1980;
Morgan et al., 1990). Early work with guar gum in the 1970’s demonstrated the 
importance of viscosity (Jenkins et al., 1978). Since the 1970’s several other viscous 
fibres such as oat bran and psyllium have been found to effective in the treatment of 
diabetes and hypercholesterolaemia (Anderson et al., 2000; Anderson et al., 1991).
One of the most viscous fibres coming from the Orient is konjac mannan fibre and has 
been shown to improve metabolic control in type 2 diabetes and improve systolic 
blood pressure (Vuksan et al., 1999b). Therefore, as both AG and konjac have been 
shown to improve diabetes control through independent physiological mechanisms, 
the next logical step was to explore the possible benefits of using these in 
combination.
8.2 Acute Studies
Two of the objectives for the acute studies, as outlined in Chapter 1, were to 
establish the effect of konjac mannan and ginseng alone and in combination on 
postprandial glycaemia, insulinaemia, and gastrointestinal hormone secretion in type 
2 diabetes. The hypothesis was that the two compounds would act synergistically and 
the acute day-profile study (Chapter 4) was designed to answer this question.
However the results were less than clear. Neither the ginseng or the konjac when 
given individually changed postprandial glucose and insulin levels by the expected 
amounts and the combination did not result in glucose levels significantly different 
from control. This study did demonstrate that konjac mannan fibre flattens the 
postprandial response of both GIP and GLP-1, an effect not previously demonstrated. 
The reduction in the postprandial response of GIP and GLP-1 after fibre confirms 
again the proposed mechanism of action of fibre i.e. the reduced rate of nutrient 
absorption from the gastrointestinal tract. The inability to demonstrate a significant
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effect of either ginseng or konjac on postprandial glucose levels may have been due to 
several factors: an ineffective ginseng preparation, lack of sufficient gelling of the 
konjac fibre to deal with the carbohydrate load, and finally, the study may have been 
underpowered. The combination of ginseng and konjac did not seem to have any 
added benefit over that of either ginseng or konjac by itself. However due to the 
subsequent findings that the ginseng used was not physiologically active, and that the 
mode of konjac incorporation interfered with the forming of a viscous solution, made 
it difficult to draw firm conclusions on the possible additive effect of ginseng and 
konjac. At the time these results became available we were the recipients of 
additional grant money to explore the long-term effects of AG and konjac used in 
combination. Considerable time and money was needed to find physiologically 
effective sources of both konjac and ginseng. Once these sources had been identified 
no further resources were available to explore the combined acute effects in more 
detail. However this could be the subject of future work.
The third objective was to establish the effect of konjac and ginseng on the 
postprandial glucose and insulin response to a second meal. Previously it has been 
shown that another viscous fibre, guar gum, flattened the postprandial glucose 
response to a second meal. Konjac was therefore expected to have a similar effect. 
Although there were no significant differences in glucose response at any time point, 
the study did show a reduction in the incremental areas under the glucose curve of the 
second meal after the konjac containing meals. This effect on the second meal may 
play an important role in the effectiveness of high fibre diets over the long term where 
consumption of fibre with each meal might not be practically possible.
The studies described in this thesis again highlight the problems when working 
with “natural products”. Many variables including, the specific species used, growing 
conditions, processing of the raw material, method of administration etc can all 
influence the physiological effect of the compound. Even though the ginsenoside 
content of the ginseng used in the day-profile study was one of the highest, the effect on 
glycaemia was minimal. The only way to make sure at this point in time that a ginseng 
is effective is to test it in vivo. Further work could explore the individual active 
components of the ginseng. Similarly, the experiments with konjac mannan highlighted 
the importance of both the method of its incorporation into food and the importance of 
viscosity. The effectiveness of the konjac when mixed into margarine vs bread was
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unexpected, as the traditional way of incorporating fibre has always been to mix it with 
the carbohydrate portion of the meal. The effectiveness of the konjac when mixed with 
fat could be related to a slowing of gastric emptying where, due to the lack of separation 
of the fat and liquid phases in the stomach, a dispersion would be formed which may 
slow the rate of gastric emptying. Slowing of gastric emptying would reduce the rate of 
glucose absorption in the small intestine. Future studies could explore the reason for the 
effectiveness of the viscous frbre/fat combination. However, this method of 
incorporation suggests a very different range of products or possible methods of 
incorporating viscous fibre.
The final objective of the thesis was to establish the effect of using viscous 
fibre and ginseng on metabolic control in a long-term trial in type 2 diabetes.
8.3 Long Term Study
In the long-term study (Chapter 7), subjects consumed approximately 6g of a 
viscous fibre blend (VFB) and 2.5g of ginseng for three months. Significant 
improvements in HbAlc, total cholesterol, LDL-cholesterol, and ApoB were observed 
when compared to the control treatment. The improvement in lipid metabolism was 
estimated to represent a 14% reduction in cardiovascular risk. Viscous fibre and 
possibly ginseng might therefore be useful additions to the armamentarium necessary 
to reduce cardiovascular risk factors. The reductions in HbAlc and lipids seen in this 
trial were comparable to previous trials with ginseng and konjac mannan used 
individually, and therefore there seemed to be again no indication of an additive or 
synergistic effect of these two compounds. It is possible that the different mechanisms 
of action of viscous fibre and ginseng are not compatible. The flattening of the 
postprandial insulin response by viscous fibre might negate the positive benefits of the 
incretin effect of the ginseng. Indeed the results from both the acute and long-term 
studies seem to indicate that any benefit seen was due to the presence of the viscous 
fibre rather than the presence of ginseng.
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8.4 Concluding Remarks
The use of viscous fibre, functional foods and the glycaemic index are now 
recognised in the effort to lower cholesterol levels (Grundy et al., 2004; Sheard et al.,
2004). Both ginseng and konjac are potentially useful compounds to be used in 
reaching target cholesterol levels. The potential incretin effect of AG and the highly 
viscous nature of konjac would seem to make these ideal candidates to be used in 
combination. However the studies in this thesis seem to indicate that no additive 
effect is present when used in combination. The studies in this thesis further illustrate 
some of the pitfalls with “natural” product but also the potentially effective use of 
these compounds.
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